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ABSTRACT 
 
Mechanism Based Anticancer Drugs That Degrade Sp Transcription Factors. 
(December 2009) 
Gayathri Chadalapaka, B.V.Sc and A.H., College of Veterinary Science, India 
Chair of Advisory Committee: Dr. Stephen H. Safe 
 
Curcumin is the active component of tumeric, and this polyphenolic 
compound has been extensively investigated as an anticancer drug that 
modulates multiple pathways and genes.  We demonstrated that curcumin 
inhibited 253JB-V and KU7 bladder cancer cell growth, and this was 
accompanied by induction of apoptosis and decreased expression of the 
proapoptotic protein survivin and the angiogenic proteins vascular endothelial 
growth factor (VEGF) and VEGF receptor 1 (VEGFR1).  Since expression of 
survivin, VEGF and VEGFR1 are dependent on specificity protein (Sp) 
transcription factors, we also investigated the effects of curcumin on 
downregulation of Sp protein expression as an underlying mechanism for the 
apoptotic and antiangiogenic activity of this compound.  Curcumin decreases 
expression of Sp1, Sp3 and Sp4 in blader cancer cells indicating that the cancer 
chemotherapeutic activity of curcumin is due, in part, to decreased expression of 
Sp transcription factors and Sp-dependent genes. Betulinic acid (BA) and 
curcumin are phytochemical anticancer agents, and we hypothesized that both 
compounds decrease EGFR expression in bladder cancer through 
downregulation of specificity protein (Sp) transcription factors.  BA and curcumin 
decreased expression of EGFR, Sp1, Sp3, Sp4 and Sp-dependent proteins in 
253JB-V and KU7 cells; EGFR was also decreased in cells transfected with a 
cocktail (iSp) containing small inhibitory RNAs for Sp1, Sp3 and Sp4 showing 
that EGFR is an Sp-regulated gene. Methyl 2-cyano-3,11-dioxo-18β-olean-1,12-
dien-30-oate (CDODA-Me) is a synthetic triterpenoid derived from glycyrrhetinic 
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acid which inhibits proliferation of KU7 and 253JB-V bladder cancer cells. 
CDODA-Me also decreased expression of specificity protein-1 (Sp1), Sp3 and 
Sp4 transcription factors. Similar results were observed for a structurally-related 
triterpenoid, methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate (CDDO-Me), 
which is currently in clinical trials for treatment of leukemia. Celastrol, a naturally 
occurring triterpenoid acid from an ivy-like vine exhibits anticancer activity 
against bladder cancer cells. Celastrol decreased cell proliferation, induced 
apoptosis and decreased expression of specificity protein (Sp) transcription 
factors Sp1, Sp3 and Sp4 and several Sp-dependent genes like Fibroblast 
growth factor receptor 3 (FGFR3). In vivo studies using KU7 cells as xenografts 
showed that celastrol represents novel class of anticancer drugs that acts, in 
part, through targeting downregulation of Sp transcription factors.  
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I. INTRODUCTION 
 
Cancer is a leading cause of death worldwide and cancer deaths are 
projected to continue rising, with an estimated 12 million deaths in 2030 
according to World Health Organization statistics. In 2007, world wide cancer 
deaths accounted for 7.6 million deaths and more than 12 million people were 
diagnosed with cancer. Cancer is the second most common cause of death in 
the US, exceeded only by heart disease and cancer accounts for nearly 1 of 
every 4 deaths. It is estimated that 1,479,350 new cancer cases will be 
diagnosed in 2009 and about 562,340 Americans are expected to die of this 
disease i.e., more than 1,500 people a day. The National Cancer Institute 
estimates that approximately 11.1 million Americans with a history of cancer 
were alive in January 2005; some of these individuals were cancer-free, while 
others still had evidence of cancer and may have been undergoing treatment 
(1). Furthermore, reports suggest that autopsies of individuals who died of ‘non-
cancer’ causes of death often reveal microscopic colonies of cancer cells, known 
as in situ tumors. It has been estimated that more than one-third of women aged 
40 to 50, who did not have cancer-related disease in their life-time, were found 
at autopsy with in situ tumors in their breast. Moreover, virtually all autopsied 
individuals aged 50 to 70 had in situ carcinomas in their thyroid gland, whereas 
only 0.1% of individuals in this age group are diagnosed with thyroid cancer 
during this period of their life. Clearly, in the male population, prostate, lung, 
colorectal, urological cancers followed by melanoma of skin are the prime organ 
sites of cancer incidence, but estimated cancer deaths are due to lung, prostate, 
colorectal, pancreatic cancer and leukemia’s (Table 1).  
 
This dissertation follows the style of Cancer Research. 
 
  
                                                                                                                                        2 
 
 
 
In females, breast, lung, colorectal, uterine and lymphomas are the major 
organ cancers, but the estimated deaths are primarily due to lung, breast, 
colorectal, pancreatic and ovarian cancers (Table 1) (2) (3). Bladder and 
pancreatic cancers will be the major focus of this section. 
Bladder and pancreatic cancer incidence 
 
 Bladder cancer develops in tissues of the bladder (the organ that stores 
urine) and most bladder cancers are transitional cell carcinomas that begin in 
cells that normally form the inner lining of the bladder. Other types include 
squamous cell carcinoma (cancer that begins in thin, flat cells) and 
adenocarcinoma (cancer that begins in cells that produce mucus). Cells that 
form squamous cell carcinoma and adenocarcinoma develop in the inner lining 
of the bladder as a result of chronic irritation and inflammation. Bladder cancer is 
the fifth most common cancer in the United States (Figure 1) and, on a per 
capita basis, is the most expensive cancer from diagnosis to death because of 
disease recurrence,extended surveillance and repeated use of endoscopic and 
intravesical therapies (4).           
In 2009 it is estimated that there will be 70,980 cases of bladder cancer in 
the United States and 14,330 patients will die from this disease. Bladder cancer 
incidence is nearly four times higher in men than in women and more than two 
times higher in white men than in African American men. Mortality rates have 
recently stabilized in men after decreasing for most of the past three decades; 
rates have been declining in women since 1975 (1). 
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Figure 1. Leading sites of new cancer cases and deaths 2009 estimates (1).  
 
An estimated 42,470 new cases and an estimated 35,240 deaths due to 
pancreatic cancer are expected to occur in the US in 2009. Incidence rates for 
pancreatic cancer have been stable in men since 1993 and have been 
increasing in women by 0.6% per year since 1994. Based on histological 
grading, pancreatic carcinomas are classified as adenocarcinomas, intraductal 
papillary mucinous neoplasm (IPMN) and pancreatoblastomas.   
Cellular and molecular mechanisms of cancer formation 
 
Cancer is characterized by uncontrolled growth and spread of abnormal 
cells. Cancer is caused by both external factors (tobacco, infectious organisms, 
chemicals, and radiation) and internal factors such as inherited mutations, 
hormones, immune conditions, and mutations that occur from metabolism (5). 
These causal factors may act together or in sequence to initiate or promote 
carcinogenesis. Ten or more years often pass between exposure to external 
factors and detectable cancer.  
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It is widely accepted that cancer arises in a multistep fashion and that 
environmental exposure, particularly to physical, chemical, and biological 
agents, is a major etiological factor. Besides chemicals, radiation, and viruses, 
other influences (e.g., genetic, hormonal, nutritional, and multifactor interactions) 
are also involved.  Experimental cancer models suggest that at least three steps 
are important for tumor formation, namely initiation, promotion, and progression. 
The process of oncogenesis has been studied only indirectly in humans; 
measurements of age-dependent cancer incidence have shown that the rate of 
tumor development is proportional to the fourth to sixth power of elapsed time, 
suggesting that four to six independent steps are necessary (6) (7). Several well 
studied cancer models of human epithelial cell carcinogenesis affirm that tumor 
formation involves multiple steps and molecular events (8):  
1. Tumor initiation. The first stage of initiation involves accumulation of genetic 
changes in a single cell as suggested by Knudson and Nowell (9).  Initiation 
occurs after exposure to mutagens and results in almost no observable changes 
in the cellular tissue morphology but it confers an increase in susceptibility to 
cancer formation. Initiation corresponds to the introduction of mutation and 
during the initiation phase mutant cells proliferate very slowly (10). Cancer 
initiation results from exposure to mutagens such as X-rays and this result in 
heritable cellular change that do not significantly change cellular or tissue 
morphology but confer a long-term increase in risk of cancer development. The 
initiation stage of mouse skin carcinogenesis involves genetic damage in the 
form of covalent adducts between the initiator and DNA and these changes 
ultimately lead to mutations in critical target stem cell genes. The Ha-ras and to 
a limited extent, N-ras oncogenes have been identified as target genes for 
certain tumor initiators (11). 
2. Tumor promotion. Tumor promotion involves non-mutagenic tissue 
disruption by wounding or inflammation resulting in formation of a non-malignant 
tumor which may regress without further stimuli. This phase is featured by 
  
                                                                                                                                        5 
 
 
 
enhanced cellular proliferation and localized increases in vascular density and 
blood flow. The promotion step results in formation of a localized altered cell 
population that displays a non-malignant, self-limited growth that may regress if 
the promoting stimulant is withdrawn. Growth in this lesion is limited by diffusion 
of oxygen as the precancerous cell expansion carries proliferating cells further 
away from blood vessels. Tumor promoters may cause up regulation of some 
receptor signaling pathways such as epidermal growth factor receptor (EGFR) 
(12). In contrast to initiators, tumor promoting agents usually cause dramatic 
morphological and biochemical effects that are reversible in the absence of 
treatment. In this promotion phase, the initiated cell expands clonally to give rise 
to a population of initiated cells. When the initiated cells acquire further genetic 
changes required for malignant phenotype, the third phase of malignancy occurs 
and this includes events such as clonal evolution of tumors after malignant 
transformation. 
Clonal selection of partially altered cells in the pathway to cancer can 
substantially increase the population of cells that have acquired some of the 
mutations critical for carcinogenesis, thus increasing the probability that a subset 
of these cells will acquire the remaining mutations required for malignant 
transformation. There is evidence that clonal expansion of premalignant cells is 
a feature of carcinogenesis in many tissue and organ sites (13). 
3. Tumor progression and malignant transformation. Tumor progression and 
malignant transformation requires some additional cellular disruption although 
most changes in this phase do not require additional external stimulus. In the 
final progression step, the tumor transitions into limitless, invasive growth. A well 
studied colon carcinogenesis model by Vogelstein and his colleagues show that 
tumor progression involves of successive waves of clonal selection (14) where 
genetic alterations cause permanent genetic instability with a high rate of 
chromosomal or base modifications resulting in morphological and karyotypic 
changes that transform pre-neoplastic cells into neoplastic cells.  Other reports 
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suggest that clonal expansion of partially altered cells on their way to 
malignancy, do not require genomic instability and this is relevant for explaining 
colon cancer rates in human populations (13).  
4. Tumor invasion and metastasis. The distant settlement or metastasis of 
cancer cells from their site of origin to distal locations are the cause of 90% of 
human cancers deaths (15). The phase of invasion involves progression of 
neoplastic cells to malignant cells with the addition of genetic and epigenetic 
changes resulting in more aggressive characteristics. These cells acquire the 
ability to secrete proteases that dissolve barriers such as basement membranes 
in host cells and they also acquire the ability to undergo angiogenesis. Proteins 
that tether cells to their surroundings are altered in the phenotype possessing 
invasive and metastatic capabilities. These characteristics include; loss of CAM 
(cell-cell adhesion molecules), inactivation of E-cadherin, β-catenin, changes in 
integrin expression, up regulation and activation of extracellular proteases such 
as matrix metalloproteinases (MMP) and kallikrein (16).   
Many human cancers exhibit age-dependent increase in incidence that 
involves four to seven rate-limiting, stochastic events. Hence the succession of 
genetic changes, each conferring one or another type of growth advantage leads 
to a progressive conversion of normal human cells into cancer cell.  Overall six 
essential alterations in cell physiology dictate malignant growth (Figure 2); Self-
sufficiency of growth signals, insensitivity to growth inhibitory signals, evasion of 
programmed cell death, limitless replicative potential, sustained angiogenesis, 
and tissue invasion and metastasis are the acquired characteristics of cancer 
cells (16). 
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Figure 2. Acquired characteristics of cancer cells. 
 
1. Self sufficiency of growth signals. Many oncogenes act by mimicking 
normal cellular growth signaling pathways and tumor cells generate their own 
internal growth signals that are not dependent on the surrounding environment. 
This autonomous functioning provides autocrine stimulation within the tumor 
cells. For example, receptor tyrosine kinases are overexpressed, amplified and 
dysregulated in many cancers. EGFR is overexpressed in many cancers of 
epithelial origin and this receptor is known for autocrine signaling as well as 
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crosstalk with other kinase signaling cascades. The frequency of overexpression 
of EGFR in human head and neck carcinomas is reported to be 100% (17). 
Heterotypic signaling within diverse tumors further explains their ability of to co-
opt their neighbors to release growth-stimulating signals suggesting oncogenic 
crosstalk between signaling cascades. 
2. Insensitivity to anti-growth signals.  Anti- proliferative signals ensure 
cellular quiescence and tissue homeostasis that satisfies the normal 
physiological needs of the cell.  E2F family members play a major role during the 
G1/S transition in the mammalian cell cycle. The Rb tumor suppressor protein 
(pRb) binds to the E2F-1 transcription factor to prevent interaction of this TF with 
the transcription machinery. In the absence of or disruption of pRb, E2F-1 (along 
with its binding partner DP-1) mediates the trans-activation of E2F-1 target 
genes that facilitate the G1/S transition and S-phase resulting in decreased 
response to inhibitory signals. Loss or mutation of pRb is involved in the etiology 
of many tumors including retinoblastomas and osteosarcomas. The 
Adenomatosis Polyposis Coli (APC) protein normally forms a complex with 
glycogen synthase kinase 3beta (GSK 3β) and axin via interactions with the 
20AA and SAMP repeats. Casein kinase 1 (CK1) catalyzes phosphorylation of 
β-catenin and there is subsequent phosphorylation by GSK-3β. This targets β-
catenin for ubiquitination and proteasome-dependent degradation degradation 
and thereby inhibiting nuclear uptake of this protein, where it acts as a 
transcription factor for genes involved in cell proliferation. Inactivation of APC/-
catenin pathway inhibits differentiation of colonic crypts and hence insensitivity 
to anti-growth signals forms a feature of many cancers (17). 
3. Evading apoptosis. Programmed cell death is a major mechanism for 
maintaining homeostasis within a population of cells and resistance to apoptosis 
is a hallmark of most types of cancer (Figure 2). The tumor-suppressor protein 
p53 accumulates when DNA is damaged due to a chain of biochemical 
reactions.  p53 prevents cells from replicating by terminating the cell cycle at G1, 
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or interphase for repair; however if damage is extensive and repair efforts fail 
p53 also induces apoptosis. Dysregulation of or p53-dependant genes may 
block apoptosis and lead to formation of tumors. In mammalian cells there is a 
balance between pro-apoptotic (BAX, BID, BAK, or BAD) and anti-apoptotic 
(Bcl-Xl and Bcl-2) members of the Bcl-2 and this balance is proportional to the 
pro-apoptotic protein homodimers that form in the outer-membrane of the 
mitochondrion. These homodimers are required to make the mitochondrial 
membrane permeable for the release of caspase activators such as cytochrome 
c (17). Resistance to apoptosis by cancer cells is acquired after the loss of p53 
tumor suppressor gene (17).  
4. Limitless replicative potential. Cells in culture have a finite replicative 
potential and after a certain number of cell divisions they stop dividing and enter 
into senescence (18). However, disabling pRb or p53 tumor suppressor genes 
enable cells to continue multiplying for additional generations until they enter a 
second phase called crisis. At this stage cells undergo massive cell death, 
karyotypic disarray, end to end fusion of chromosomes resulting in variant 
immortalized cells that have acquired the ability for limitless replication (19).  
Telomeres are repeat sequences at the end of chromosomes that protect the 
genetic stability during DNA replication. Telomeres are lost during each cell 
division, and this increases chromosomal instability and cellular senescence. 
Telomere maintenance is evident in all types of malignant cells and 90% of 
cancers exhibit increased telomerase activity that adds hexanucleotide repeats 
to the ends of telomeric DNA  (20).  
5. Sustained angiogenesis. Once a tissue is formed, the growth of new blood 
vessels (angiogenesis) is transitory and carefully regulated. Vascular endothelial 
growth factor (VEGF) and fibroblast growth factors (FGF) are key angiogenic 
proteins and integrin signaling also contributes to the regulatory balance of 
angiogenesis. The ability to induce and sustain angiogenesis in cancer cells 
appears to be acquired in a discrete step during tumor development. Many 
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tumors overexpress VEGF and FGF proteins when compared to normal tissue 
and endogenous inhibitors of angiogenesis like thrombospondin, tumstatin, 
endostatin are downregulated (2). The VEGF gene is under complex 
transcriptional control and the role of specificity protein (Sp) transcription factors 
in the regulation of VEGF has been reported and will be discussed later in this 
section (21). 
6. Tissue invasion and metastasis. Invasion and metastasis are hallmarks of 
an advanced stage of cancer and are associated with poor patient prognosis. 
This phase is characterized by loss of cell adhesion, gain of motility and 
proteolysis. Epidermal growth factor EGF-mediated downregulation of focal 
adhesion kinase (FAK) is necessary for early dissemination and cell detachment 
from the primary tumor. At secondary sites, interactions with extracellular matrix 
via integrins activate FAK and mediate cell attachment which is necessary for 
establishment of metastatic tumors. Loss of E-cadherin is also observed in 
invasive human tumors and its re-expression can reverse the invasive 
phenotype and restores epithelial morphology (22). Recruitment of PLC1, 
interaction of mitogen activated protein kinase (MAPK) with the cytoskeletal 
machinery and RHO family of GTPases regulate the motility of tumor cells. 
Proteolysis of the extracellular matrix barriers is attributed to matrix 
metalloproteinases (MMPs) which are enhanced and facilitate tumor invasion in 
vitro and in vivo. Overexpression of  urokinase plasminogen activator (uPA) 
correlates positively with invasive potential for a variety of cancers because uPA 
plays a key role in tumor invasion and metastasis by its ability to initiate 
proteolytic cascade (23) (24).  Apart from these hallmarks of cancer cells, 
genomic instability is an enabling characteristic that facilitates evolving 
populations of premalignant cells to reach these six biological endpoints.  
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Bladder cancer incidence and classification 
 
Bladder cancer is the fourth most prevalant cancer in males and ninth in 
females. Risk factors include smoking, occupational exposure to aromatic 
amines, consumption of arsenic contaminated water, and chronic infection with 
parasite Schistosoma species, radiation therapy of neighboring organs and 
therapeutic use of alkylating agents. The term ‘superficial bladder cancer’ has 
been used to describe tumors that have not invaded into muscularis propria. 
This designation includes noninvasive papillary urothelial carcinoma (pTa), 
carcinoma in situ (CIS) (pTis), and tumor invading lamina propria (pT1). It is now 
recommended that the term ‘superficial’ be entirely eliminated from bladder 
cancer nomenclature (25). 
 The 2002 revision of the American Joint Committee on Cancer/ 
International Union against Cancer (AJCC/UICC) TNM systems is the most 
widely used staging system at this time. Seventy to eighty percent of diagnosed 
bladder tumors are non-muscle invasive tumors (Stage Ta, Tis- [Carcinoma in 
situ/CIS], T1), 25% are muscle invasive (Stage T2, T3), and 5% are metastatic. 
Recurrence is observed in 60-70% of muscle invasive tumors of which 20-30% 
progress to a higher stage or grade 4. The frequencies of nonmuscle invasive 
bladder cancer at stages Ta, T1 and Tis are 60, 30 and 10% respectively (26);  
90% of the tumors are of transitional (urothelial) cell type and the rest are 
adenocarcinomas, small cell carcinomas and squamous cell carcinomas.  
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Table 1. The staging of urothelial carcinoma (27). 
   
The urinary bladder consists of a transitional epithelial layer covering the 
inner surface of bladder and the lamina propria is a thin layer of loose 
connective tissue lies beneath the epithelium. The next layer is sub-mucosa 
which acts as structural support for the mucosal layer. The third layer is 
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muscularis mucosa which is formed by interlacing three smooth muscles 
together known as detrusor muscle. The outermost layer of the bladder wall is 
called is adventitia (28).  
The specific features, in brief, of various stages of bladder cancer are 
outlined below: 
1. Stage pT0 carcinoma is defined by no evidence of residual carcinoma after 
biopsy or transurethral resection (TUR) specimens. The incidence of pT0 is 
nearly 10%. In patients with pT0 carcinomas, the recurrence free, overall 
survival ranges from 84-88%. 
2. Stage pTa carcinoma, based on the 2002 TNM (tumor, lymph node and 
hematogenous metastasis) staging, pTa carcinoma is defined as noninvasive 
papillary carcinoma and is distinguished from pT1 cancer by the absence of 
lamina propria invasion.  
3. Stage pT1 carcinoma is defined by invasion into lamina propria but not 
muscularis propria (Table 1). pT1 carcinomas invade the underlying stroma as 
single cells or irregularly shaped nests of tumor cells. If the tumor invasion, in 
patients, is greater than 1.5 mm, the 5 year progression free survival is 67% and 
if the invasion is less than 1.5 mm, then the survival is 93%.  
4. Stage pT2 carcinoma is characteristized by tumor invasion into muscularis 
propria. Ten year recurrence free survival rates range from 72-84% for lymph 
node negative bladder cancer patients. 
5. Stage pT3 carcinoma is defined by tumor invasion into perivascular soft 
tissue. (Table 1) The presence of adipose tissue is well documented.  
6. Stage pT4 is defined by tumor invasion into an adjacent organ such as the 
uterus, vagina, prostate, pelvic wall or abdominal wall. Overall survival of these 
patients was only 10% and the overall survival for patients with prostatic stromal 
involvement was 38% and overall relative 5 year survival is only 15% (27).   
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Animal models for bladder cancer 
                                                                                                                            
 With the exception of transgenic rodent models, carcinogen-induced 
bladder tumors are not observed in rodents until 8-12 months after initiation. 
Bladder cancer can also be induced by pellet implantation, urinary caliculi, 
radiation and chemicals as discussed in this section (29).  
Spontaneous bladder tumors are extremely rare and most wild type strains of 
rodents do not develop spontaneous bladder cancer, although some tumors 
have been observed in older animals. Exceptionally high levels of urothelial and 
ureteric neoplasms have been reported in two rat stains, Brown/Norway 
(BN/RijHsd) and Dark Agouti (DA/OlaHsd), and they were associated with the 
presence of calculi (30). Some spontaneous bladder tumors in rats can be 
explained by infection with the bladder parasite Trichosomoides crassicauda 
(31). Spontaneous bladder tumors in other rodent species including hamsters, 
guinea pigs, and rabbits are also rare (32).  Yamagiwa and Ichikawa, in 1918, 
were the first to prove that cancer could be induced in experimental animals by 
chemical means (33).  The induction of bladder cancer in dogs by 2 –
naphthylamine was reported by Hueper in 1938 and this established the 
experimental basis of bladder carcinogenesis (34). Early attempts to induce 
tumors in mice by chemicals were unsuccessful until Armstrong and Bronser 
(1944) induced papillomas and carcinomas through the oral administration of 2 -
acetylaminofluorene (AAF) in CBA strain mice (35): 
1. Pellet implantation and urinary calculi. During the past three decades, 
numerous rodent bladder carcinogens have been identified and their activity has 
been associated with the appearance of urinary calculi. The presence of foreign 
bodies within the lumen of the bladder can cause irritation or trauma to the 
urothelium and stimulate mitotic activity, thereby causing nodular and papillary 
hyperplasia (36). This technique involves surgical implantation of pellets into the 
lumen of the rodent bladder. The pellets containing paraffin or cholesterol  have 
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been used and it was hypothesized that they would remain inert in the bladder 
lumen and it was also assumed that the bladder epithelium was incapable of 
metabolizing these chemicals (37). In 1979 Jull demonstrated that insertion of 
pellets alone (without enclosed carcinogen) into the mouse bladder resulted in 
bladder cancer. In addition, surgical procedure, to implant the pellet, produced 
nodular and papillary hyperplasia. Chemicals used in the pellet formulation 
include uric acid, calcium oxalate, uracil, thymine and melamine (38).  
2. Bladder Carcinogens:  
i. 2 -Acetylaminoflourene (AAF) is a pluripotent carcinogen inducing tumors in 
liver, pancreas, breast, and skin, fore stomach and ear duct apart from 
urothelium. Three chemicals are particularly effective given the appropriate 
route, dose and appropriate strain of animal. Chemicals that produce 100% 
incidence of bladder tumors and are complete carcinogens include N-[4-(5-nitro-
2- furyl)-2-thiazolyl] formamide (FANFT), N-butyl-N-(4-hydroxybutyl) nitrosamine 
(BBN) and N-Methyl-N-nitrosurea (39). The nitrofuran FANFT specifically 
induces urinary bladder tumors in the rat, mouse, hamster and dog. FANFT is 
deformylated in kidney and liver to give 2 -amino-4-(5-nitro-2-furyl) thiazole 
metabolite which is subsequently excreted (40). FANFT is incorporated into the 
diet and induction of bladder cancer requires 8 to 11 months (41). Tumors 
induced by this compound are predominantly transitional cell carcinomas (TCC), 
with a large proportion exhibiting squamous cell differentiation. 
ii. N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) is widely used as bladder 
carcinogen and tumors are induced in rats and mice resemble their human 
counterparts (42). BBN is metabolite of symmetric dibutylnitrosamine (DBN) and 
is a bladder specific carcinogen in rats, mice and dogs. One hundred percent 
incidence of tumors can be induced by continuous administration of BBN in 
drinking water or by intra-vesicle instillation. BBN is a genotoxic compound and 
is rapidly oxidized to N-butyl-N-(3-carboxybutyl) nitrosamine (BCPN) which is 
also a bladder carcinogen and comes in contact with the urothelium via urinary 
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excretion. BCPN binds covalently to cellular macromolecules and  acts as an 
initiator of carcinogenesis and in vitro studies confirm that this compound 
induces transformation of rat urothelial cells (29).  
iii. N-Ethyl-N-(4-hydroxybutyl) nitrosamine (EHBN) is a genotoxic compound 
more potent than BBN. EHBN is metabolized by hepatic enzymes to give N-
ethyl-N-(3- carboxypropyl) nitrosamine which is excreted in urine (45). 4-
Ethylsulfonylnaphthalene-1-sulfonamide (ENS) is a carbonic anhydrase 
inhibitor that produces alkaline, hypoosmolar urine with crystalluria and calculi 
formation. Benzidine, 3, 3´-dichlorobenzidine, 2 -naphthylamine, 4- 
aminobiphenyl, 2 -acetylaminofluorene, phenacetin, and sodium ο-
phenylphenate are also urinary bladder carcinogens. Bracken fern (Pteridium 
aquilinum) also induces upper alimentary tract and bladder cancer in a number 
of species (43).  
iv. Dimethylarsinic acid (DMA) is a rat urinary bladder carcinogen, but is not 
carcinogenic in mice. The carcinogenic mode of action involves cytotoxicity 
followed by regenerative cell proliferation. Dietary DMA does not produce urinary 
solids or significant alterations in urinary composition. The cytotoxicity is due to 
formation of a reactive metabolite, which may be dimethylarsinous acid (DMA), 
and this is concentrated and excreted in the urine (44). 
3. Promoting agents.  Multistage models of bladder carcinogenesis involves 
initiation of neoplastic change in cells by a threshold dose of carcinogen, 
followed by alteration of these latent tumor cells into an autonomous cancer by 
additional doses of the same and/other carcinogens, and/or promoting agents. 
Animals exposed subsequently to promoters will develop bladder cancer (45) . 
Urinary bladder promoters can be broadly classified into: 1) sodium and 
potassium salts associated with increased concentration of urinary levels of 
sodium and potassium ions and alkaline urine 2) urolithiasis inducing agents 3) 
antioxidants 4) anticancer drugs 5) amino acids 6) drugs and other compounds 
(46).   
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4. Radiation. Ionizing radiation also causes bladder cancer in humans. For 
example X-rays induce preneoplastic urothelial hyperplasia and development of 
urothelial carcinoma in rodents. A single dose of radiation generated from a 
linear accelerator induced hyperplasia of the urothelium in mice, 3-19 months 
after exposure (47).  
Genetic models for bladder cancer 
Transgenic or gene targeted mice, are frequently used as models to 
determine specific genetic changes, including oncogene 
overexpression/mutation or tumor suppressor gene loss, that increases the risk 
for neoplasic progression. These animals can be used to investigate cooperation 
of two or more genes during bladder carcinogenesis and how the genetic 
signature of a neoplasm correlates with specific aspect of tumor development 
(48).  A tumor suppressor gene protects cells from one or more steps required 
for tumor formation, growth and inactivating mutations of tumor suppressor 
genes enhance cancer progression and this usually involves multiple genetic 
changes. The p53 tumor-supressor protein, is lost in 70% of colon cancers, 30-
50% of breast and 50% of lung cancers due to homologous loss (49). Wild-type 
p53 binds to DNA and activates several genes such as p21 which in turn binds 
to G1-S phase cyclin dependent kinases and inhibit their effects on cell cycle 
progression.  Phosphatase and tensin homolog (PTEN), is another tumor 
suppressor that inactivates the activity of phosphoinositide 3-kinase (PI3K), 
which is essential for several pro-survival pathways (50). Mutations of p53 or  
PTEN,  are among the most frequent causal events in many cancers, and their 
combined inactivation has profound consequences for tumor development (51) 
(52). The oncogene Ras encodes for small GTPases involved in cell growth, 
survival, differentiation and activation of Ras mutations or overepxression 
enhances the role of tumor formation. Some Ras mutations result in constitutive 
activation of signaling associated with growth and survival.  Activating Ras 
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mutations are found in 20-25% of all humans up to 90% in gastrointestinal and 
colorectal cancers  (53). 
Transgenic mice carrying the human C-Ha-ras proto-oncogene, v-Ha-ras 
transgenic mice, pim-1 transgenic mice, and several knockout strains of mice 
deficient in tumor suppressor genes such as p53 exhibit increased susceptibility 
to carcinogens (54). p53 knockout mice are more sensitive to N-butyl-N-(4-
hydroxybutyl) nitrosamine (BBN)-  induced urinary bladder tumor formation 
compared to the parental C57Bl/6 mice (55). A transgenic rat line carrying three 
copies of the human c-Ha-ras proto-oncogene and its original promoter is highly 
susceptible to BBN-induced carcinogenesis and is utilized as a rat model for 
genetic analysis of bladder tumor development (56). Tsuda et al generated 
transgenic rats with the same human c-Ha-ras protooncogene used for 
generation of transgenic mice called Hras128 and the rat model is highly 
susceptible to BBN-induced bladder carcinogenesis. 
Cory-Abate-Shen and colleagues recently demonstrated for the first time 
that the combined deletion of p53 and PTEN in bladder epithelium leads to 
invasive bladder cancer in a novel mouse model. Combined inactivation of p53 
and PTEN were reported to be major causal factors that predicts poor outcome 
of invasive bladder cancer patients (57). Surgically an adenovirus expressing 
Cre recombinase was delivered into the bladder lumen of adult male mice to 
induce conditional deletion of p53 and PTEN alone or together in the epithelium.  
p53flox/flox; PTENflox/flox mice produced large tumors with features of 
carcinoma in situ (CIS), as well as high-grade invasive carcinoma with areas of 
transitional cell, squamous, and sarcomatoid carcinoma. Furthermore, the 
transgenic mouse study documents synergistic interaction of p53 and PTEN 
deletion that lead to deregulation of mammalian target of rapamycin (mTOR) 
signaling, and this is correlates with the ability of rapamycin to block bladder 
tumorigenesis in preclinical studies.  
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A murine bladder cancer model in which the uroplakin II gene promoter 
drives the urothelial expression of EGFR in transgenic mice has also been 
reported (58). Three established transgenic lines express higher levels of EGFR 
mRNA and protein in the urothelium compared to the nontransgenic controls. 
The overexpressed EGFR was functionally active due to constitutive 
autophosphorylation and activation of downstream mitogen-activated protein 
kinases  The luminal surface of mammalian urothelium is covered with 
numerous plaques composed of semi-crystalline, hexagonal arrays of 12-nm 
protein particles called uroplakins (59)  and the urothelial plaque associated 
proteins or uroplakins are excellent markers for identifying  urinary carcinomas 
(60). Uroplakin ablation elevates urothelial permeability as uroplakins perform 
the permeability barrier function (61).  
Phenotypically, the urinary bladders of all transgenic rodents developed 
simple urothelial hyperplasia. Coexpression of the EGFR and the activated Ha-
ras oncogene in double transgenic mice did not enhance tumerogenicity 
compared to effects observed with H-ras oncogene alone. However, when H-ras 
was coexpressed the SV40 large T antigen, EGFR accelerated tumor growth 
and converted the carcinoma in situ observed in of SV40 largeT mice into high-
grade bladder carcinoma (62). This study indicates that overexpression of 
urothelial EGFR induces proliferation but not frank carcinoma formation and that 
EGFR and Ha-ras, both of which act on some of the same kinase pathways, 
stimulate urothelial hyperplasia, but not urothelial tumorigenesis. Moreover, it 
was also reported that EGFR overexpression can cooperate with p53 and 
mutated pRB to enhance bladder carcinogenesis (63). 
This same group in 2007 reported that hyperactivation of Ha-ras 
oncogene triggered bladder tumorigenesis suggesting that overactivation of Ha-
ras is both necessary and sufficient to induce bladder tumors (64). Activation of 
H-ras by an activating point mutation, or intensified signaling from fibroblast 
growth factor receptor 3 (FGFR3) (Figure 3) is frequently observed in human 
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bladder tumors. These RTKs can functionally overactivate the ras pathway in the 
presence or absence of ras mutations (65). 
 
Figure 3. Schematic diagram of signaling pathway underlying the 
formation of low-grade, noninvasive papillary urothelial tumors (65). 
Prognostic markers for bladder cancer 
Prognosis is a prediction of a disease outcome. The depths of infiltration, 
differentiation grade and histological staging (Table 1) have been the most 
important prognostic parameters for predicting bladder tumor progression and 
survival. Patients are diagnosed and monitored with urethrocystoscopy, 
cytology, and imaging of the upper urinary tract. Urethrocystoscopy is the 
examination of interior of urinary bladder; this technique is considered the gold 
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standard for bladder examination however, certain lesions, particularly small 
areas of carcinoma in situ (CIS) are often not detected. Cytological examination 
of bladder tissue is also used extensively and is useful for detecting high-grade 
tumors and CIS; however, it has a median sensitivity of only 35% and median 
specificity of 94%. Predicting which invasive tumors will or will not recur or 
metastasize is crucial for selecting initial therapies and for counseling patients. 
Tumor markers when incorporated into clinical practice add prognostic 
information to the conventional ‘Tumor, Node, Metastasis’(TNM) grading 
systems in terms of treatment response and prognosis (66).  The limitations of 
cytology and the invasiveness of urethrocystoscopy for detecting bladder cancer 
have generated interest in developing other noninvasive diagnostic tools 
including urinary biomarkers that aid in detection and follow up of bladder cancer 
(67). 
1. Fluorescence in situ hybridization (FISH). The FISH technique consists of 
coupled antibodies and fluorochromes to detect chromosomal anomalies in the 
exfoliated bladder cells. A commercially available test, the UroVysionTM Bladder 
Cancer Kit (Vysis Inc, Downers Grove, IL, USA), has probes for chromosome 3, 
7, and 17, and a locus-specific probe for 9p21.  The overall cancer detection 
sensitivity of FISH varies between 69 and 87% and the detection of carcinoma in 
situ (CIS) is close to 100%. The specificity of FISH is high (89–96%) and is 
comparable to cytology. Another advantage of FISH is that it is unaffected by 
Bacillus Calmette-Guerin (BCG) therapy and therefore this technique can be 
used for surveillance of patients treated with intravesical BCG (68). A 
disadvantage of the FISH procedure is the labor intensity and requirement of an 
extensive learning curve before it can be used reliably and these results in 
minimal use of the FISH assay.    
2. Microsatellite analysis. Microsatellites are highly polymorphic, short, tandem 
DNA repeats found in the human genome. Two types of microsatellite alterations 
can be found in many cancers namely, Loss of heterozygosity (LOH), which is 
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an allelelic deletion, and somatic alteration of microsatellite repeat length (69). In 
bladder cancer, most mutations are in the form of LOH. Microsatellite alterations 
in exfoliated cells in urine are detected by a polymerase chain reaction (PCR) 
using DNA primers for a panel of known microsatellite markers. This test has 
good overall sensitivity and specificity, but is complex and expensive and this 
limits its clinical usage.  
3. Telomerase. Telomeres are repeat sequences at the end of chromosomes 
that protect genetic stability during DNA replication. Telomeres are lost during 
each cell division, and this increases chromosomal instability and cellular 
senescence. Bladder cancer cells express telomerase, an enzyme that 
regenerates telomeres at the end of each DNA replication and therefore sets the 
cellular clock to immortality. Overall sensitivity and specificity of the telomerase 
assay, varies between 70 to 100% and 60 to 70%, respectively (70).  The 
telomerase assay has good sensitivity but lacks sufficient specificity and test 
results can be influenced by inflammation and age. These disadvantages make 
it a suboptimal test for detection of bladder cancer. 
4. BTA-TRAKTM and BTA-statTM (Alidex Inc, Redmond, WA, USA). These are 
both versions of the bladder tumor antigen assay that measures complement 
factor H–related protein in urine. These tests exhibit sensitivity slightly higher 
than that of cytology, however specificity is lower due to false-positive test 
results in patients with benign genitourinary conditions, inflammation, infection, 
or haematuria  (71).  
5. Hyaluronic acid (HA). HA is a glycosaminoglycan and a normal component 
of tissue matrices and body fluids. In tumor tissues, elevated HA is primarily 
localized to tumor stroma, in bladder carcinoma and elevated HA levels have 
been detected in urinary samples of bladder cancer patients (72). The 
concentration of HA is also associated with tumor metastases and hyaluronidase 
(HA-ase); an enzyme that cleaves HA into fragments. HA-ase levels are 
elevated in bladder tumor tissue, and an increase is correlated with tumor grade 
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(73). In conclusion, the test has high sensitivity to detect both low- and high-
grade/stage tumors indicating that the HA-HA-ase is a promising assay that 
deserves further study. 
6. Nuclear matrix protein 22 (NMP22). NMP22 is a nuclear matrix protein that 
regulates mitosis and in tumor cells the nuclear mitotic apparatus is elevated 
and NMP22 is released from tumor cells. Grossman et al (74) investigated the 
capability of this test for detecting malignancy in 1331 patients with risk factors 
of bladder cancer; the assay sensitivity was 55.7 and specificity was 85%.  
7. Cytokeratins. These are intermediate filaments and their main function is to 
enable cells to withstand mechanical stress. In humans 20 different cytokeratin 
isotypes have been identified. Cytokeratins 8, 18, 19, and 20 have been 
associated with bladder cancer (75). CYFRA 21-1 is a soluble fragment of 
cytokeratin 19 and is used as a urinary marker for bladder cancer. CYFRA21-1 
levels are strongly influenced by benign urological diseases, intravesical 
instillations and do not detect early stage bladder cancer. 
8. Survivin. It is a member of the inhibitor of apoptosis (IAP) family of proteins 
that regulate cell death. Overexpression of survivin inhibits extrinsic and intrinsic 
pathways of apoptosis (76). Survivin is expressed during fetal development but 
not in terminally differentiated adult tissues (77) and is one of the most 
commonly overexpressed genes in cancer. In bladder cancer, survivin is found 
in urine, and levels of survivin are associated with disease recurrence, stage, 
progression, and mortality (78) . Survivin identified 71.4 and 69.6% of the 
patients with long or short recurrence-free periods, respectively.  Urinary survivin 
seems predictive for bladder cancer recurrence and can be helpful in preventing 
unnecessary urethrocystoscopies. 
9. Growth factors. Growth factors such as EGFR, vascular endothelial growth 
factor (VEGF), tumor necrosis factor alpha (TNF-a), type 1 insulin like growth 
factor receptor (IGFR), fibroblast growth factor receptor (FGFR)- 3, and heparin-
binding epidermal growth factor are overexpressed in multiple cancers. 
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Members of the EGFR family, a type I tyrosine kinase, are involved in various 
forms of cancers and serve as prognostic markers and therapeutic targets (79). 
EGFR is considered one of the most important oncogenes in bladder cancer 
development and high levels of EGF were found in of certain transitional cell 
carcinomas (TCC)(80). Tumors with elevated expression of high-molecular-
weight cytokeratin and EGFR positive cases were associated with higher 
metastases and shorter patient life span. Increased EGFR and HER2 also 
predict a poor prognosis, and HER4 and FGFR3 are favorable prognostic 
indicators. However, validation studies are required to answer many remaining 
questions on the prognostic value of growth factors and their receptors. 
Current treatments for bladder cancer 
Surgery, alone or in combination with other treatments, is used in more 
than 90% of bladder cancer cases. Superficial, localized cancers may also be 
treated by administering immunotherapy or chemotherapy directly into the 
bladder. Chemotherapy alone or combined with radiation before cystectomy 
(bladder removal) has improved treatment results.  
1. Transurethral Resection (TUR). TUR is used to surgically remove 
cancerous tissue from the bladder and it remains the mainstay for the diagnosis 
and treatment of Ta and T1 bladder cancer. After this procedure, the 10-year 
disease-free specific survival for Ta tumors is 85%, and for T1 tumors it is 
70%.5. Biopsy samples should be taken from the bladder neck and prostate to 
assess whether the tumor has spread within the bladder neck musculature, 
prostatic urethra, ducts, and stroma. 
2. Intravesical therapy. This is a treatment procedure where in the therapeutic 
agent is deposited in bladder directly. The high recurrence rate and the 
unpredictability of the progression pattern of bladder cancer have resulted in the 
widespread use of intravesical therapy as a supplement to TUR. Superficial 
bladder cancer lends itself to intravesical therapy owing to direct contact of the 
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chemotherapeutic agent with the bladder mucosa and tumor. Furthermore, some 
agents can be used at high doses with minimal systemic side effects because of 
a lack of absorption. 
3. Early radical cystectomy. The removal of bladder as well as surrounding 
tissues based on the extent of spread of the tumor is called cystectomy. The 
indications for radical cystectomy among patients with superficial bladder cancer 
include high-grade disease recurrence after intravesical BCG and CIS refractory 
to intravesical immunotherapy. The case for performing early cystectomies is 
strengthened by low peri-operative mortality and morbidity, improvements in 
surgical techniques and perioperative care, and increased acceptance of 
orthotopic neobladder as a choice of urinary diversion (81). Radical cystectomy 
remains the standard, accepted treatment for muscle- infiltrating bladder cancer 
(82). 
4. Chemotherapeutic agents. The common chemotherapeutic agents that are 
used for bladder cancer treatment are briefly described: 
i. Methotrexate. It inhibits folic acid reductase which is responsible for the 
conversion of folic acid to tetrahydrofolic acid. At two stages in the biosynthesis 
of purines (adenine and guanine) and at one stage in the synthesis of 
pyrimidines (thymine, cytosine, and uracil), one-carbon transfer reactions occur 
and require specific coenzymes synthesized in the cell from tetrahydrofolic acid. 
Tetrahydrofolic acid itself is synthesized from folic acid and requires the enzyme, 
folic acid reductase. Methotrexate binds the enzyme and inhibits its activity and 
thereby DNA synthesis (83). Methotrexate is used as part of the major 
chemotherapeutic treatment for bladder cancer namely the combination of 
Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC).                                       
ii. Triethylenethiophosphoramide (thiotepa). It is an organophosphorus 
alkylating agent known to cross-link DNA and prevent cells from replicating. 
Thiotepa has a low molecular weight (189 kDa), and is readily absorbed into the 
systemic circulation. A review of nine randomized trials revealed a 61% average 
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bladder cancer recurrence rate with Transurethral Resection (TUR) compared 
with 49% among the patients treated with thiotepa, yielding an overall advantage 
of a 12% decrease in tumor recurrence (84). Thiotepa is rarely used in the US 
because of its high associated risk of myelosuppression (up to 54%).                                           
iii. Doxorubicin (trade name- Adriamycin). It is an anthracycline produced by 
the Streptomyces species. Anthracyclines interact with topoisomerase II (Topo 
II) and inhibit its activity. Topo II  enzyme  controls changes in DNA structure by 
catalyzing the breaking and rejoining of the phosphodiester backbone of DNA 
strands during the normal cell cycle. Topoisomerase inhibitors block the ligation 
step of the cell cycle, generating single and double stranded breaks that harm 
the integrity of the genome (85). These strand breaks subsequently lead to 
apoptosis and cell death. In seven randomized trials, the average recurrence 
rate was 58% with transurethral resection versus 38% with doxorubicin, a 20% 
lowering of tumor recurrence. Toxic side-effects have hampered the use of 
doxorubicin; chemical cystitis has been reported in as many as 56% of patients, 
with a decreased bladder capacity in 16% and hematuria (blood in urine) in 40%. 
Also, systemic reactions, including fever and allergy, have been reported in 5% 
of patients (86). Epirubicin (4'-epi-doxorubicin). Epirubicin is a synthetic 
derivative of doxorubicin, with a a similar therapeutic efficacy to that of 
doxorubicin. However, epirubicin is accompanied by fewer toxic side-effects 
which are generally mild, with the most common being cystitis, hematuria, or 
both (87).  
iv. Mitomycin C. This is an alkylating agent that causes DNA cross-linking and 
is produced by Streptomyces. The most effective dose of mitomycin C is 40 mg 
in 20 ml distilled water which is administered once weekly for 6 consecutive 
weeks (88). Dysuria, cystitis, dermatitis, rash and increased urinary frequency 
have been reported in 41% of the patients. Current data suggest that all current 
intravesical chemotherapeutic agents are similar in efficacy but differ in toxicity.                            
v. Cisplatin. It is  platinum-based chemotherapeutic drug used to treat various 
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types of cancers, including sarcomas, some carcinomas (e.g. small cell lung 
cancer, and ovarian cancer), lymphomas, and germ cell tumors. These platinum 
complexes bind to and cause crosslinking of DNA which ultimately triggers 
apoptosis (programmed cell death). In spite of its efficacy for treating various 
cancers, cisplatin suffers from two major setbacks. First, it is particularly toxic 
against normal tissues and second; many tumors develop resistance or acquire 
resistance to cisplatin-induced chemotherapy. Gemcitabine and Cisplatin (GC) 
are used in combination therapy. Gemcitabine is a pyrimidine (nucleoside) 
analog in which the hydrogen atoms on the 2' carbons of deoxycytidine are 
replaced by fluorine atoms. The drug replaces cytidine, a building block of 
nucleic acid during DNA replication and causes tumor growth arrest since the 
new nucleosides cannot be attached to the ‘anti-metabolite’ nucleoside, resulting 
in apoptosis.                                                                                                                
5. Immunotherapy. Multiple clinical trials have directly compared transurethral 
resection (TUR) alone with TUR plus BCG for tumor prophylaxis. BCG is 
obtained from attenuated live bovine tuberculosis virus, Mycobacterium bovis. 
BCG elicits immune response against residing cancer cells by inducing a variety 
of cytokines, including interferon (interferon-inducible protein (IP-10), interferon 
gamma (IFN-gamma)) and interleukins (IL-12). In addition to cellular immune 
response, BCG also induces cytokines that mediate antiangiogenic responses 
that inhibit future tumor growth and progression (89). Numerous studies with 
BCG combination therapy have demonstrated statistically significant benefits in 
the reduction of bladder cancer recurrence rates and these ranges from 20 to 
57%.  More than 50% of complete responders remain disease free for more than 
5 years from the start of therapy. The effect of BCG in reducing tumor 
progression is controversial due to local and systemic toxic effects (90). 
Intravesical valrubicin, a synthetic analog of doxorubicin, although not commonly 
used in clinical practice, was approved by the FDA for the treatment of BCG-
refractory CIS in patients. Co-treatment of intra vesical BCG and α-2b interferon 
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has demonstrated activity in patients who did not respond to BCG, with a 2-year 
disease-free estimate of 42% in patients with prior BCG failures (91). 
6. Radiotherapy. Brachytherapy is the usage of radiation placed very close to or 
inside the tumor.  A study by Nieuwenhuijzena and colleagues compared 
combination radiotherapy with cystectomy for stage T1–2 bladder cancer (92). In 
total, 108 patients received 30 Gy external beam radiotherapy followed by 40 Gy 
brachytherapy; they were compared with 77 patients who were treated with 
cystectomy alone. Overall survival after 5 and 10 years was 62 and 50% after 
radiotherapy (brachytherapy), and 67 and 58% after cystectomy, respectively. 
There are also reports that radiation therapy tends to release radiolytic products 
that are stored in urinary bladder and may thereby enhance bladder 
carcinogenesis. Overall, these treatment options appear to be effective for 
certain patients with specific bladder cancer stages, but their use is limited by 
the acute and chronic adverse side effects elicited by chemotherapy and 
radiation. Patients experience more chemotherapy-related adverse effects than 
reported in clinical trials. Most of the toxicity is attributable to the effects on non-
target tissue including, granulocytopenia, and stomatitis, hematologic toxicity 
(leucopenia and febrile neutropenia), nephrotoxicity and other organ toxicities 
(93). Adverse effects include in loss of hair, loss of appetite, diarrhoea, nausea 
and fatigue due to toxic effects of radation on rapidly proliferating tissue.  
Pancreatic cancer incidence and classification 
 
Incidence. Pancreatic cancer is the fourth leading cause of cancer-
related mortality, accounting for about 6% of all cancer-related deaths, in both 
men and women in U.S.A.  The median age of diagnosis is 72 years and 
patients with pancreatic cancer have a mean relative 5-year survival rate of 5%, 
and this disease remains a major unsolved health problem (94).  Predisposing 
etiologies for pancreatic cancer include cigarette smoking, diabetes mellitus, 
heavy alcohol consumption and a family history of pancreatic cancer (95). 
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Classification. Classification of pancreatic cancer is based on the 
anatomical origin and molecular signatures of the tumors. Jones et al identified 
more than 1500 somatic mutations in a pool of 1007 genes in 24 pancreatic 
cancer patients and reported that genes mutated at the highest frequency 
include KRAS, p16/CDKN2A, TP53, and SMAD4 (96) (97). The KRAS gene was 
activated by point mutations in virtually all of the 24 cancers.  A number of other 
potentially significant (“driver”) genes were mutated at a much lower frequency: 
1. Ductal adenocarcinoma. This class of pancreatic cancer is featured by small 
microscopic lesions, called pancreatic intraepithelial neoplasia (PanIN), as well 
as larger intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic 
neoplasms. Mutations in KRAS, in TP53, in SMAD4, and in the p16/CDKN2A 
genes have all been reported in PanINs, as well as in infiltrating ductal 
adenocarcinomas (Figure 4) (98). Brune and Detlefsen et al (99) have shown 
that PanINs are often associated with a distinctive lobulocentric atrophy and 
fibrosis. PanINs may be too small to be detected using currently available 
imaging technologies, but focal areas of pancreatic fibrosis may serve as an 
indirect marker for the presence of a PanIN. 
2. Medullary carcinoma.  Medullary carcinoma of the pancreas is characterized 
by poor differentiation, a syncytial growth pattern, and pushing borders. These 
cancers also may have necrosis, a Crohn-like lymphocytic infiltrate and unstable 
microsatellites due to inherited or acquired mutations. The recognition that 
medullary carcinomas of the pancreas are associated with microsatellite 
instability has prognostic and therapeutic implications. Despite their poor 
differentiation, microsatellite unstable carcinomas may have a better prognosis 
(100).   
3. Undifferentiated carcinoma. Undifferentiated carcinomas, like medullary 
carcinomas, lack significant differentiation, but unlike medullary carcinomas, 
undifferentiated carcinomas are among the most aggressive of all of the 
carcinomas of the pancreas. The mean survival for some groups is only 5 
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months (101). Undifferentiated carcinomas are highly malignant epithelial 
neoplasms without a more definite direction of differentiation. Winter et al have 
recently identified a molecular basis for the undifferentiated appearance of these 
neoplasms. Undifferentiated carcinomas are typically noncohesive, and these 
noncohesive pancreatic cancers are characterized by the loss of e-cadherin and 
β-catenin protein expression (102).  Thus, at the poorly 
differentiated/undifferentiated end of the spectrum of pancreatic neoplasia, are 
two very different carcinomas i.e., medullary carcinomas that are associated with 
microsatellite instability and have a good prognosis, and undifferentiated 
carcinomas with the loss of E-cadherin, and that have a poor prognosis. 
4. Undifferentiated carcinoma with osteoclast-like giant cells. 
Undifferentiated carcinomas with osteoclast-like giant cells are a poorly 
differentiated/undifferentiated carcinoma of the pancreas. These histologically 
striking carcinomas contain a mixture of highly atypical pleomorphic cells and 
dramatic multinucleated giant cells with uniform nuclei.  These are 
undifferentiated carcinomas with reactive, nonneoplastic, multinucleated giant 
cells. The undifferentiated cells in these neoplasms harbor the same mutations 
as do their associated noninvasive epithelial precursors. These distinctive 
neoplasms are classified as epithelial neoplasms (carcinomas) that arise from 
well-differentiated epithelial precursor lesions (103). 
5. Colloid carcinoma.  Colloid carcinoma, also known as mucinous noncystic 
adenocarcinoma, almost always arises in association with an Intraductal 
papillary mucinous neoplasm (IPMN). Colloid carcinoma is characterized by 
well-demarcated pools of mucin infiltrating stroma. Some of the mucin pools 
contain clusters of well-differentiated neoplastic cells in variable patterns 
including strips, stellate units, and individual signet-ring like cells. The neoplastic 
cells of colloid carcinoma show intestinal differentiation.  CDX2, a transcription 
factor that regulates intestinal programming, is not normally expressed in 
pancreatic tissues nor is it significantly expressed in conventional ductal 
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adenocarcinoma of the pancreas. However, CDX2 is uniformly expressed in 
colloid carcinomas along with expression of MUC2, the goblet-type (or intestinal 
type or gel forming) mucin, not unexpectedly, colloid carcinomas of the pancreas 
express high-levels of MUC2 (104). 
6. Intraductal papillary mucinous neoplasm (IPMN). Intraductal IPMNs are 
large noninvasive mucin-producing epithelial neoplasms that arise in the larger 
pancreatic ducts (105). IPMNs can be a precursor to invasive adenocarcinoma 
of the pancreas, particularly invasive colloid carcinomas. Activating mutations in 
the KRAS oncogene and inactivating mutations in the TP53 and p16/CDKN2A 
tumor suppressor genes are observed in this type of tumors. (106). In the 
pancreas, the diffuse/strong expression of CDX2 and MUC2 is seen only in the 
intestinal type of IPMNs and in the colloid carcinomas associated with intestinal 
type IPMNs (107). 
7. Solid-pseudopapillary neoplasm.  Grossly, solid-pseudopapillary 
neoplasms can be solid and cystic or almost completely cystic. The cysts are 
filled with necrotic and hemorrhagic material. By light microscopy, solid-
pseudopapillary neoplasms are composed of uniform poorly cohesive cells 
surrounding thin delicate blood vessels composed of foam cells, clear cells, 
cholesterol clefts, and eosinophilic hyaline globules are often present. More than 
90% of solidpseudopapillary neoplasms have mutations in exon 3 of the β-
catenin gene.These mutations interfere with the degradation of the β-catenin 
protein, and as a result, the β-catenin protein abnormally accumulates in the 
neoplastic cells and is translocated to the nucleus where it increases the 
transcription of c-myc and cyclin D1 (108).  
8. Pancreatoblastoma. Pancreatoblastomas are distinctive neoplasms 
characterized by the presence of neoplastic cells with acinar differentiation and 
squamoid nests (109).  The most common genetic abnormality in 
pancreatoblastomas is loss of one copy of the short arm of chromosome 11 near 
the WT-2 gene locus (11p15.5)  (110)  (111). Genetic mutations in the β-
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catenin/APC pathway are seen in up to 80% of pancreatoblastomas, and most 
of these are in the β-catenin gene. Unlike the solid-pseudopapillary neoplasms, 
pancreatoblastomas with β-catenin gene mutations remain cohesive. 
9. Acinar. Acinar carcinomas of the pancreas are distinctive neoplasms 
characterized by the production of exocrine enzymes (trypsin, chymotrypsin and 
lipase) by the neoplastic cells (112). The cells are often pyramidal in shape, with 
abundant granular apical cytoplasm and minimal fibrous stoma.  Most acinar cell 
carcinomas do not harbor KRAS gene mutations, or mutations in the TP53, p16/ 
CDKN2A, or SMAD4 genes. Thus, these morphologically distinct neoplasms are 
also genetically distinct from other pancreatic carcinomas. 
10. Serous cystic neoplasms. Serous cystic neoplasms are benign cyst-
producing neoplasms in which the cysts are lined by cuboidal cells with clear 
cytoplasm. Hypoxia induced factor-1 α is expressed uniformly in serous cystic 
neoplasms. The accumulation HIF-1 initiates a cascade of events in glucose 
metabolism, via modification glucose uptake and glucose transferase-1 as well 
as carbonic anhydrase IX, the accumulation of glycogen and thus the 
characteristic clear cell appearance. HIF-1 also induces overexpression of 
vascular endothelial growth factor, which in turn may lead to the recruitment of 
capillaries immediately adjacent to the neoplastic epithelial cells (113). 
Animal and genetic models for pancreatic cancer  
Environmentally-induced cancers in certain strains of mice develop either 
spontaneously or following various ‘environmental’ exposures, including 
radiation, chemicals, pathogenic viruses and microbial flora. 
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Figure 4. Genetic progression of pancreatic adenocarcinoma (114). 
 
Development of a genetic mouse model for pancreatic cancer 
recapitulates the exact multistep progression of human pancreatic 
adenocarcinoma. In 2003, Hingorani et al. reported a mouse model of pancreatic 
neoplasia by conditional mis-expression of mutant KRAS in the pancreas from 
its endogenous promoter (115). The bitransgenic mice express a ‘knock-in’ 
KrasG12D upon Cre-mediated recombination and removal of a lox-STOP-lox 
allele within the Pdx1 expression domain. Pdx1 is a transcription factor that is 
expressed in the developing pancreas and foregut, restricting mutant KRAS 
expression to these organs. The Pdx1-Cre, lox-STOP-lox-KrasG12D mice develop 
the entire histologic compendium of murine PanIN (mPanIN) lesions observed in 
the cognate human disease, and a subset of mice develop invasive pancreatic 
carcinomas. Subsequent models have utilized additional mutations with Kras (for 
example, an oncogenic Trp53R172H allele or biallelic deletions of INK4a/Arf); 
these compound transgenic mice develop metastatic pancreatic cancers with 
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near-universal penetrance, and represent biologically relevant models of 
advanced pancreatic cancer in humans (116). K-ras (Kirsten Rat sarcoma virus 
oncogene) is a protooncogene located in chromosome 12p12.1. The ras 
pathway is a growth-promoting signal transduction from cell surface receptors to 
the nucleus, affecting the production and regulation of several key proteins. 
There are three RAS family protooncogenes namely H-ras, K-ras and N-ras and 
all are located in the inner plasma membrane, bind GDP and GTP and possess 
an intrinsic GTPase activity which cleaves the GTP to GDP (switch off position). 
K-ras protein is active and transmits signals by binding to GTP (turned on), but it 
is inactive (turned off) when GTP is converted to GDP.  
Mutations of K-ras proto-oncogene lead to an inactive GTPase and 
therefore persistent activation (switch on position). This type of K-ras mutation is 
expressed in pancreatic adenocarcinoma, colorectal adenocarcinoma, lung 
cancer and other solid tumors. The frequency of K-Ras mutations in pancreatic 
cancer ranges from 74 to 100%  (117). There is an absolute requirement for 
mutant Kras to initiate pancreatic neoplasia along the mPanIN pathway, and this 
is consistent with the extremely high frequency of KRAS abnormalities in human 
PanIN lesions and pancreatic cancer (Figure 4) (118). These mouse models 
have provided some insights into the putative cell-of-origin of pancreatic cancer. 
For example, recent studies by Guerra and colleagues have demonstrated that 
mPanINs and adenocarcinomas can be reproduced in the pancreas of adult 
mice by conditional misexpression of mutant Kras to the elastase-expressing 
acinar/centroacinar compartment accompanied by ongoing injury such as 
chronic pancreatitis (119). The development of these models has provided an 
unprecedented opportunity to explore preclinical diagnostic and therapeutic 
strategies in autochthonous models that are not afforded by short-term mouse 
xenograft studies.  
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Prognostic markers of pancreatic cancer 
1. Growth factors and their receptors.The pattern and level of expression of 
growth factor receptors and their ligands are important prognostic factors for 
pancreatic cancer: 
i. Epidermal growth factor receptor (EGFR) family and its ligands 
The epidermal growth factor receptor family is comprised of four transmembrane 
tyrosine kinases that include the epidermal growth factor receptor (EGFR), c-
erbB2, c-erbB3 and c-erbB4. EGFR is activated by various peptide ligands that 
include the EGF, TGFα, heparin– binding EGF–like growth factor, betacellulin, 
and amphiregulin. EGF is a polypeptide of 53 amino acids that stimulates 
proliferation and differentiation of a wide variety of cell types through binding the 
EGFR. In the normal pancreas, EGFR is expressed only in the islets of 
Langerhans. The EGFR gene, however, is overexpressed in 95% of ductal 
adenocarcinomas and human pancreatic cell lines, and this increases 
production of EGF and TGFα, promoting autocrine and paracrine loops that 
enhance cell proliferation. While the EGF is not detectable in the normal 
pancreas, it is found in 12% of pancreatic cancers. 
ii. Transforming growth factor (TGF) receptors. Transforming growth factors 
are a family of cytokines that actively influence cell division, cell death, and 
cellular differentiation. They bind to specific cell surface receptors and 
downregulate transcription factors, decrease phosphorylation of target proteins, 
and inactivate cell-cycle regulatory enzymes such as the G1 cyclins and cyclin-
dependent kinases. The three isoforms (TGF1–3) are overexpressed in 
pancreatic cancer.   
iii. Fibroblast growth factors Fibroblast growth factors (FGFs) belong to a 
large group of closely homologous polypeptide growth factors which include two 
main members, acidic FGF (aFGF) and basic FGF (bFGF). These growth 
factors are highly abundant in the basement membrane and extracellular matrix 
of a variety of tissues. FGFs influence cell differentiation, tissue homeostasis, 
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tissue regeneration and repair, cell migration, and angiogenesis.Both aFGF and 
bFGF are overexpressed in pancreatic cancer tissue at the mRNA and protein 
levels (120).  
2. Tumor suppressor genes: 
i. p53. The p53 gene encodes a 53-kDa nuclear phosphoprotein consisting of 
393 amino acids. Under normal conditions, p53 protein is found in the cell 
nucleus and p53 controls the entry of cells into the growth cycle at the G1/S 
boundary and has a critical role in initiating the repair of damaged DNA before it 
is replicated. The inability to affect DNA repair with accuracy may result in p53-
dependent apoptosis. The p53 gene is mutated in over 50% of human cancers. 
In pancreatic cancer it is inactivated in approximately 65% of all cases by a 
missense point mutation; loss of the remaining normal allele commonly occurs in 
pancreatic cancer cell lines. Point mutations result in production of mutant p53 
proteins which are more stable than the wild-type protein and accumulate in the 
nucleus. Patients with combined p53 positive and p21 negative tumors exhibited 
poor survival and those who have undergone chemotherapy exhibited a 
nonsignificant trend for improved survival (121). 
ii. p21WAF1. p21WAF1, a cyclin-dependent kinase inhibitor, is a downstream 
target and effector of p53. The 21-kDa product of the WAF1 gene forms part of a 
quaternary complex, along with cyclin/CDKs and the proliferating cell nuclear 
antigen (PCNA) in normal cells, but not in transformed cells, and is a universal 
inhibitor of CDK activity. Loss of p21 activity has been observed in 
approximately 30–60% of pancreatic tumors (121). 
3. Oncogenes. 
i. K-ras. The ras family of protooncogenes includes Hras, N-ras, and K-ras, and 
encodes proteins with GTP-ase activity; function as molecular switches in signal 
transduction. The K-ras gene is mutated in 75 to 90% of pancreatic cancers and 
the mutations present in pancreatic cancer are almost exclusively at codon 12. 
The presence or the type of K-ras mutations in pancreatic tumors has not been 
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shown to be associated with patient survival (122). K-ras is a signature gene for 
initiation of pancreatic carcinogenesis and is an important prognostic marker. 
ii. Cyclin D1.Cyclin D1 is a cell cycle regulator that may act as an oncoprotein. It 
is part of the enzyme complexes that are active in G1 phase of the cell cycle and 
which inactivate retinoblastoma (pRb) by phosphorylation.  Overexpression of 
cyclin D1 leads to constitutive phosphorylation of pRb and increased expression 
E2F activity. A study of 82 pancreatic cancers reported overexpression (by 
immunostaining) of cyclin D1 in 65% of tumors, and this was associated with 
decreased survival for these patients (123).  
4. Apoptotic factors. Apoptosis or programmed cell death is a central regulator 
of homeostasis in normal tissue. The bcl-2 family of antiapoptotic genes includes 
bcl-2, bcl-x, bax and other related proteins, and the majority has four conserved 
domains. Bcl-2 is an antiapoptotic factor and has been referred to as a 
cooperating oncogene. By itself it is unable to transform cells, but, when 
activated in the presence of other oncogenes, bcl-2 is important for malignant 
transformation.  Bcl-x is a bcl-2-related gene and exists as two subforms; bcl-xL 
is the longer form and functions as an apoptotic inhibitor; bcl-xS is the shorter 
form and functions as an apoptosis promoter. Bax is a promoter of apoptosis 
and bax/bcl-2 ratios can be important for determining cell survival.  Several 
studies have shown that the expression of bcl-xL is significantly associated with 
poor survival in pancreatic cancer patients (124).  
5. Tumor angiogenesis. Angiogenesis is essential for tumor growth and 
metastasis and angiogenic factors are produced by the tumor, by endothelial 
and stromal cells. 
i. Angiogenin Angiogenin (ANG) is a polypeptide and inducer of 
vascularization. ANG interacts with endothelial cells via a cell surface receptor 
and extracellular matrix (ECM) molecules such as proteoglycans. ANG binds to 
actin on the endothelial cell surface, and this complex may lead to the activation 
of several protease cascades. In patients with pancreatic cancer, high serum 
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levels of ANG mRNA expression  were significantly associated with poor survival 
(125). 
ii. Vascular endothelial growth factor (VEGF) and platelet-derived 
endothelial cell growth factor (PD-ECGF). VEGF is a potent and selective 
endothelial cell mitogen that is associated with tumor progression and 
metastases in a variety of gastrointestinal malignancies. VEGF is a 38 to 46-kDa 
dimeric N-glycoprotein that is chemotactic, as well as mitogenic, for endothelial 
cells in vitro and induces angiogenesis in vivo by increasing the permeability of 
the vascular endothelium. PD-ECGF stimulates the chemotaxis of endothelial 
cells and, therefore, indirectly induces angiogenesis. VEGF and PD-ECGF are 
frequently coexpressed in human cancers. Two studies in pancreatic cancer (a 
relatively hypovascular tumor) did not show prognostic value for micro vessel 
density (MVD); the expression of PD-ECGF, however, was associated with a 
significantly reduced survival. (126).  
6. Stromal factors and adhesion molecules. 
i. Urokinase plasminogen activator (uPA) and its receptor (uPAR) Plasminogen 
is an inactive proenzyme that can be converted to urinary or tissue plasminogen 
activator (uPA and tPA). uPA appears to play a pivotal role in pericellular 
proteolysis during cell migration and tissue remodelling. The resultant cellular 
activation and extracellular matrix proteolysis enhance the ability of pancreatic 
cancer cells to invade and metastasize. There is concomitant overexpression of 
uPA and uPAR in pancreatic cancer.Coexpression of uPA and uPAR in 
pancreatic cancer was associated with significantly decreased survival 
compared to patients with tumors that do not express one or both proteins (127). 
ii. E-cadherin and matrix-metalloproteinases (MMPs) E-cadherin is a 
transmembrane glycoprotein that is responsible for homotypic binding and 
morphogenesis of epithelial tissues. E-cadherin is associated with a decrease in 
cellular and tissue differentiation and higher metastatic potential. 
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Levels of MMP enzyme activity correspond to tumor grade, regional lymph node 
metastases, and distant metastases. MMP-2 (gelatinase A) and MMP-9 
(gelatinase B) are type IV collagenases and are overexpressed in pancreatic 
cancer.  The expression of these MMPs directly correlates with invasion and 
metastasis in pancreatic cancer. Patients with cancers that express MMP/E-cad 
ratios of less than 3 had a significantly better prognosis compared to those with 
ratio > 3 (128). 
7. Cytokeratins. Cytokeratins comprise a multigene family of 20 related 
polypeptides (CKs 1-20), are constituents of the intermediate filaments of 
epithelial cells, and are expressed in various combinations depending on the 
epithelial type and the degree of differentiation. The differential expression of 
individual CKs in various types of carcinomas provides relevant information 
concerning the differentiation and origin of carcinomas, especially when tumors 
initially undergo metastases. The CKs that are of particular value for differential 
diagnosis include CK 20, since it is mainly expressed in carcinomas derived 
from CK 20-positive epithelia; it is also found in bile-tract and pancreatic 
adenocarcinomas, and is not detected in most other carcinomas. In certain 
carcinoma types, changes in expression of individual CKs that occur during 
tumor progression may be of prognostic relevance (129). 
8. Micro-RNAs (miRNAs). MiRNAs, a novel class of 18–23 nucleotide 
noncoding RNAs, have gained attention as another family of molecules involved 
in cancer development. There is evidence that miRNAs are misexpressed in 
various human cancers, suggesting that miRNAs can function as tumor 
suppressors (‘TSGmiRs’) or oncogenes (‘oncomiRs’) ‘. Upon binding to their 
target RNAs, miRNAs cause posttranscriptional gene silencing by either 
cleaving the target mRNA or by inhibiting the translation process (130). Several 
studies have shown that, miRNA expression is deregulated in pancreatic cancer. 
A miRNA signature of pancreatic cancer has been elucidated, and it includes the 
up regulation of miR-21, miR-155, miR-221 and miR-222 (131) Moreover, Chang 
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et al.found that miR-34a is frequently lost in pancreatic cancer cell lines (132). 
These studies demonstrate that miRNAs may become useful biomarkers and 
diagnostic factors for pancreatic cancer. In addition, these aberrantly expressed 
miRNAs might be useful as potential therapeutic targets, with the recent 
availability of in vivo miRNA knockdown strategies (‘antagomirs’).       
                                                                  
Pancreatic cancer therapy 
 
Surgery, radiation therapy, and chemotherapy are treatment options that 
may extend survival and/ or relieve symptoms in many patients, but rarely 
produce a cure. The drug erlotinib, that inhibits EGFR, blocks tumor cell growth 
but only has minimal effects on survival of pancreatic cancer patients. It has 
been approved by the FDA for the treatment of advanced pancreatic cancer. 
Clinical trials with several new agents, combined with radiation and surgery, may 
offer improved survival and should be considered as a treatment option. 
Interestingly, the cross-talk between RAS/MAPK and Hedgehog signaling 
pathways in pancreatic carcinomas also suggest that targeting the RAS and 
Hedgehog pathways synergistically may represent a new therapeutic strategy. 
Additionally, there are a few promising agents undergoing clinical trials that 
include, bevacizumab, the monoclonal antibody against VEGF, which targets 
tumor vascularization and cetuximab, the monoclonal antibody against the 
EGFR. Trastuzumab (Herceptin) is a humanized monoclonal antibody that acts 
on the HER2/neu (erbB2), a member of the EGFR family that shows profound 
beneficial results with breast cancer patients whose tumors overexpress this 
receptor (Table 2) (133).  Gemcitabine (2´,2´-difluorodeoxycytidine) is a 
deoxycytidine-analog antimetabolite with broad activity against a variety of solid 
tumors and lymphoid malignancies. It was approved as standard of care in 
patients with pancreatic cancer one decade ago, based primarily on improved 
clinical benefits such as pain reduction, improvement in Karnofsky performance 
status and increase in body weight (134). 
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Table 2. Ongoing Phase III clinical trials for targeted therapies in 
pancreatic cancer  (135).  
 
Chemotherapy based on 5-fluorouracil (5-FU) prolongs survival of 
patients with advanced pancreatic cancer and Gemcitabine improves major 
symptoms and survival outcomes compared with bolus 5-FU. Many novel small 
molecule anticancer drugs are being investigated and include mechanism-based 
compounds and biological therapies targeting novel cellular survival pathways. 
Some examples include fluoropyrimidines, nucleoside cytidine analogues, 
platinum analogues, topoisomerase inhibitors, antimicrotubule agents, 
proteasome inhibitors, vitamin D analogues, arachidonic acid pathway inhibitors, 
histone deacetylase inhibitors, farnesyltransferase inhibitors and epidermal 
growth factor receptor therapies which are discussed elsewhere in this section. 
A recent randomized trial compared chemoradiotherapy with best supportive 
care in 31 patients with advance pancreatic carcinoma. Chemoradiotherapy was 
delivered in 16 patients using a standard fractionation scheme to a planned total 
dose of 50.4 Gy concurrently with a continuous infusion of fluorouracil (FU) at 
200 mg/m2/d and results demonstrated a significant benefit of 
chemoradiotherapy (136).  
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Cancer chemotherapy 
 
Historically anti cancer drugs have originated from all available chemical 
sources and include synthetic and natural products from plants, microbes and 
fungi and currently used drugs for cancer chemotherapy can be classified into 
the following groups: 
1. Nitrogen mustards. Nitrogen mustards are highly reactive alkylating agents 
that dissociate to give positively charged carbonium ion intermediates. These 
electrophilic alkyl groups form covalent bonds with electron rich nucleophiles, 
such as sulfhydryl, hydroxyl, acetyl, phosphoryl, amino and imidazole groups 
present in normal and neoplastic cells. Thus they interact with a large variety of 
biological molecules including DNA, RNA and proteins. There is evidence linking 
alkylation of DNA to the cytotoxic carcinogeneic and mutagenic effects of these 
agents. Formation of interstrand-DNA cross links inhibits DNA replication, repair 
and transcription and they also inhibit protein synthesis (137). Chlorambucil, 
Melphalan and Myleran (Busulfan) are phenylbutyric acid derivatives of nitrogen 
mustards.  Chlorambucil is commonly used in the treatment of low-grade 
lymphomas and leukemias as well as in some immunological diseases such as 
glomerulonephritis and rheumatoid arthritis (138). Long term usage of these 
drugs causes permanent gonadal dysfunction and carcinogenicity. The nitrogen 
mustards damage DNA and their use as anti-cancer agents has declined due to 
these side effects. 
2. Phosphoramide and Oxazaphosphorine mustards. These compounds are 
also alkylating agents and phosphoramide and oxazaphosphorine mustards are 
the only phosphorylated mustard compounds currently prescribed for cancer 
treatment (139). Cyclophosphamide is sulfur mustard that causes delayed bone 
marrow suppression and low doses of this compound are used for treatment of 
cancer even though the in vivo half-life of this compound is short. Tris (2-
chloroethyl) amine is a nitrogen mustard agent used against Hodkin’s lymphoma 
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and this compound disrupts cell renewal of lymphatics, bone marrow and 
gastrointestinal epithelia.  
3. Nitrosoureas. In the 1950s National Cancer Institute organized a 
comprehensive screening program to identify new compounds with anti-cancer 
activities against malignant gliomas (140).  One of the compounds, N-methyl-N-
nitrosourea (MNU) was effective against intra-cerebrally implanted tumor cells 
(141).  Nitrosoureas decompose rapidly in aqueous solution and alkylate both 
DNA and proteins (142). Lijinsky at al. showed that fully deuterated methyl 
groups were transferred intact from MNU to DNA. Kohn then showed that DNA 
modified by MNU underwent reversible denaturation indicating that interstrand 
crosslinks had been formed (143). Nitrosoureas cause adverse effects similar to 
that of other alkylating agents. 
4. Platinum complexes. The platinum based drug Cisplatin (cis-
diamminedichloro platinum [II]) was approved as an anti-cancer drugs over 25 
years ago.  Cisplatin crosslinks DNA causing 1,2-intrastrand cross-links with 
purine bases. These include 1,2-intrastrand d(GpG) adducts which form nearly 
90% of the adducts and the less common 1,2-intrastrand d(ApG) adducts. 1,3-
Intrastrand d(GpXpG) adducts occur but are readily excised by nucleotide 
excision repair (NER). Other adducts include inter-strand crosslinks and 
nonfunctional adducts that may also contribute to activity of cisplatin. Cisplatin 
also interacts with cellular proteins, particularly high mobility group (HMG) 
domain proteins resulting in interference with mitosis. Although cisplatin is 
frequently designated as an alkylating agent, it has no alkyl group and does not 
undergo alkylating reactions. There was dramatic increase in long term survival 
of patients with small-cell lung, bladder, cervical, head and neck carcinomas 
after treatment with cisplatin. Carboplatin is a less toxic analog and exhibits 
lower nephrotoxicity, neurotoxicity and nausea however myelosupression is 
dose-limiting for this compound (144). Oxaliplatin, another analog, exhibited 
neurotoxicity during phase I clinical trials (145). In spite of the efficacy of 
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cisplatin against cancers, this compound suffers from two major drawbacks. 
First, it is higly toxic against normal tissues and second many tumors develop 
resistance to the tumor inhibitory properties of cisplatin.  
5. Anthracyclins. Actinomycin D was the first anthracyclin to be discovered 
during its application in treatment of Wilm’s kidney tumor in 1950.  The drug is 
produced by Streptomyces soil mold and is effective against blood leukemias. 
Actinomycin D inhibits DNA topoisomerase I and II, and helicases and induces 
formation of toxic free radicals that alter membrane structure and function and 
endonucleolytic cleavage (146). Doxorubicin, another anthracyclin analog is 
employed as single agent as well as in combination therapies for treatment of 
lymphomas, breast and small cell lung carcinoma and sarcomas but is 
ineffective against colon, neuronal cancers and renal cancer (147). 
Anthracyclins have a narrow therapeutic index and documented toxicities 
include myelosupression, gastrointestinal toxicity, alopecia and stomatitis. 
Leucopenia is the dose-limiting step.  The acute and chronic effects of 
doxorubicin and daunorubicin on the heart can lead to cardiotoxicity and 
congestive heart failure which is a major adverse health effect (148).  Another 
major drawback is drug resistance which is due to elevation of the multidrug 
resistance phenotype (MDR) and multi-drug resistance protein (MRP). The MDR 
phenotype which is characterized by increased membrane associated P-
glycoprotein confers cross-resistance to a broad spectrum of natural product-
derived drugs including anthracyclins.  
6. Topoisomerase inhibitors. The helical structure of DNA was proposed by 
Watson and Crick in 1953 and Vinograd et al found that the helical axis can also 
be coiled in circular DNA called supercoiling. Since most of the functions of DNA 
require untwisting, the importance of topoisomerases are self-evident. The first 
enzyme identified as topoisomerase I, is ubiquitous, and breaks only one of the 
two strands as it untwists the DNA. Topoisomerase II, also known as gyrase, 
breaks both strands (149). Topoisomerase I inhibition is an important target for 
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anticancer drugs and and camptothecin (CAM), obtained from Chinese tree 
Camphtotheca acuminata is a potent Topo I inhibitor and a potent anti-cancer 
drug. The topo I enzyme forms a complex with DNA and then rolls along the 
DNA to release the super coiling. CAM derivatives stabilize and prolong this 
process rendering the clevable complex (Topo 1+DNA+CAM) vulnerable to 
degradation by other nucleases that first produce reversible and then irreversible 
DNA damage (150). Cells in S phase are 1000 times more sensitive to CAM 
than cells in other phases of cell cycle (151).  Resistance to these drugs is 
explained by the presence of Topo I mutated genes and loss of topoisomerase 
activity (152). Combinations of Toptecan and cisplatinum has been investigated 
in vitro but Topo I inhibitors can interfere with cisplatinum-induced DNA damage 
(153). 
7. DNA Topoisomerase II inhibitors. DNA topoisomerases represent a major 
focus for not only cancer research but also for gene regulation, cell cycle 
progression, and mitosis and chromosome structure. DNA gyrase is a bacterial 
equivalent of Topo II. Antibacterial quinolones (nalidixic acid, ciprofloxacin, 
norfloxacin and derivatives) are gyrase inhibitors with limited effects on host 
human Topo II. Topoisomerase mediated DNA strand breakage corresponds to 
transesterification reactions where a DNA phosphoester bond is transferred to a 
specific enzyme tyrosine residue. Topo I relaxes DNA by forming a covalent 
bond with the 3’-terminus of the DNA single stranded break (154). Topo II forms 
a dimer and a double stranded break as it binds covalently to the 5’-terminus of 
the double stranded DNA break (155). Topo II suppressors inhibit DNA cleavage 
steps by trapping the enzyme in the form of a closed protein clamp and inhibit 
their function either before or after DNA strand passage depending on the 
inhibitor (156). 
Topo I poisons like Camptothecin do not affect Topo II and Topo II 
poisons (etoposide, doxorubicin, amsarcine) do not trap Topo I cleavable 
complexes. Enzyme deletion mutants may prove useful for understanding 
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interactions of the Topo II domain with drugs and other cellular proteins during 
the sub-cellular distribution and phosphorylation of the enzyme (157). The 
epipodophyllotoxins are Topo II inhibitors extracted from plants and they act as 
antimitotic agents that bind tubulin at a site distinct from those occupied by the 
Vinca alkaloids. Anthracyclins like anthraquinalones (Mitoxantrone) inhibit Topo 
II activity and also cause DNA intercalation (158). Ellipticines derived from 
alkaloids of Apocyanaceae plant family are also potent DNA intercalators as well 
as Topo II inhibitors.  
8. The taxoids. Paclitaxel and docetaxel belong to the taxoid family, a relatively 
new class of antineoplastic drugs. The name taxoids refer to compounds, natural 
or modified that have a taxane skeleton. Paclitaxel was extracted from the bark 
of the Pacific Yew, Taxus brevifolia. Because of the scarcity of the drug and 
difficulty in formulation, initial development was slow. Preliminary studies 
indicated that taxoids act as a spindle poison that inhibit cell proliferation at the 
G2-M phase in cell cycle and thereby block mitosis (159).  
Together with actin microfilaments and intermediate filaments 
microtubules form the cytoskeleton of eukaryotic cells. The microtubules are 
involved in a variety of cell functions including chromosome movement, 
regulation of cell shape and motility (160). The depolymerization of mitotic 
spindle microtubules is essential for specific mitotic events like movement of 
chromosomes to the metaphase plate and their correct segregation during 
anaphase (161). Micotubules are long hollow cylinders assembled form a 
heterodimeric globular protein called tubulin. They consist of 13 aligned proto-
filaments within the tubulin subunits that interact with longitudinal and lateral 
bonds (162). Paclitaxel stabilizes microtubules and inhibits depolymerization 
back to tubulin. This differs from the mechanism of action of other poisons such 
as vinca alkaloids that bind tubulin and inhibit its polymerization (Figure 5) (163).      
 The dose-limiting toxicity of paclitaxel was neutropenia in seven out of 
nine Phase I trials (164). The mechanism of action of taxoids is unique, since all 
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other known mitiotic spindle poisons in particular the vinca alkaloids shift the 
tubulin-microtubule equilibrium towards tubulin. 
 
 
Figure 5. Mechanism of action of Vinca alkaloids and taxoids.  
 
9. Sequence selective groove binders.  A large number of agents bind DNA 
and interfere with multiple DNA functions in living cells. The ability to interact 
with DNA is associated with several biological effects including anti-viral 
antibacterial anti-protozoal and anti-tumor activities. From a pharmacological 
viewpoint, the most relevant DNA binding agents are antitumor drugs. They 
exert their cytotoxic effects as a consequence of random DNA damage and 
these drugs often have a low therapeutic index since they cause DNA lesions 
not only in tumors, but also in normal cells. However, certain selectivity toward 
specific tumor types has been recognized for some agents as documented by 
the efficacy of platinum compounds in the treatment of testicular and ovarian 
cancers. 
MICROTUBULES
TUBULIN
VINCA 
ALKALOIDS 
TAXOIDS 
DEPOLYMERIZATIONPOLYMERIZATION
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i. Major groove binders.  Although the major groove has a greater recognition 
potential based on the number of hydrogen bonds, only a few DNA intercalating 
agents are major-groove specific. The bi-functional alkylating agents, 
methylating agents and cisplatin covalently interact with the N-7 position of 
guanine located in the major groove.  
ii. Intercalating anti-tumor agents. Doxorubicin is the widely used anthracyclin 
and DNA binding and intercalation are necessary but not sufficient for optimal 
antitumor activity of this drug (165). Indeed strong intercalating agents like 
ethdium bromide have minimal anti-tumor activity and it is likely that the mode 
and site of binding are more critical than the binding affinity. The mechanism of 
cytotoxic and antitumor activity of intercalating agents is related to their ability to 
interfere with the function of Topo II (166), a nuclear enzyme that regulates DNA 
topology during multiple metabolic DNA processes. 
iii. Noncovalent DNA minor groove binders. Non-intercalating drugs have 
been extensively studied for their sequence-specific in DNA binding (1). Anti-
viral antibiotics like distamycin and netropsin bind non-covalently to the minor 
groove with an AT preference and cause widening of the minor groove (167).  
These agents are incorrectly identified as antitumor agents since they have low 
cytotoxicity and negligible antitumor activity.   
iv. Minor groove alkylating agents. Mitomycin C is well known for its antibiotic 
and antitumor activities and it binds covalently binds to the minor groove of DNA 
resulting in mono and bi functional adducts. Mitomycin C preferentially crosslinks 
a 4 bp CG sequence. Groove binding drugs exhibit sequence-specific DNA 
interaction however the sequence-specific recognition potential of DNA-
intercalating drugs is not sufficient to provide selective cytotoxicity against tumor 
cells. Many of the lesions produced by these intercalating are not required for 
the therapeutic activity (168). Other disadvantage includes chemical and 
pharmacological problems associated with stability of carriers, poor cellular 
penetration and synthetic diffculties. 
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10. Bis-Naphthalimides. Naphthalamides were synthesized as a new series of 
antitumor compounds in the late 1970s as bis-intercalating agents with a high 
binding affinity for DNA (169). Amonfide and Mitonafide bind to double stranded 
DNA by intercalation. These drugs stabilize DNA against thermal denaturing, 
inhibit RNA and DNA synthesis, and initiate DNA cleavage by activation of 
topoisomerase II. Amonfide and Mitonafide specifically induce DNA cleavage 
near nucleotide No. 1830 on pBR322 DNA. However it is unclear if the antitumor 
effects are due to alterations of topoisomerase II activity. These drugs also have 
anti-viral activity specifically against DNA viruses and their dose-limiting 
toxicities are myelosupression and stomatitis (170). 
11. Radiation. Radiation therapy uses ionizing radiation to kill cancer cells and 
shrink tumors. Radiation therapy is used to treat almost every type of solid 
tumor, including cancers of the brain, breast, cervix, larynx, lung, pancreas, 
prostate, skin, spine, stomach, uterus, or soft tissue sarcomas (171). Radiation 
can also be used to treat leukemia and lymphoma (cancers of the blood-forming 
cells and lymphatic system, respectively). The dose of radiation to each site 
depends on a number of factors, including the type of cancer and whether there 
are tissues and organs nearby that may be damaged by radiation. 
Approximately 50% of all patients are treated with radiation therapy, either alone 
or in combination with other types of cancer treatments (172). The amount of 
radiation absorbed by the tissues is called the radiation dose and the unit is 
called a gray (abbreviated as Gy).  External radiation therapy usually is given 
on an outpatient basis and most patients do not need to stay in the hospital. 
External radiation therapy is used to treat most types of cancer, including cancer 
of the bladder, brain, breast, cervix, larynx, lung, prostate, and vagina (173). 
Internal radiation therapy (brachytherapy) uses radiation that is placed very 
close to or inside the tumor. The radiation source is usually sealed in a small 
holder called an implant which are in the form of thin wires, plastic tubes called 
catheters, ribbons, capsules, or seeds (174) and placed directly into the body. 
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Internal radiation sources are iodine 125 or 131, strontium 89, phosphorus, 
palladium, cesium, iridium and cobalt isotopes. 
Target based anti cancer drugs 
1. Matrix Metalloproteinase (MMP) inhibitors. Members of this family 
selectively degrade collagen triple helix. Liotta et al showed that destruction of 
the basement membrane is often associated with tumor invasion, and that tumor 
cells selectively degrade components of the basement membrane ((175).  Type 
IV collagen is a major structural component of the basement membrane. A direct 
correlation exists between MMP expression and the invasive phenotype of 
human lung, prostate, stomach, colon, breast, ovary and thyroid tumors and 
squamous cell carcinomas. MMP family members are overexpressed in cancers 
and they are Stromelysin-3, gelatinase A and gelatinase B and they cooperate 
with other proteases to facilitate matrix turnover. The relative expression of 
MMPs varies with tumor heterogeneity, progression as well as differential 
expression in response to changing extracellular matrices encountered during 
tumor progression. Substrate analog inhibitors of MMPs are used as anticancer 
agents. Batimastat (BB-94) is a hydroxamic acid analog with broad spectrum 
MMP inhibitory activity but little activity against other unrelated 
metalloproteinases. The low solubility and poor oral bioavailability of BB-94 are 
severe limitations for the formulation and delivery of this compound. Malignant 
tumor cell invasion is a dysregulated physiologic process similar to 
angiogenesis, wound healing, embryonic development and tumor invasion (176). 
These pathways are regulated spatially and temporally and are responsive to 
negative regulatory signals in non tumor tissues and MMP’s activity is a common 
denominator for these processes. Abrogation of MMP activity through use of 
synthetic, low molecular weight substrate inhibitors can effectively block tumor 
dissemination and growth. The suppression of tumor growth is indirectly linked 
to suppression of tumor-induced angiogenesis by the MMP inhibitors. Neovastat 
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obtained from shark cartilage extract exhibtis antitumor and anti-metastatic 
properties in experimental tumor models. It targets several angiogenic pathways 
including VEGF signaling, MMP signaling and endothelial apoptosis. Neovastat 
is well tolerated in phase I studies with no dose limiting toxicities, patient survival 
was significantly increased and there was a 50% decrease in relative risk of 
death in patients with non small cell lung carcinoma (NSCLC).  
2. Interferons and other cytokines. Cytokines are proteins that regulate cell 
behavior in a paracrine or autocrine manner and when administered 
exogenously these proteins often possess biological activities that make them 
attractive for cancer therapy. IFN-γ, an antiviral agent effects cell growth and 
differentiation and in combination with other cytotoxic agents such as, 
doxorubicin, cisplatin, vinblastine and methotrexate and synergistic activities 
have been reported (177). IFN-γ slows growth of tumor cells by increasing the 
length of their cell cycle in G0/G1 transition and suppressing cellular oncogenes 
like c-myc and c-fos oncogene expression (178). IFN-γ increases expression of 
class I major histocompatibility complex (MHC) antigens (179) on tumor cells 
resulting in efficient recognition and killing of tumor cells by cytotoxic T-cells and 
natural killer cells. IFN also inhibits angiogenesis due to degeneration of 
endothelial cells in tumor vessels (180) and leucocyte IFN inhibits capillary 
endothelial cell motility in vitro (181). Gresser and others showed that IFN not 
only inhibits virally induced tumors but also spontaneous and transplantable 
tumors (182). Limitations of interferons include species-specific effects on some 
cytokines, and the immunogenicity of some synergistic tumors, tumor growth 
inhibition and decreased metastasis are often not observed in patients.  
3. Angiogenesis inhibitors. Most current chemotherapies are cytotoxic and are 
designed to kill rapidly growing tumor cells. Because many normal tissues 
contain stem cells that also proliferate rapidly (bone marrow, hair follicles, 
intestines), the effectiveness of these agents is limited because of toxic side 
effects. One of the novel approaches to cancer therapy does not target the 
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tumor cells directly but inhibits growth of new capillary blood vessels that feed 
the growing tumor, and thereby inhibits angiogenesis. Tumors that grow larger 
than approximately 1-2 mm3 in size, must stimulate growth of new capillaries 
(183) in order to obtain a continuous supply of oxygen and nutrients for growth. 
TNP-470, a compound isolated from Aspergillus fumigatus Fresenius fungus 
inhibited endothelial cell proliferation in vivo, embryonic angiogenesis, and tumor 
induced neo-visualization in a mouse model (184). A woman with metastatic 
cervical carcinoma treated with TNP-470 continuously remained free of tumors 
and toxicity for over a year (185).  
4. Antisense oligonucleotides. Antisense therapy that interferes with signaling 
pathways involved in cell proliferation and apoptosis are promising treatments in 
combination with conventional anticancer drugs (186). Aptamers, also termed as 
decoys or “chemical antibodies,” represent an emerging class of therapeutics. 
They are short DNA or RNA oligonucleotides or peptides that assume a specific 
and stable three-dimensional shape in vivo, thereby providing specific tight 
binding to protein targets. In contrast to antisense oligonucleotides, effects 
aptamers can be used against extracellular targets and thereby circumvent the 
need for intracellular transportation. The most advanced aptamer in the cancer 
setting is AS1411, formerly known as AGRO100, which is being administered 
systemically in clinical trials. AS1411 is a 26-mer unmodified guanosine-rich 
oligonucleotide, which induces growth inhibition in vitro, and exhibited activity 
against human tumor xenografts in vivo. In a dose escalation phase I study in 
patients with advanced solid tumors, doses up to 10 mg/kg/d have been studied. 
Promising signs of activity have been reported and this includes multiple cases 
of stable disease and one near complete response in a patient with renal cancer 
in the absence of any significant adverse side effects (187).  AS1411 represents 
the first nucleic acid-based aptamer to be tested in humans for the treatment of 
cancer.  
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5. Growth factor receptors and their inhibitors. Members of the EGF receptor 
family are overexpressed in many cancers and this often correlates with 
increased tumor grade, increased metastatic potential, and poor prognosis in 
bladder breast and gastric cancers (188). EGFR was originally cloned in 1984 
and belongs to a family of transmembrane receptor tyrosine kinases involved in 
cell growth and differentiation. EGFR tyrosine kinase inhibitors inhibit the EGF 
receptor function by binding to its ATP binding pocket and inhibiting auto 
phosphoryation. The adverse toxic effects of gefitinib, an EGFR inhibitor, are 
skin rashes due to inhibition of EGFR in the basal epidermal layer that 
expresses high levels of EGFR. Phase III trials with gefitinib have been reported 
and neither the addition of gefitinib to paclitaxel/carboplatin or 
gemcitabine/cisplatin improved the outcome of patients with NSCLC. It is 
currently approved for use in Japan and cancer-organ specific growth factor 
receptors and their inhibitors are discussed elsewhere in this section. 
6. Immuno-conjugates. Bevacizumab is a humanized antibody against VEGF 
and is generated by engineering the VEGF binding sites of murine neutralizing 
antibody into the framework of a normal human immunoglobulin G (IgG). This 
antibody binds all biologically active forms of VEGF and In phase II clinical trials, 
in breast cancer there was complete response and prolonged time-to-disease 
progression compared to chemotherapy alone. The primary toxicity concern is 
hemorrhaging which was observed in squamous cell carcinoma patients in a 
phase II trials.  
Transcription factors as drug targets 
Pro-cancer signals are controlled by the expression and transcription of 
oncogenes. Gene transcription is dependent on the spatially and temporally 
coordinated interactions between the transcriptional machinery (RNA 
polymerase II, transcription factors (TFs) and transcriptional regulatory 
components (gene promoter elements, enhancers, silencers and locus control 
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regions). Several TFs have been associated with cancer.  In one study, it was 
reported that among the 50% of promoter sequence variants that alter gene 
expression, more than 1.5-fold were located within 50-100 bases from the 
transcription start site.  Gene regulation at the level of transcription initiation is 
important and this has encouraged attempts to establish topologies of 
transcriptional regulatory networks to facilitate analysis of regulatory links 
(transcription factor (TF)-gene) in addition to changes in expression and co-
expression of specific genes (189). TFs, the transcriptional machinery and 
transcriptional regulatory elements are novel therapeutic targets and 
understanding transcriptional regulatory networks has revealed their critical roles 
in carcinogenesis (Table 3). Transcription factors form an integral part of each of 
the hallmarks of cancer and contribute to the overall tumor-specific phenotypes.  
Transcription factors have been successfully targeted in several clinical 
trials (Table 4) and these outcomes support the rationale for their selection as 
drug targets. 
Sp proteins as targets for anti-cancer drugs. Studies from this 
laboratory have identified the importance of Sp transcription factors as potential 
targets for cancer chemotherapy.   Specificity protein 1 (Sp1) and other Sp and 
Krüppel-like factor (KLF) proteins are members of the Sp/KLF family of 
transcription factors that bind GC/GT-rich promoter elements through three 
C2H2-type zinc fingers present in their C-terminal domains. 
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Table 3. Hallmark traits of oncogenic transcription factors (190).  
 
 
 
 
Table 4. Preclinical studies that have focus on modulation of the TF 
expression and/or function (190).  
 
 
Transcription 
factor 
Justification summary 
AP-1 (c-Jun)  
Inhibition of AP-1 reduced breast cancer cell proliferation in 
mice (191) 
AR  
Downregulation of AR resulted in prostate tumor size  
reduction in mouse xenograft (192) 
ATF-1/CREB Knockdown of ATF-1/CREB in mice resulted in a decrease in 
size of subcutaneously transplanted tumors via induction of  
apoptosis (193) 
BRN-3b (POU) Results suggest that Brn-3b elevation in breast cancer is a 
significant transcription factor in regulating mammary cell 
growth (194) 
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                          Table 4 continued.  
 
 
CREB Mice transfected with CREB300/310 dramatically enhanced tumor 
growth, whereas CREB300/310/133 inhibited hepatoma growth (195) 
E2F-
1/RB1 
Knockdown of E2F in mouse embryonic fibroblast leads to 
phosphorylation of RB1 and increased cell proliferation (196) 
 
Myc Overexpression of Myc in mice resulted in downregulation of IL-6- and 
VEGF-induced rabbit corneal angiogenesis (197) 
 
NF-kB Bortezomib-induced downregulation of NF-kB pathway has been 
observed in refractory multiple myeloma and relapsed myeloma 
patients in phase II clinical trials (198) 
 
PEA3 Use of a dominant-negative PEA3 delayed onset, reduced number and 
size of mammary tumors in mice (199) 
 
RARα Downregulation of RARa resulted in lymphoma in 44% of homozygous 
transgenic mice (200) 
 
SP-1 Celecoxib-affected Sp1-binding sites on VEGF gene expression and 
limited metastasis in nude mice (201) 
 
STAT5 Downregulation of STAT5b mediates proliferation of SCCHN cancer 
cells (202) 
 
p53 Adenovirus-mediated wild-type p53 gene transfer with chemotherapy 
and radiation inhibits progression of lung cancer growth in animal 
models with minimal toxicity (203) 
 
 
 
Each of the three zinc fingers in Sp1 recognizes three bases in one 
strand, and a single base in the complementary strand of the GC-rich elements 
and the consensus Sp1 binding site is 5′-(G/T)GGGCGG(G/A)(G/A)(C/T)-3′.  
Sp/KLF transcription factors have similar modular structures. Sp1–Sp4 form a 
subgroup (Figure 6) containing several distinct overlapping features/regions 
which include activation domains (AD), the C-terminal zinc finger DNA-binding 
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region, and an inhibitory domain (ID) in Sp3 that is involved in the suppressive 
activity of Sp3. Sp5–Sp8 are structurally similar and appear to be truncated 
forms of Sp1–Sp4 in which portions of the N-terminal regions have been 
deleted.   
Sp1–Sp6 proteins contain several common domains in their C-terminal 
region, whereas Sp5 and Sp6 exhibit a truncated N-terminal structure. 
Buttonhead (Btd) and Sp boxes are conserved regions in all Sp proteins (204). 
Sp1–Sp4 proteins regulate expression of multiple genes in normal tissues and 
tumors. Sp1 directly interacts with TATA-binding protein associated factors 
(TAFs) and other basal transcription factors. 
Sp1−/− embryos exhibit multiple abnormalities and retarded development 
and embryolethality on day 11 of gestation. Sp3−/− mice exhibit growth 
retardation, defects in late tooth formation, and the animals die at birth and 
Sp4−/− mice either die shortly after birth or survive with significant growth 
retardation (205). 
Mechanisms of Sp-mediated gene expression. The primary 
mechanism of Sp protein-dependent transactivation in cancer and non-cancer 
cell lines involves initial binding to GC-rich promoter sequences and subsequent 
interactions with components of the basal transcription machinery to activate 
gene expression. Sp-dependent activation of genes has been extensively 
investigated primarily using Sp1 and Sp3 proteins as models. Courey and 
coworkers first reported synergistic interactions of Sp1 on GC-rich promoters 
where it has been hypothesised that four Sp1 proteins cooperatively bind to form 
a homooligomeric complex (206). 
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Figure 6. Structural features of Sp proteins. 
 
Sp1 and Sp3 both bind GC-rich sequences, and these interactions can be 
cooperative or Sp3 can decrease Sp1-dependent transactivation. Genes 
regulated by Sp1 and other Sp transcription factors may contain their respective 
cis-element but transcripton may also be due to direct protein–protein 
interactions with other nuclear factors in which only the Sp protein is bound to 
promoter DNA. Sp1-dependent transactivation is dependent on additional 
protein complexes designated as cofactors required for Sp1 coactivation 
(CRSP). The precise role of these proteins in mediating Sp-dependent 
transactivation is not completely defined (207). Sp-dependent transactivation 
through interactions with GC-rich sites is also modulated by Sp1 interactions 
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with other proteins like the AhR, Arnt, several GATA transcription factors, p53, 
MEF2C, SMAD2, SMAD3, SMAD4, Msx1, cyclin A, Oct-1, TBP, HNF3, BRCA1, 
and others.  
Sp1 also binds to several ligand-activated nuclear and orphan nuclear 
receptors, and these include the estrogen receptor (ER), progesterone receptor 
(PR), androgen receptor (AR), retinoic acid receptor (RAR), retinoic X receptor 
(RXR), peroxisome proliferator-activated receptor γ (PPARγ), vitamin D receptor 
(VDR), steroidgenic factor-1 (SF-1), chicken ovalbumin upstream promoter 
transcription factor-II (COUP-TFII) and HNF-4 (208). The C-terminal C/D domain 
of Sp1 is the major site for protein interactions.  Thus, Sp1 and possibly other Sp 
proteins act as multifunctional modulators of gene expression through direct 
interactions with different nuclear proteins (DNA-independent) or by interacting 
with DNA-bound transcription factors.  
Several reports indicate that phosphorylation of Sp1 by various kinase 
pathways is important for Sp1-dependent activation of some genes, and this 
adds to the functional complexity of this transcription factor. Regulation of VEGF 
in several prostate cancer cell lines is dependent on phosphatidylinositol-3-
kinase (PI3-K) activity, and this is linked to increased phosphorylation of Sp1 
and enhanced binding to the proximal GC-rich −88/−66 VEGF promoter 
sequence. In contrast, mitogen-activated protein kinase (MAPK)-dependent 
phosphorylation of Sp1 is important for induction of α6-integrin gene expression 
in prostate cancer cells (209).  Acetylation of Sp1 and Sp3 have also been linked 
to increased transactivation, for example topoisomerase II inhibitors activate the 
SV40 promoter in cancer cell lines through acetylation of Sp1 (210) and 
acetylation of Sp1 and Sp3 is dependent on the coregulator p300 which exhibits 
histone acetyltransferase activity.  
Sp proteins and critical Sp-dependent tumor genes as targets for 
therapeutic intervention.  Sp family proteins regulate basal/constitutive 
expression of genes in normal and tumor tissues. Initially, the ubiquitous 
  
                                                                                                                                        60
 
 
 
transcription factor Sp1 was considered a constitutive activator of housekeeping 
genes and other TATA-less genes. Genes that regulate growth and cell cycle 
progression frequently contain proximal GC-rich promoter sequences, and their 
interactions with Sp proteins and other transcription factors are critical for their 
expression. Several studies show that VEGF expression in cancer cell lines is 
regulated through Sp protein interactions with several proximal GC-rich motifs 
and this suggests that Sp transcription factors may contribute to cancer cell 
proliferation, survival and angiogenesis. (211).  Mapping of GC-rich Sp binding 
sites on chromosomes 21 and 22 indicates that the full genome has at least 
12000 GC-rich Sp binding sites in the full human genome. (212).  
Among Sp1 target genes in cancer cells (Figure 7) are many key players 
in cell proliferation, survival and metastasis including prominent oncogenes and 
tumor suppressors. Several Sp-regulated genes are important for phenotypes 
associated with the six hallmarks of cancer (16), namely self-sufficiency in 
growth signals, insensitivity to anti-growth signals, evasion of apoptosis, limitless 
replicative potential, sustained angiogenesis and tissue invasion and metastasis 
genomic instability and cell growth/metabolism (mobilization of resources) (213) 
are also regulated by Sp transcription factors. With respect to cell cycle 
progression Sp1 activates transcription of several genes importantly for cell 
proliferation and G1 to S phase cell cycle progression and thse include D-type 
cyclins, cyclin E, Cdk2, E2F-1 and c-Myc (Figure 7). Thus, Sp transcription 
factors promote the G1/S-transition because cyclin D/Cdk4 and cyclin E/Cdk2 
induce the entry of cells into S-phase and because E2F-1 and c-Myc are the two 
transcription factors, that induce S-phase entry of quiescent cells (214).  In some 
cells Sp1 can be phosphorylated specifically in mid-late G1-phase (215)  and 
expression of a dominant-negative form of Sp1 prolonged S-phase and 
decreased the growth of fibroblast cells. Sp1 is versatile and also activates 
transcription of genes encoding all seven cyclin-dependent inhibitors, i.e. 
p15INK4B, p16INK4A, p18INK4C, p19INK4D, p21WAF1/CIP1, p27KIP1 and p57KIP2 indicating 
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that Sp1 also has the potential to contribute to cell cycle arrest. In addition, p53 
synergizes with Sp1 in transactivation of the p21 promoter (216). Sp1 target 
genes include both pro- and anti-angiogenic factors/proteins that promote and 
inhibit invasion and metastasis. Depletion of Sp1 by siRNA impaired the 
angiogenic potential of PANC-1 pancreatic adenocarcinoma cells (217) and in 
another study, Sp1 U1snRNA/ribozyme inhibited the anchorage-independent 
growth on soft agar of malignantly transformed PH2MT and γ2-3A/SB1 
fibrosarcoma cells (218). Sp1 is  overexpressed in several cancers and the Sp1 
levels correlated with tumor grade/stage and poor prognosis (204) (219) (220) 
(221). Thus, the outcome of Sp1 action is highly cell context-dependent 
underscoring the versatility of this transcription factor. Studies in this laboratory 
have demonstrated that an underlying mechanism of action of anticancer agents 
such as tolfenamic acid (TA), betulinic acid and curcumin is due to repression of 
Sp proteins in cancer cells (222). 
Genes regulated by Sp1 and other Sp transcription factors promote cell 
proliferation, self-suffeciency of growth signals, limitless replicative potential, cell 
survival, angiogenesis, invasion and metastasis and cell growth (223). Sp-
regualted gene products are also important for maintaining and perturbing 
genomic stability.  Sp1 overexpression induced apoptosis whereas a dominant-
negative form of Sp1 suppressed apoptosis (224). In contrast, siRNA-mediated 
knockdown of Sp1 enhanced the H2O2-induced apoptosis of U2OS 
osteosarcoma cells, but had no effect in untreated cells. Depletion of Sp1 in 
normal human dermal fibroblast (NHDF) cells by siRNA increased the number of 
DNA double-strand breaks after exposure to ionizing radiation, but had no effect 
in untreated cells (225).  The Sp1 target gene c-Myc (226) (227) is a potent 
oncogene, which stimulates every aspect of cell proliferation, cell growth and 
oncogenesis and hence Sp1 has the potential to support tumorigenesis. 
Moreover, depletion of Sp1 by siRNA decreased tumor growth and metastasis of 
N67 gastric cancer cells in nude mice (228).  Sp/KLF gene knockout studies 
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emphasized the critical role of these transcription factors in normal development 
of tissues/organs. For many human cancers, Sp protein overexpression is a 
negative prognostic factor for survival and these transcription factors contribute 
to the proliferative and metastatic tumor phenotype. Strategies for inhibiting Sp-
dependent pathways have focused on several approaches which include drugs 
that inactivate GC-rich DNA motifs, oligonucleotides and peptide nucleic acid–
DNA chimeras that specifically interact with Sp1 binding motifs (decoys), and 
chemicals that modulate Sp protein expression. The DNA binding antitumor drug 
hedamycin complexes with G-rich DNA, and this compound inhibits survivin 
transcription through interactions with a proximal GC-rich Sp1 binding site (−115 
to −95) in the survivin promoter.  Double stranded oligodeoxynucleotides 
containing a consensus GC-rich Sp1 binding site (Sp1 decoys) have been 
developed for inhibiting Sp1-dependent gene expression (229).   
Transcription factors are now recognized as targets for development of 
new anticancer drugs (230), and the important role of Sp-dependent gene 
expression in tumor development, growth and metastasis has been established 
(204) (204). The complexity of Sp-dependent regulation of genes in cancer has 
primarily been reported for Sp1 and to a lesser extent Sp3; however, based on 
recent reports it is conceivable that Sp4 protein may also be important. The 
complexity of Sp protein-dependent regulation of genes is illustrated in Figure 7 
and regulation of these genes is dependent on domain-specific interactions of 
Sp1 with other nuclear factors (DNA-independent), DNA-bound transcription 
factors, and chemical- and enzyme-induced modifications. Elevated Sp protein 
expression in tumors is correlated to up regulation of multiple genes that are 
involved in tumor growth and metastasis. Targeting transcription factors as a 
therapeutic strategy in cancer patients raises three major concerns: Selectivity, 
specificity and differential sensitivity. The global inhibition of a specific TF is 
likely to result in undesirable side effects in non-target tissues. The requirement 
for selective targeting necessitates optimization through cancer-directed delivery 
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and cancer-specific effector activation (that is, using cancer-specific promoters, 
such as hTERT). Transcription factors in the same family also have similar or 
shared motifs, or structures, but different functions. This presents the second 
challenge. For treatments to be effective, the targeting moieties will have to be 
able to distinguish between TFs of the same family.  
Finally, quantitative rather than qualitative differences between cancer 
and normal tissues may be important for differential sensitivity to drugs targeting 
Sp proteins. Recent developments in delivery vehicles and directed targeting (for 
example, liposomes, nanoparticles and aptamers) along with more accurate and 
potent effectors (that is, shRNA, siRNA, ribozymes, antisense oligonucleotides, 
small-molecule inhibitors and zinc finger proteins) may be important for 
enhancing the effectiveness and selectivity of agents that target Sp and other 
transcription factors. 
Natural products and their use as ancient medicinals 
 
Phytochemicals from plant extracts have been used throughout human 
history for health benefits. Medicines derived from plants have played a pivotal 
role in the health care of many cultures, both ancient and modern (231) (232) 
(233). Of the approximately 877 small molecule drugs introduced worldwide 
between 1981 and 2002, approximately 60% can be traced back to their origins 
as natural products (231).  Examples of natural products that provide frontline 
pharmacotherapy include steroids, cardiotonic glycosides (Digitalis glycosides), 
anticholinergics (belladonna type atropine alkaloids), analgesics and antitussives 
(opium alkaloids), antihypertensives (reserpine), cholinergics (physostigmine, 
pilocarpine), antimalarials (Cinchona alkaloids), antigout (colchicine), anesthetic 
(cocaine), skeletal muscle relaxant (tubocurarine), and anticancer agents. It has 
been estimated that plant-derived drugs represent about 25% of the entire 
prescription drug market in the United States and over one-half of the top 25 
prescription products are plant-derived (234).  
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Figure 7. Functions of Sp target genes in regulating hallmarks of cancer 
cells.  
1. Cell proliferation 
Cell cycle progression  
G1/S transition 
Cyclin D1, D2, D3, E and 
cdk2 
G2/M transition 
Cyclin B1, cdc25C 
Mitosis 
Cyclin B1, survivin  
Transcription factors stimulating 
S-phase entry 
c-Myc, c-jun, N-Myc, c-Fos 
Nucleoside biosynthesis 
DHFR, dCK, TK, TS, ODC 
2. Self sufficiency in growth signals 
Receptor kinases and their ligands. 
PDGF-a, b, PDGFR-a, b, c-Met, TGF-a, EGFR 
Non-receptor tyrosine kinases 
c-Src 
3. Limitless replicative 
potential  
4. Cell survival 
IGF-II, IIR, MCL-1, survivin, XIAP 
5. Angiogenesis 
VEGF, VEGFR1, R2, FGFR1, 
PAI-1, MMP-2, MMP-9 
6. Invasion, metastasis 
MMP-2, MMP-9, vimentin, uPA 
7. Cell growth 
c-Myc, N-myc, HSP70 
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Moreover certain natural compounds polyphenols, flavonoids, and 
isothiocyanates have multiple pharmaceutical effects including their antioxidant, 
antiviral, antibacterial, anti-inflammatory, antifungal, immunomodulatory, and 
cancer preventive and anti-cancerous activities (235).  
 
Cancer chemoprevention  
 
During the 1960s and 1970s, studies by Wattenberg et al demonstrated 
that various compounds, especially those associated with fruits and vegetables 
such as indoles and isothiocyanates; inhibit chemically-induced tumor formation 
and growth in laboratory animals. This was the advent of “chemoprophylaxis of 
carcinogenesis” (236), and the implications of these observations in terms of 
human health maintenance were immediately apparent. Subsequently based on 
certain hallmark studies performed with a variety of retinoids, Sporn coined the 
term “cancer chemoprevention” (237) to further define the phenomenon. Cancer 
chemoprevention in human populations is defined as prevention of cancer by 
ingestion of chemical agents that prevent carcinogenesis. It is important to 
differentiate the concept of cancer chemoprevention from primary cancer 
prevention, which is exemplified by the cessation of cigarette smoking, or cancer 
chemotherapy, which may enhance or initiate cancers after treatment. Cancer 
chemoprevention has developed as a well-defined and distinct discipline of 
science. Epidemiological studies show that dietary factors decrease the 
incidence of some cancers (238) presumably through chemopreventive 
mechanisms and various prospective studies are currently underway (239) 
(240). It is likely that dietary constituents such as garlic, ginger, soy, curcumin, 
onion, tomatoes, cruciferous vegetables, chillies and green tea exhibit 
chemopreventive activity against some cancers. There is a diverse structural 
array of compounds that may be considered “chemopreventive,” and over 600 
agents may be considered in this category (241). Examples include inhibitors of 
initiation such as phenols, flavones, aromatic isothiocyanates, diallyldisulfide, 
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ellagic acid, antioxidants and inhibitors of post-initiation events such as 
carotene, retinoids, terpenes, protease inhibitors, prostaglandin inhibitors, and 
nerolidol. Natural products have been classified as chemopreventive agents due 
to their ability to delay the onset of the carcinogenic process and since these 
chemopreventive agents are derived from natural sources, they are considered 
pharmacologically safe. Some dietary agents suppress the transformative, 
hyperproliferative and inflammatory processes that initiate carcinogenesis 
(Figure 8) and thus may ultimately suppress the final steps of carcinogenesis, 
i.e., angiogenesis and metastasis.   
 
Natural products and their synthetic analogs as anti-cancer agents    
                                                                                                                                        
  It has been estimated that genetic factors cause only 5–10% of all 
human cancers, while the remainder is caused by lifestyle. In spite of extensive 
research on development of safe and efficacious drugs for cancer 
chemotherapy, most agents are also toxic and associated with adverse side 
effects, suggesting a need for mechanism based, less toxic alternatives. 
Interestingly, more than 70% of the FDA approved anticancer drugs can 
be traced back to their origin as plant-derived natural products, which were 
traditionally used as ancient remedies for various ailments (94). Vinblastine from 
Vinca rosea is one of the earliest example of an anticancer drug from an oriental 
medicine and paclitaxel is a recent example of a compound that originated from 
the Chinese pacific yew plant (242). 
There is increasing evidence that natural products are important as 
pharmaceuticals particularly for antitumor drugs such as paclitaxel (Taxol), 
vincristine (Oncovinm), vinorelbine (Na, velbine), teniposide (Vumon), and 
various water-soluble analogs of camptothecin (e.g., Hycamtin) (234). Cancer 
chemopreventive agents, many of which are natural products, can also inhibit 
and prevent carcinogenesis. 
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Figure 8. The multistep process of carcinogenesis showing steps of 
intervention by chemopreventive agents.  
 
Cancer rates increase with advancing age and it is estimated that 
tumorigenesis begins at a young age (around 20 years) and tumors are not 
observed until 20–30 years after initiation (243) (94). Recent studies indicate 
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that in any given type of cancer 300–500 normal genes have been modified 
(dysregulated) to give the cancer phenotype. Although cancers are 
characterized by dysregulation of cell signaling pathways, most current 
anticancer therapies are directed against a single target and these are 
ineffective when compared to multitargeted therapies. Several phytochemical-
derived drugs including curcumin, triterpenoids and betulinic acid modulate 
several pathways in cancer cells and are discussed in the following section.  
 
Curcumin 
 Curcumin (diferuloylmethane), a polyphenol, is a yellow colored active 
principle of the perennial herb Curcuma longa (commonly known as turmeric) 
that belongs to the ginger (Zingiberaceae) family (235).  Curcumin was first 
isolated in 1815, obtained in crystalline form in 1870, and ultimately identified as 
1,6-heptadiene-3,5-dione-1,7-bis(4-hydroxy-3-methoxyphenyl)-(1E,6E) or 
diferuloylmethane. In 1910, the feruloylmethane skeleton of curcumin was 
confirmed and synthesized by Lampe (244). Curcumin is insoluble in water and 
ether but soluble in ethanol, dimethylsulfoxide, and acetone. Curcumin has a 
melting point of 183 °C, a molecular formula of C21H20O6, and a molecular 
weight of 368.37 g/mol. Curcumin exists in enolic and β-diketonic forms. The 
fact that curcumin in solution exists primarily in its enolic form has an important 
influence on the radical-scavenging ability of curcumin.   
Curcumin, the active component of turmeric and is now recognized as 
being responsible for most of the therapeutic effects. It is estimated that 2–5% of 
turmeric is curcumin. Turmeric contains three different analogues of curcumin 
(i.e., diferuloylmethane, also called curcumin, demethoxycurcumin, and 
bisdemethoxycurcumin) (Figure 9). Whether all three analogues exhibit equal 
activity is not clear. 
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Figure 9. Natural analogs of curcumin and curcumin metabolites. 
 
When administered orally, curcumin is metabolized into curcumin 
glucuronide and curcumin sulfate. In contrast, when administered systemically or 
intraperitoneally, it is metabolized into tetrahydrocurcumin, hexahydrocurcumin, 
and hexahydrocurcuminol (Figure 9) (245). Curcumin can act as a food 
preservative, a coloring agent and enhances the taste of various foods and in 
recent years the health promoting affects of curcumin have been recognized. 
Curcumin was once considered a cure for jaundice, an appetite 
suppressant, and a digestive. This spice was also used for alleviating stomach 
and liver problems, to heal wound healing and as a cosmetic (246). Curcumin 
exhibits antioxidant, anti-inflammatory, antiviral, antibacterial, antifungal, and 
anticancer activities and has potential for treating several malignant diseases, 
diabetes, allergies, arthritis, Alzheimer’s disease and other chronic illnesses. 
The effects of curcumin are mediated through regulation of various transcription 
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factors, growth factors, inflammatory cytokines, protein kinases, and other 
enzymes. 
Turmeric’s pharmacological safety is accepted, since it has been 
consumed as a dietary spice, at doses up to 100 mg/d, for centuries (247). 
Research over the last 20 years has shown that curcumin is a potent anti-
inflammatory agent with strong therapeutic potential against a variety of cancers. 
Curcumin suppresses transformation, proliferation, and metastasis of tumors. It 
also inhibits proliferation of cancer cells by arresting cancer cell cycle 
progression and by inducing apoptosis. Curcumin inhibits carcinogen 
bioactivation via suppression of specific cytochrome P450 isozymes, and 
induces expression of phase II carcinogen detoxifying enzymes, and this may 
account for the cancer chemopreventive effects of this compound. Curcumin 
exhibits therapeutic effects against cancers of the blood, skin, oral cavity, lung, 
pancreas, and intestinal tract, and suppresses angiogenesis and metastasis in 
rodent tumor models (248).  Curcumin inhibits proliferation of various tumor cells 
in culture, prevents carcinogen-induced cancers in rodents and inhibits growth of 
human tumors in xenograft or orthotopic animal models either alone or in 
combination with other chemotherapeutic agents or radiation. Several phase I 
and phase II clinical trials indicate that curcumin is quite safe and exhibits 
therapeutic efficacy. Phase I clinical trials indicate that doses as high as 12 g of 
curcumin per day for over 3 months is well tolerated in humans (242). Curcumin 
modulates expression of several critical genes in cancer and these are 
discussed in this section: 
1. Transcription Factors. Curcumin regulates the expression of various 
transcription factors as discussed: 
a. NF-κB. NF-κB is a family of five closely related proteins which are found in 
several dimeric combinations and bind to the κB sites on DNA. Under resting 
conditions, NF-κB dimers reside in the cytoplasm. On activation by free radicals, 
inflammatory stimuli, cytokines, carcinogens, tumor promoters, endotoxins, 
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gamma-radiation, ultraviolet (UV) light, or x-rays, NF-κB is translocated to the 
nucleus, where it induces the expression of more than 200 genes that suppress 
apoptosis and induce cellular transformation, proliferation, invasion, metastasis, 
chemoresistance, radioresistance, and/or inflammation (235). Curcumin 
suppresses activation of NF-κB induced by various tumor promoters, including 
phorbol ester, TNF, and hydrogen peroxide. Recently, it was shown that 
curcumin down-regulated cigarette smoke-induced NF-κB activation through 
inhibition of IKK in human lung epithelial cells and curcumin also suppresses 
constitutively active NF-κB in multiple myeloma, head and neck cancers, 
pancreatic cancers, and mantle cell lymphoma.  NF-κB plays important roles in 
inflammation, cell proliferation, apoptosis, and oncogenesis. Suppression of NF-
κB activation by curcumin is important for its anticancer activity (249). 
b. STAT. signal transducers and activators of transcription (STAT) proteins 
are signaling molecules with dual functions that are activated by phosphorylation 
through janus kinase (JAK) or cytokine receptors, G-protein-coupled receptors, 
or growth factor receptors. Of the seven STAT proteins constitutively activated 
STAT3 and STAT5 have been implicated in multiple myeloma, lymphomas, 
leukemias, and several solid tumors, making these proteins logical targets for 
cancer therapy. STAT proteins contribute to cell survival and growth by 
preventing apoptosis through increased expression of antiapoptotic proteins, 
such as bcl-2 and bcl-XL. Recently, STAT3 was shown to be a direct activator of 
the angiogenic VEGF gene. Bharti et al demonstrated that curcumin inhibited 
interleukin (IL) 6-induced STAT3 phosphorylation and subsequent STAT3 
nuclear translocation (250). The constitutive phosphorylation of STAT3 found in 
multiple myelomas was decreased after treatment with curcumin (251) (Figure 
10).   
c. AP-1. AP-1 is a transcription factor that is frequently associated with 
activation of NF-κB and has been closely linked with proliferation and 
transformation of tumor cells. Curcumin inhibits activation of AP-1 induced by 
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tumor promoters. Activation of AP-1 requires the phosphorylation of c-jun 
through activation of stress-activated kinase JNK, and curcumin suppresses 
carcinogen-induced JNK (25). Hydrogen peroxide stimulates proliferation and 
migration of human prostate cancer cells through activation of AP-1 and up-
regulation of the heparin affin regulatory peptide (HARP) gene. Curcumin 
abrogated both hydrogen peroxide-induced HARP expression and LNCaP cell 
proliferation and migration (252).  
d. PPAR-γ. Peroxisome proliferator-activated receptors (PPARs) are a subfamily 
of the nuclear receptor superfamily of ligand-activated receptors; PPAR , 
PPAR , and PPARβ/ , are lipid sensors and play a key role in regulating tissue-
specific lipid homeostasis and metabolism. PPARs also play an important role in 
many diseases, particularly those related to obesity, metabolic disorders, cancer, 
and atherogenesis. Endogenous ligands for PPARs include fatty acid-derived 
compounds and 15-deoxy- 12,14-prostaglandin J2 (PGJ2), which exhibits high 
affinity for PPAR ; however, PGJ2 might not be the endogenous ligand for this 
receptor because of the low cellular expression of this metabolite. Synthetic 
PPAR  agonists, such as the thiazolidinediones rosiglitazone and pioglitazone, 
are insulin-sensitizing drugs that are widely used for clinical treatment of type II 
diabetes. PPAR  is overexpressed in many tumor types and cancer cell lines 
(253), and PPAR  agonists show promise for clinical treatment of various types 
of tumors (254). Ligands for this receptor typically inhibit G0/G1-to S-phase 
progression, and this is accompanied by downregulation of cyclin D1 expression 
and induction of the cyclin-dependent kinase inhibitors p27 or p21. Activation of 
PPAR-γ inhibits the proliferation of cancer cells and nonadipocytes (255).  
Inhibition of PPARγ dependent transactivation by PPARγ antagonists markedly 
decreases the growth-inhibitory effects of curcumin. Chen and coworkers 
recently reported that curcumin-dependent activation of PPARγ inhibited Moser 
cell growth and mediated suppression of cyclin D1 and EGFR gene expression 
(256).  
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e. CAMP Response Element-Binding Protein. p300/CBP, along with other 
histone acetyltransferases (HATs), have been implicated in cancer cell growth 
and survival. HAT-dependent acetylation of specific lysine residues on the N-
terminal tail of core histones results in uncoiling of DNA and increased 
accessibility for binding transcription factors. In contrast, histone deacetylation 
by histone deacetylase represses gene transcription by promoting DNA winding, 
thereby limiting access to transcription factors. Curcumin is a selective HAT 
inhibitor (257). The α and β unsaturated carbonyl groups in the curcumin side 
chain function as Michael reaction sites, which are required for its HAT-inhibitory 
activity. Balasubramanyam and coworkers found that curcumin is a specific 
inhibitor of the p300/CBP HAT activity but not of p300/CBP-associated factor, in 
vitro and in vivo (258).  
f. β-Catenin. β-Catenin is a central component of the cadherin cell adhesion 
complex and plays an essential role in the Wingless/Wnt signaling pathway. In 
the nucleus, β-catenin interacts with members of the TCF/LEF family of 
transcription factors to stimulate expression of target genes.  Curcumin 
treatment impairs both Wnt signaling and cell–cell adhesion pathways, resulting 
in cell cycle arrest at the G2/M phase and induction of apoptosis in HCT-116 
colon cancer cells. Mahmoud and coworkers, while investigating the efficacy of 
curcumin for prevention of tumors in C57BL/6J-Min/+ (Min/+) mice, found that 
curcumin decreased expression of the oncoprotein β-catenin in the enterocytes 
of the Min/+ mouse, and this was important for the antitumor effect of curcumin 
(259). 
g. Tumor Suppressor Gene p53. p53 is a tumor suppressor and a transcription 
factor. It is a critical regulator of many cellular processes, including cell signaling, 
the cellular response to DNA damage, genomic stability, cell cycle control, and 
apoptosis. P53 activates transcription of downstream genes such as p21WAF1 
and Bax to induce the apoptotis and inhibit the growth of cells with damaged 
DNA (260). In neuroblastoma, curcumin up-regulated p53 expression and 
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induced nuclear translocation of p53, followed by induction of p21WAF-1/CIP-1 and 
Bax expression (261). 
h. Sp. Several reports show that Sp1 protein is overexpressed in various cancer 
types including gastric, colorectal, pancreatic, epidermal, thyroid and breast 
cancers and recent studies in this laboratory clearly show overexpression of the 
Sp1, Sp3 and Sp4 proteins in cancer versus non-cancer cells (220) (262). Lou et 
al. have shown that malignant transformation of human fibroblasts resulted in an 
8- to 18-fold increase in Sp1 expression and the transformed cells formed 
tumors in athymic nude mouse xenografts (218). In contrast, Sp1 knockdown 
gave cells that were non-tumorigenic in the same mouse xenograft model. This 
suggests that Sp transcription factors may contribute to tumor phenotype and 
studies in this laboratory have demonstrated that an underlying mechanism of 
action of anticancer agents such curcumin is the targeted repression of Sps in 
cancer cells (263).  
2. Tumor necrosis factor (TNF). TNF mediates tumor initiation, promotion, and 
metastasis and the pro-inflammatory effects of TNF are due primarily to its ability 
to activate NF-κB (264).  TNF activates NF-κB in most cells, leading to 
expression of inflammatory genes such as COX-2, LOX-2, cell adhesion 
molecules, inflammatory cytokines, chemokines, and inducible nitric oxide 
synthase. Curcumin suppresses expression of TNF at both the transcriptional 
and posttranscriptional levels (265).  
3. Inflammatory Enzymes. 
a. Cyclooxygenase-2 . Cyclooxygenases are forms of prostaglandin H 
synthase, which converts arachidonic acid released by membrane phospholipids 
into prostaglandins. COX-2 is regulated by mitogens, tumor promoters, 
cytokines, and growth factors. It is overexpressed in practically every 
premalignant and malignant condition involving the colon, liver, pancreas, 
breast, lung, bladder, skin, stomach, head and neck, and esophagus (266).   
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Figure 10. Molecular targets of curcumin (94).   
 
Preclinical studies have shown that curcumin suppresses COX-2 activity 
through suppression of the NF-κB-inducing kinase and IKK enzymes. Plummer 
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et al showed that inhibition of COX-2 is a biomarker of drug efficacy and is used 
in clinical trials of many chemopreventive drugs that inhibit this enzyme. When 1 
μM curcumin was added in vitro to blood from healthy volunteers, LPS-induced 
COX-2 protein levels and concomitant prostaglandin E2 production was reduced 
by 24 and 41%, respectively (267). 
b. Lipoxygenase . Lipoxygenases (LOX) are enzymes responsible for 
generating leukotrienes from arachidonic acid. There are three types of LOX 
isozymes, namely, 15-LOX which is required for the synthesis of anti-
inflammatory 15-HETE; 12-LOX which is involved in provoking 
inflammatory/allergic disorders; and 5-LOX produces 5-HETE and leukotrienes 
which are potent chemo- attractants that promote development of asthma. 
Aberrant arachidonic acid metabolism is involved in the inflammatory and 
carcinogenic processes. Curcumin and its metabolite tetrahydrocurcumin 
effectively inhibited the release of arachidonic acid and its metabolites in LPS-
stimulated RAW cells and A23187-stimulated HT-29 colon cancer cells. They 
were potent inhibitors of prostaglandin E2 formation in LPS-stimulated RAW 
cells. Curcumin affects arachidonic acid metabolism by blocking phosphorylation 
of cytosolic phospholipase A2, decreasing the expression of COX-2, and 
inhibiting the catalytic activities of 5-LOX. These activities may contribute to the 
antiinflammatory and anticarcinogenic actions of curcumin and its analogs 
(Figure 10) (268). 
4. Cyclin D1. Cyclin D1 is a component subunit of the Cdk4 and Cdk6 
complexes which are rate-limiting for progression of cells through the G1 phase 
of the cell cycle. The loss of this regulation is a hallmark of cancer. (269).  Cyclin 
D1 is overexpressed in many cancers, including those of the breast, esophagus, 
head and neck, and prostate, and mantle cell lymphoma (247). Curcumin down-
regulates expression of cyclin D1 in bladder cancer cells (Figure 10) (263). 
Suppression of NF-κB in mantle cell lymphoma by curcumin also decreased 
cyclin D1 levels and formation of the cyclin D1-Cdk4 holoenzyme complex 
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resulting in inhibition of cell proliferation and induction of apoptosis. In another 
study, curcumin induced G0/G1 and/or G2/M phase cell cycle arrest, up-regulated 
cdk inhibitors such as p21/Cip1/waf1 and p27Kip1, and down-regulated cyclin B1 and 
cdc2 (270).  
5. Protein Kinases.       
i. EGFR/HER2/neu . HER2/neu (also known as ErbB-2, avian erythroblastosis 
oncogene B) is a member of the EGFR family and is notable for its role in the 
pathogenesis of breast cancer. HER2/neu is a cell membrane surface-bound 
tyrosine kinase and is involved in the signal transduction pathways leading to 
cell growth and differentiation. Almost 30% of breast cancers overexpress the 
HER2/neu protooncogene, and both HER2 and EGF receptors stimulate 
proliferation of breast cancer cells. Overexpression of these two proteins 
correlates with progression of human breast cancer and poor patient prognosis 
(271). Curcumin downregulates the activity of EGFR and HER2/neu and 
depletes cells of HER2/neu protein (272) (273).  EGFR is expressed at high 
levels in colorectal, bladder, prostate and other cancers. Curcumin down-
regulates EGFR signaling in prostate cancer cells by down-regulating levels of 
EGFR protein; curcumin also inhibits the intrinsic EGFR tyrosine kinase activity, 
by blocking ligand-induced activation of EGFR (274). 
ii. Other Protein Kinases. Curcumin can mediate its effects through modulation 
of other protein kinases involved in carcinogenesis including protein kinase A 
(PKA), protein kinase C (PKC), protamine kinase (cPK), phosphorylase kinase 
(PhK), autophosphorylation-activated protein kinase (AK), and pp60c-src 
tyrosine kinase.  Approximately 0.1 mmol/L cucrumin inhibited PhK, pp60c-src, 
PKC, PKA, AK, and cPK by 98, 40, 15, 10, 1, and 0.5%, respectively. The 
ubiquitously expressed nonreceptor tyrosine kinase c-Abl regulates stress 
responses induced by oxidative agents such as ionizing radiation and hydrogen 
peroxide and curcumin activates c-Abl, which in turn mediates the cell death 
response, in part through activation of JNK (275).  
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6. Adhesion molecules. Cell adhesion molecules are transmembrane proteins 
required for cell-cell interactions and for binding of other extracellular molecules. 
Expression of various cell surface adhesion molecules, such as intercellular cell 
adhesion molecule-1, vascular cell adhesion molecule-1, and endothelial 
leukocyte adhesion molecule-1, on endothelial cells is critical for tumor 
metastasis (276). Curcumin blocks the cell surface expression of adhesion 
molecules in endothelial cells (Figure 10), and this is accompanied by 
suppression of tumor cell adhesion to endothelial cells by modifying cell receptor 
binding. Curcumin inhibits binding of fibronectin, vitronectin, and collagen IV to 
the extracellular matrix (ECM) proteins. It also suppresses the expression of 
α5β1 and α5β3 integrin receptors, pp125 focal adhesion kinase (FAK) and 
collagenase activity. Curcumin also enhances expression of antimetastatic 
proteins, TIMP-2, nonmetastatic gene 23 (Nm23), and E-cadherin (259) (277).  
In summary, curcumin exhibits antiproliferative effects by suppressing the 
cell cycle regulatory proteins by blocking entry to the cell cycle from G2 to M by 
inhibiting expression of cdc2/cyclin B (278), inhibiting growth of transplantable 
tumors in different animal models and increasing the life span of tumor-harboring 
animals.  Curcumin decreases repression of antiapoptotic members of the Bcl-2 
family and increases expression of p53, Bax, and procaspases-3, -8, and -9 
(279).  Inhibition of metastasis by curcumin is due to up regulation of anti- 
metastatic proteins TIMP-2, Nm23, and E-cadherin, which reduce the metastatic 
tendency of the melanoma cells (277).  Curcumin inhibits angiogenesis by 
downregulation of VEGF and its receptors as well as MMPs involved in 
aggressive tumor phenotypes (280). Furthermore, curcumin enhances the 
cytotoxic effects of chemotherapeutic drugs, including doxorubicin, tamoxifen, 
cisplatin, camptothecin, daunorubicin, vincristine, and melphalan (281) (282) and 
radiation. Curumin is a radio-sentitizer that overcomes the radio-induced 
prosurvival gene expression. Curcumin decreases the dose of chemotherapeutic 
agents; helps to enhance the effect at lower doses and thus minimize 
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chemotherapy-induced toxicity (283).                                                                                                    
7. Bladder cancer. Many deaths due to bladder cancer involve advanced, un-
resectable, chemotherapy-resistant tumors. Numerous reports indicate that 
curcumin has activity against bladder cancer; for example, curcumin decreases 
proliferation of bladder cancer cells in culture through modulation of several 
genes/gene products and some synthetic curcumin analogs are also active 
against bladder cancer cell lines (284). Curcumin effectively inhibits tumor 
implantation and growth in a murine bladder tumor model and a phase I clinical 
trial in patients with resected bladder cancer indicates that up to 12 g per day of 
curcumin for 3 months is pharmacologically safe. Moreover the investigators 
noted an indication of  histologic improvement of precancerous lesions in one 
out of two patients (242). 
8. Pancreatic cancer.  Research over the past decade has indicated that 
curcumin has an anticarcinogenic effect in various pancreatic cell lines (242) and 
in combination with gemcitabine, curcumin exhibited synergistic antiproliferative 
effects in pancreatic cancer cell lines (285). A polymeric nanocurcumin 
formulation demonstrated therapeutic efficacy comparable to that of free 
curcumin in a panel of human pancreatic cancer cell lines in vitro (286). 
Curcumin in combination with gemcitabine significantly down-regulated 
expression of the cell proliferation marker Ki-67 in tumor tissues compared with 
the control group and curcumin alone significantly suppressed  expression of 
microvessel density marker CD31 and the presence of gemcitabine further 
enhanced the down-regulation of CD31 (286). In a clinical trial, researchers 
evaluated the effect of oral curcumin with piperine on markers of oxidative stress 
in patients with tropical pancreatitis (TP). Twenty patients with pancreatitis were 
randomized to receive 500 mg of curcumin with 5 mg of piperine, or placebo for 
6 weeks, and the effects on the pattern of pain, and in red blood cell levels of 
malonyldialdehyde (MDA) and glutathione (GSH) in red blood cells were 
assessed. There was a significant reduction in the erythrocyte MDA levels 
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following curcumin therapy compared with the placebo there was a significant 
increase in GSH levels, but not a corresponding improvement in pain. In another 
clinical trial, 25 patients received 8 grams of curcumin (orally) every day until 
disease progression, with restaging every 2 months. Serum cytokine levels for 
interleukin IL-6, IL-8, IL-10, and IL-1 receptor antagonists and peripheral blood 
mononuclear cells (PBMC) expression of NF-κB and COX-2 were monitored. In 
the 21 patients evaluated, circulating curcumin was detectable as glucuronide 
and sulfate conjugates suggesting poor oral bioavailability. Two of the patients 
demonstrated clinical biologic activity. One had ongoing stable disease for more 
than 18 months and one additional patient had a brief, but marked, tumor 
regression (73%), accompanied by significant increases (4- to 35-fold) in serum 
cytokine levels (IL-6, IL-8, IL-10, and IL-1 receptor antagonists). No toxicities 
were observed. Curcumin down-regulated expression of NF-κB,   COX-2 and 
phosphorylated STAT3 in PBMC in patients (287).                                                      
 In spite of the above mentioned array of anti-cancer properties of 
curcumin, there are additional undefined targets and also disadvantages 
associated with the use of this compound (286).  Orally administered curcumin 
has poor bioavailability and low tissue accumulation, yet it has been found to be 
effective. The low levels of curcumin in the serum and tissue may account for its 
safety; however, it is doubtful if a therapeutic dose can be attained. Several 
other agents such as piperine and ginger are known to improve the 
bioavailability of curcumin, but, they interfere with drug metabolism by 
suppressing glucuronidation in the liver, this may affect drug safety for 
combination therapies. Adjuvants, nanoparticles, liposomal preparations, 
micelles, phospholipid- conjugates and other potent analogs of curcumin may 
overcome the problems of low bioavailability, low tissue distribution and low half-
life (286), however several significant concerns remain. 
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Triterpenoid acids  
 
Triterpenoids are structurally diverse organic chemicals derived from six 
isoprene units that are assembled in plants by cyclization of squalene, the linear 
precursor of steroids. The basic triterpenoid backbone can be modified in 
numerous ways and more than 20000 different compounds are naturally 
occuring (288). Several triterpenoids, including ursolic and oleanolic acid, 
betulinic acid, celastrol, lupeol, and the triterpenoids of ginsenosides, possess 
modest antitumorigenic or anti-inflammatory properties. Triterpenoids are also 
studied for their anti-inflammatory, hepatoprotective, analgesic, antimicrobial, 
antimycotic, virostatic, immunomodulatory and tonic effects. They are used in 
the prevention and treatment of hepatitis, parasitic and protozoal infections and 
above all, for their cytostatic effects. In addition, several triterpenoid compounds 
structurally related to oleanolic and ursolic acids exhibit anti-inflammatory and 
anticarcinogenic activities and synthetic analogs  with enhanced antitumor 
activity have been developed and these include 2-cyano-3,12-dioxooleana-1,9 
(11)-dien-28-oic acid (CDDO), its methyl ester (CDDO-Me), and imidazolide 
(CDDO-Im), methyl (CDDO-MA), ethyl amides (CDDO-EA), and dintirile (Di-
CDDO) derivatives. Of these CDDO, CDDO-Me, betulinic acid, and the 
ginsenosides have shown promising anticancer activities and are presently 
being evaluated in phase 1 clinical trials for leukemia, lymphoma, and solid 
tumors (Figure 10) (289). The major disadvantage of using triterpenoids is the 
toxicity associated with their haemolytic and cytostatic properties (290). 
Triterpenoids such as CDDO inhibit multiple pathways and this may be 
mediated, in part, by reversible Michael addition of these compounds to 
biological nucleophilic groups such as accessible cysteine sulfides. Synthetic 
oleanane triterpenoids have profound effects on inflammation and the redox 
state of cells and tissues, and also inhibit growth and induced apoptosis in 
rodent cancer models. These drugs have unique molecular and cellular 
mechanisms of action and may act synergistically in combination cancer 
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chemotherapy regimens (288). CDDO, a synthetic oleanane triterpenoid, inhibits 
proliferation of various malignant p53 dependent and independent cells at 
nanomolar concentrations (291). CDDO, CDDO-Me, or CDDO-Im alter the 
expression of several key cell-cycle proteins, including cyclin D1, p21, p27, 
caveolin and Myc (292). CDDO and related compounds activate PPARg and 
induce several receptor-dependent genes including caveolin 1 (293) ; however 
in most cancer cell lines the anticancer activities of these compounds are PPAR-
g independent. Triterpenoids suppress activation of NF B by directly binding to 
and inhibiting its kinase activator, IKK  (294).  STAT transcription factors are 
constitutively activated in many cancers, and CDDO-Im suppresses both 
constitutive and interleukin 6 (IL6) inducible STAT3 and STAT5 phosphorylation 
in myeloma and lung cancer cells, resulting in the cell growth arrest and 
apoptosis (295).   
In another study, using human umbilical vein endothelial (HUVE) cells, 
CDDO-Me and CDDO-Imm inhibited activation of the extracellular signal-
regulated kinase ERK1/2 pathway after stimulation with vascular endothelial 
growth factor (VEGF). CDDO also induced apoptosis in leukemia cells through 
enhanced oxidative stress and loss of mitochondrial membrane potential (296). 
CDDO inhibited growth of ER-positive and -negative breast cancer cells and 
tumor growth in athymic nude mouse models, and this correlated with the 
modulation of genes associated with cell-cycle progression, apoptosis, and ER 
stress (291) In COLO 16 human skin cancer cells, CDDO induced apoptosis, 
and this was in part caused by ER stress and direct mitochondrial effects that 
disrupted calcium homeostasis.  CDDO-Me induced both the intrinsic and 
extrinsic apoptosis pathways in lung cancer cell lines and a caspase-8–
dependent apoptotic pathway was activated by CDDO in human osteosarcoma 
cells (297). These triterpenoid compounds are potent inducers of differentiation 
and apoptosis in leukemia cells; however, their proapoptotic effects were 
somewhat variable among different cell lines.  
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Methyl 2-cyano-3,11-dioxo-18β-olean-1,12-diene-30-oate (CDODA-Me) 
CDODA-Me is a synthetic analog of the naturally occurring triterpenoid 
glycyrrhetinic acid; the major bioactive phytochemical in licorice, CDODA-Me 
contains a 2-cyano substituent in the A-ring (Figure on page 86)  and is a potent 
inhibitor of LNCaP prostate cancer cell growth and activated peroxisome 
proliferator-activated receptor (PPAR ). CDODA-Me induced cyclin dependent 
kinase inhibitors, p21 and p27, down-regulated cyclin D1 protein expression, and 
induced two other proapoptotic proteins, namely nonsteroidal anti-inflammatory 
drug-activated gene-1 (NAG-1) and activating transcription factor-3 (ATF-3) in 
pancreatic cancer cells. However, induction of these responses by CDODA-Me 
was PPAR -independent and due to activation of phosphatidylinositol-3-kinase, 
mitogen-activated protein kinase, and jun N-terminal kinase pathways. CDODA-
Me also decreased androgen receptor (AR) and prostate-specific antigen (PSA) 
mRNA and protein levels through kinase-independent pathways. Potent 
inhibition of LNCaP cell survival by CDODA-Me is due to PPAR -independent 
activation of multiple pathways that selectively activate growth-inhibitory and 
proapoptotic responses. A recent study demonstrated that CDODA-Me induced 
PPAR -dependent transactivation in Panc28 and Panc1 pancreatic cancer cells 
and expression of several growth inhibitory and proapoptotic proteins including 
p21, p27, NAG-1 and ATF3 and downregulated cyclin D1 proteins, and effects 
on these growth inhibitory responses were receptor-independent. CDODA-Me 
also activated multiple kinases in pancreatic cancer cells including p38 and p42 
MAPK, PI3-K, and JNK pathways, and the role of these kinases in the induction 
of NAG-1 and apoptosis was cell context-dependent (298). Recent study 
indicates that in colon cancer cell lines, the anti-cancer activity of -CDODA-Me 
is mediated by the oncogenic microRNA 27-a (miR27-a). MicroRNAs (miRNAs) 
are 20-25 basepair oligonucleotides that interact with complementary binding 
sites in 3 -untranslated regions of target mRNAs to inhibit their expression by 
blocking translation or by decreasing mRNA stability.  Reports show that miR-
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27a targets ZBTB10 mRNA, a putative zinc finger protein that suppresses 
specificity protein (Sp) transcription factors and Sp-dependent gene expression. 
Its been reported that Sp transcription factors Sp1, Sp3 and Sp4 are highly 
expressed in cancer cell lines (299) (263) (262), and results of RNA interference 
studies show that Sp proteins regulate expression of angiogenic genes such as 
vascular endothelial growth factor (VEGF), VEGF receptor 1 (VEGFR1, Flt-1), 
VEGFR2 (KDR) and the antiapoptotic gene survivin (262) (263). CDODA-Me 
acts through downregulation of miR-27a and this is accompanied by enhanced 
expression of ZBTB10 and Myt-1 which arrests colon cancer cells at G2/M 
phase. The cell culture studies were complemented by inhibition of tumor growth 
and decreased miR-27a expression in tumors from athymic nude mice bearing 
RKO cells as xenografts and treated with CDODA-Me (15 mg/kg/d) (300).   
Betulinic acid                                                                                                    
 Lup-20(29)-ene-3β,28-diol (betulin) is a lupane-derived triterpenol that is 
present in high concentrations in birch bark and betulinic acid (BA), an oxidation 
product of betulin, has also been detected in bark extracts (Figure 11) (301). 
Betulin has been used in folk medicine for treating skin diseases; however, 
betulinic acid (BA), induces a broad range of pharmacological activities. BA and 
several derivatives exhibit anticancer activity, inhibit HIV and other viruses 
through multiple pathways, are effective antibacterial and antimalarial drugs, and 
exhibit anti-inflammatory activity. Betulinic acid was initially identified as a 
melanoma-specific cytotoxic agent that exhibits low toxicity in animal models. 
Subsequent studies show that betulinic acid induces apoptosis and 
antiangiogenic responses in tumors derived from multiple tissues (Figure 11) 
(302). The antitumorigenic activities of BA have been extensively investigated 
and this compound inhibits tumor growth through multiple pathways and these 
responses are also cancer cell/tumor-dependent. BA is shown to induce 
apoptosis through decreased mitochondrial membrane potential, activation of 
mitogen-activated protein kinase, and modulation of nuclear factor κB (NFκB) 
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(303, 304). Using LNCaP prostate cancer cells as a model, betulinic acid 
decreased expression of vascular endothelial growth (VEGF) and the 
antiapoptotic protein survivin. The mechanism of betulinic acid–induced 
antiangiogenic and proapoptotic responses in prostate cancer cells and 
xenograft tumors was due to activation of proteasome-dependent degradation of 
Sp1, Sp3 and Sp4 transcription factors, which regulate VEGF and survivin 
expression. Betulinic acid, thus, acts as a novel anticancer agent through 
targeted degradation of Sp proteins that are highly overexpressed in tumors 
(305).                                                                                                                         
 Rzeski and coworkers demonstrated the involvement of bcl-2 and cyclin 
D1 in the induction of apoptosis and growth inhibition mediated by BA in HT-29 
colon cancer cells; overexpression of Bcl-2 correlates with chemoresistant 
phenotype and bcl-2 is a negative prognostic marker for cancer survival (306). 
BA decreased Bcl-2 genes expression and significantly changed the bax/Bcl-2 
ratios in the treated cells. The combined antitumor activity of BA with Vincristine 
(VCR) was evaluated in murine melanoma B16F10 cells in vitro and in vivo and 
the results showed synergistic cytotoxic effects. The drug combination induced 
cell cycle arrest at different points (BA at G1 phase and VCR at G2/M phase) 
and caused apoptosis in B16F10 melanoma cells. In the in vivo study, VCR 
inhibited metastasis of tumor cells to the lung. The addition of BA to VCR also 
augmented suppression of the experimental lung metastasis of melanoma tumor 
cells in C57BL/6 mice suggesting that BA enhanced the chemotherapeutic effect 
of VCR on malignant melanoma (307).  
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Figure 11. Structures of synthetic and natural triterpenoids (288).   
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Structural modifications of BA and other lupane-derived triterpenoids 
differentially affect their pharmacologic activities. Modification of the C-20 
exocyclic position of BA did not affect the cytotoxicity of these derivatives to a 
panel of prostate and colon cancer and melanoma cell lines (308) . In contrast, 
A-ring modifications of betulinic acid containing a 1-ene-3-oxo moiety substituted 
at C-2 with electron withdrawing groups were highly cytotoxic (309). These result 
were similar to ursane and oleanane triterpenoid acids where analogs containing 
electron-withdrawing substituents at C-2 within a 1-ene-3-one functionality were 
also highly cytotoxic to cancer cells compared to the parent acids (310).  
Chintharlapalli et al reported that introduction of a 2-cyano group into the lupane 
skeleton of BA gave a new class of PPARγ agonists (305).  
 
Celastrol 
Celastrol, a quinone methide triterpenoid isolated from Tripterygium 
wilfordii Hook. f. (Celastraceae), also called Thunder God's Vine, is a woody 
wine distributed widely in the Orient. Its debarked root has long been used in 
traditional Chinese medicine to treat immune-inflammatory diseases such as 
rheumatoid arthritis, chronic nephritis, chronic hepatitis and lupus 
erythematosus. An ethyl acetate (EA) partition fraction from an ethanol extract of 
T. willfordii has been evaluated in a phase II double blind clinical trial. Patients 
with rheumatoid arthritis that received the EA partition showed improvement in 
both clinical manifestations and laboratory findings. Over 200 chemical 
constituents are found in this plant (311) and this may account for its multiple 
uses in China fro treating immune-inflammatory diseases, cancer and 
neurodegenerative diseases.  Ro and coworkers reported that oral 
administration of celastrol suppressed ovalbumin-induced airway inflammation, 
hyperresponsiveness, and tissue remodeling by regulating the imbalance of 
MMP-2/-9 and TIMP-1/-2 induced by inflammatory cytokines via NF-κB-
dependent manner. Hence celastrol is a useful therapeutic agent for treating 
allergy-induced asthma (312). In low nanomolar concentrations celastrol 
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suppressed production of pro-inflammatroy cytokines TNF-α and IL-1β by 
human monocytes and macrophages. Celastrol suppressed adjuvant arthritis in 
the rat, demonstrating an in vivo anti-inflammatory activity. Low doses of 
celastrol administered to rats significantly improved their performance in 
memory, learning and psychomotor activity tests. The potent antioxidant and 
anti-inflammatory activities of celastrol, and its effects on cognitive functions, 
suggested a use for this compound in treating neurodegenerative diseases such 
as Alzheimer’s disease (AD) (313).  
Celastrol exhibited potent anticancer activity against pancreatic cancer 
cells (Panc-1) in vitro and in vivo in xenografts and also inhibited the tumor 
metastasis in the RIP1-Tag2 transgenic mice model of pancreatic islet 
carcinomas. Yang and coworkers demonstrated that celastrol preferentially 
inhibits the chymotrypsin-like activity of a purified 20S proteasome and human 
prostate cancer cellular 26S proteasome. Inhibition of the proteasome activity by 
celastrol in PC-3 (androgen insensitive) or LNCaP (androgen sensitive) cells 
resulted in the accumulation of ubiquitinated proteins of three natural 
proteasome substrates (I B- , Bax, and p27), and this was accompanied by 
suppression of AR protein expression (in LNCaP cells) and induction of 
apoptosis. Treatment of PC-3 tumor–bearing nude mice with celastrol resulted in 
significant inhibition of the tumor growth (314). Celastrol activates heat shock 
gene transcription synergistically with other stressors and exhibits cytoprotection 
against subsequent exposures to other forms of lethal cell stress.  The structure 
of celastrol is remarkably specific (Figure 11) and activates heat shock 
transcription factor 1 (HSF1) with kinetics similar to those of heat stress, as 
determined by the induction of HSF1 DNA binding and expression of chaperone 
genes. These results suggest that celastrol exhibits promise as a new class of 
pharmacologically active regulators of the heat shock response as well as an 
anti-cancer agent (315). 
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II. CURCUMIN DECREASES SPECIFICITY PROTEIN (Sp) EXPRESSION IN 
BLADDER CANCER CELLS * 
 
 Curcumin is the active component of tumeric, and this polyphenolic 
compound has been extensively investigated as an anticancer drug that 
modulates multiple pathways and genes.  In this study, 10 - 25 μM curcumin 
inhibited 253JB-V and KU7 bladder cancer cell growth, and this was 
accompanied by induction of apoptosis and decreased expression of the 
proapoptotic protein survivin and the angiogenic proteins vascular endothelial 
growth factor (VEGF) and VEGF receptor 1 (VEGFR1).  Since expression of 
survivin, VEGF and VEGFR1 are dependent on specificity protein (Sp) 
transcription factors; we also investigated the effects of curcumin on Sp protein 
expression as an underlying mechanism for the apoptotic and antiangiogenic 
activity of this compound.  The results show that curcumin induced proteasome-
dependent downregulation of Sp1, Sp3 and Sp4 in 253JB-V and KU7 cells.  
Moreover, using RNA interference with small inhibitory RNAs for Sp1, Sp3 and 
Sp4, we observed that curcumin-dependent inhibition of nuclear factor κB 
(NFκB)-dependent genes such as bcl-2, survivin and cyclin D1, was also due, in 
part, to loss of Sp proteins.  Curcumin also decreased b ladder tumor growth in 
athymic nude mice bearing KU7 cells as xenografts and this was accompanied 
by decreased Sp1, Sp3 and Sp4 protein levels in tumors.  These results 
demonstrate for the first time that one of the underlying mechanisms of action of 
curcumin as a cancer chemotherapeutic agent is due, in part, to decreased 
expression of Sp transcription factors in bladder cancer cells. 
 
*Reprinted with permission from “Curcumin decreases Specificity protein 
expression in bladder cancer cells” by Chadalapaka G, Jutooru I, Chintharlapalli 
S, Papineni S, Smith R, Li X and Safe S. Cancer Res. 68:5345-5354, 2008. 
Copyright 2009 by American Association for Cancer Research, Inc. 
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Introduction 
 
 Phytochemicals, microbial metabolites, and other natural products and 
their synthetic analogs have been extensively used for drug development and 
treatment of various diseases including cancer (316, 317).  Curcumin 
(diferuloylmethane) is a polyphenolic natural product and the active component 
of tumeric (Curcuma species) which is used in cooking and in traditional 
medicines (318) (283) (319).  Curcumin has been extensively investigated as an 
anticancer drug in various cancer cells and laboratory animal models.  Curcumin 
has also been evaluated in humans, and one of the major problems associated 
with clinical applications of curcumin is the low bioavailability (320) (321) (322) 
(323).  The effects of curcumin in various tumor models are highly variable and 
dependent on both tumor type and cell context.  In many studies, curcumin 
inhibits cancer cell proliferation, induces apoptosis, and inhibits angiogenesis 
(324) (325) (326) (327) (328) (329) (330) (331) (332). Mechanisms associated 
with these effects are variable and may involve direct effects on mitochondria, 
activation of endoplasmic reticulum (ER) stress, and modulation of kinase 
pathways including the inhibition of nuclear factor κB (NFκB). 
 Recent studies reported that curcumin decreased survival of RT4V6 and 
KU7 bladder cancer cells, and this was accompanied by increased DNA 
fragmentation and other parameters associated with apoptosis (333).  In 
addition, there was also evidence that curcumin potentiated the effects of other 
drugs and cytokines in bladder cancer cells, and this has been observed in other 
studies (329) (333) (332)  (334). Curcumin alone had minimal effects on NFκB in 
RT4V6 or KU7 cells; however, in cells treated with agents such as gemcitabine, 
tumor necrosis factor (TNF), and cigarette smoke that induce NFκB, cotreatment 
with curcumin inhibited NFκB activation.  It was concluded that suppression of 
induced NFκB by curcumin may play a role in sensitizing bladder cancer cells 
and other cancer cell lines to various chemotherapeutic agents (333). 
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 Betulinic acid (BA) is a triterpenoid natural product that inhibits growth of 
multiple cancer cell lines, and this compound induces apoptosis and inhibits 
angiogenesis (301).  Studies in this laboratory showed that one of the underlying 
mechanisms of action of this compound in prostate cancer cells was the 
targeted degradation of specificity protein 1 (Sp1), Sp3 and Sp4 and Sp-
dependent genes involved in cell growth, survival and angiogenesis.  We also 
observed similar effects for the analgesic tolfenamic acid  (299) (21), and RNA 
interference studies with small inhibitory RNAs for Sp1, Sp3 and Sp4 confirmed 
the role of these proteins in regulating expression of vascular endothelial growth 
factor (VEGF), VEGF receptor 1 (VEGFR1), VEGFR2, and survivin and 
repression of p27 by Sp3  (335) (336) (337) (204). 
 Curcumin induced apoptosis and inhibited KU7 and 253JB-V bladder 
cancer cell proliferation, and we hypothesized that curcumin may also affect Sp 
protein expression in these cells.  Curcumin decreased Sp1, Sp3 and Sp4 
protein expression in the bladder cancer cell lines and similar results were 
observed in tumors in a xenograft study.  These results demonstrate that the 
curcumin-induced growth inhibitory, proapoptotic and angiogenic responses in 
bladder cancer cells and tumors are due, in part, to decreased expression of 
Sp1, Sp3 and Sp4.  Moreover, curcumin-induced downregulation of Sp proteins 
also plays a role in the effects of curcumin as an inhibitor of NFκB-dependent 
genes. 
Materials and methods 
 
 Cell lines, antibodies, chemicals and other materials.  KU-7 human 
bladder cancer cells were obtained from the American Type Culture Collection 
(Manassas, VA) and 253JB-V cells were provided by Dr. A. Kamat (M.D. 
Anderson Cancer Center, Houston, TX) and maintained essentially as described 
(17).  With the exception of cleaved PARP (Cell Signaling Technology, Danvers, 
MA), NFκB-p65 (Abcam Inc., Cambridge, MA), and β-actin antibodies (Sigma-
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Aldrich), all remaining antibodies were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA).  Curcumin (98% pure) was purchased from 
Indofine Chemical Company, Inc. (Hillsborough,NJ).  Lipofectamine and 
Lipofectamine 2000 were purchased from Invitrogen (Carlsbad, CA).  β-
Galactosidase reagent was obtained from Tropix (Bedford, MA).  
 Cell proliferation assays.  Bladder cancer cells (3 x 104 cells per well) 
were plated using DMEM:Ham's F-12 medium containing 2.5% charcoal-
stripped FBS in 12-well plates and left to attach for 24 hr.  Cells were then 
treated with either vehicle (DMSO) or the indicated concentrations of curcumin.  
Fresh medium and test compounds were added every 48 hr, and cells were then 
counted at the indicated times using a Coulter Z1 particle counter.  Each 
experiment was done in triplicate and results are expressed as means ± SE for 
each determination. 
 TUNEL assay.  253JB-V and KU7 cells (7 x 104) were seeded in four-
chambered glass slides and left overnight to attach.  After curcumin treatment 
for 12 hr, the in situ cell death detection POD kit was used for the TUNEL assay 
according to the instructions in the protocol manual for fixed cells.  The 
percentage of apoptotic cells was calculated by counting the stained cells in 8 
fields, each containing 50 cells.  The total number of apoptotic cells was plotted 
as a percentage in both the cell lines. 
 Transfection and luciferase assays.  Bladder cancer cells (1 x 105 per 
well) were plated in 12-well plates in DMEM:Ham's F-12 medium supplemented 
with 2.5% charcoal-stripped FBS.  After 16 hr, various amounts of DNA (i.e., 0.4 
μg pGL3/pGL2-Luc, 0.04 μg β-galactosidase, and 0.4 μg pSp1For4-Luc, 
pSp3For5-Luc, pVEGF-Luc, pNFκB-Luc and pSurvivin-Luc were transfected 
using Lipofectamine reagent according to the manufacturer’s protocol and 
luciferase activity (normalized to β-galactosidase) was determined essentially as 
described (24-29).   
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 Western blot assays.  Bladder cancer cells were seeded in 
DMEM:Ham's F-12 medium containing 2.5% charcoal-stripped FBS.  Twenty-
four hr later, cells were treated with either vehicle (DMSO) or the indicated 
compounds for 24 hr and Western blot analysis was determined as described 
(26-29).  Nuclear and cytoplasmic extracts were separated using NE-PER 
nuclear and cytoplasmic extraction reagents (Pierce, Rockford, IL). The tumor 
tissues were also processed similarly and probed for Sp1, Sp3 and Sp4 proteins 
and -actin served as loading control.  Protein quantification used Image J 
software, and optical densities for each protein was normalized to β-actin in the 
iLamin-treated group. 
Fluorescence-activated cell-sorting assays (FACS).  Both 253JB-V 
and KU7 bladder cancer cells were treated with either the vehicle (DMSO) or the 
indicated compounds for 24 hr.  Cells were analysed on a FACS Calibur flow 
cytometer using CellQuest acquisition software (Becton Dickinson 
Immunocytometry Systems).  PI fluorescence was collected through a 585/42 
nm band pass filter, and list mode data were acquired on a minimum of 20,000 
single cells defined by a dot plot of PI width versus PI area.  Data analysis was 
performed in Modfit LT using PI width versus PI to exclude cell aggregates. 
 SiRNA interference assays.  Small inhibitory RNAs for Sp1, Sp3 and 
Sp4 were prepared by Dharmacon RNA Technologies (Chicago, IL).  The iRNA 
complexes used in this study are indicated as follows:  
 LMN    5’-CUG GAC UUC CAG AAG AAC ATT 
 Sp1      SMARTpool L-026959-00-0005, Human Sp1, NM_138473ss 
 Sp3      5'- GCG GCA GGU GGA GCC UUC ACU TT  
 Sp4      5'- GCA GUG ACA CAU UAG UGA GCT T   
 p65 (REL1096)    5’-GATTGAGGAGAAACGTAAATT 
 p50 (REL 1911)   5’- GTCACTCTAACGTATGCAATT 
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The two bladder cancer cell lines, 253JB-V and KU7, were seeded (1 x 105 per 
well) in 12-well plates in DMEM:Ham's F-12 medium supplemented with 2.5% 
charcoal-stripped FBS without antibiotic and left to attach for one day.  The triple 
Sp SiRNA knockdown (iSp1, iSp3, iSp4 complex) along with iLamin as control 
was performed using Lipofectamine 2000 transfection reagent as per the 
manufacturer’s instructions.  SiRNA for p65 and p50 and NC were purchased 
from Integrated DNA Technologies (Coralville, IA).  
 EMSA assay.  Cells were rinsed in cold PBS buffer and harvested in 
reporter lysis buffer (Promega).  After 15 min incubation on ice and 10 min 
centrifugation at 16,000 x g, 4°C, the pellet was resuspended in reporter lysis 
buffer supplemented with 0.5 M KCl and incubated on ice for 30 min.  The 
supernatant containing nuclear proteins was collected after centrifugation for 10 
min at 16,000 x g, 4°C and quantified for protein concentrations by Bradford 
method.  The GC-rich probe was prepared by annealing the two complementary 
polynucleotides: 5’- CTC GTC GGC CCC CGC CCC TCT -3’ and 5’- AGA GGG 
GCG GGG GCC GAC GAG -3’.  The NFκB sense strand probe was 5'- AGT 
TGA GGG GAC TTT CCC AGG C -3'.  The annealed probe was 5'-end-labeled 
using T4 polynucleotide kinase (Invitrogen) and [γ-32P] ATP (PerkinElmer).  The 
labeled probe was purified with the Chroma Spin TE-10 column (BD 
Biosciences).  The EMSA reaction was carried out in the reporter lysis buffer 
(Promega) supplemented with 0.1 M KCl.  Each reaction contained 2 μg nuclear 
protein, 500-1000 ng of poly (dI-dC) (Roche Molecular Biochemicals) with or 
without unlabeled competitor oligonucleotides, and 10 fmol of labeled probe; the 
mixture was incubated for 15 min on ice.  Protein-DNA complexes were resolved 
by 5% native PAGE at 160 V at room temperature for 1.5 hr and visualized using 
a Storm A60 PhosphoImager system (Molecular Dynamics).  
 Xenograft study.  Female athymic nude mice, age 4-6 weeks were 
purchased from Harlan (Indianapolis, CA).  KU7 cells (1×106 cells) in 1:1 ratio of 
Matrigel (BD Biosciences, San Jose, CA) were injected into the either side of the 
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flank area of nude mice.  Seven days after the tumor cell inoculation, mice were 
divided into two groups of ten animals each.  The first group received 50 µL 
vehicle (corn oil) by intraperitoneal injection, and the second group of animals 
received 50 mg/kg/d injection of curcumin in corn oil every second day for 18 
days (9 doses) by intraperitoneal injection.  The mice were weighed, and tumor 
areas were measured throughout the study.  After 20 days, the animals were 
sacrificed; final body and tumor weights were determined and plotted. 
Results 
 
 Figures 12A and 12B illustrate the concentration-dependent effects of 5, 
10 and 25 μM curcumin on proliferation of 253JB-V and KU7 bladder cancer 
cells over a 6 day period with change of media and treatment with DMSO 
(control) or curcumin every 48 hr.  Proliferation of both 253JB-V and KU7 cells 
was inhibited by curcumin.  However, the pattern of inhibition was slightly 
different; 5 and 10 μM curcumin significantly inhibited 253JB-V cells after 
treatment for 4 and 6 days, whereas 10 μM (but not 5 μM) curcumin significantly 
inhibited KU7 cell proliferation after treatment for 2, 4 and 6 days.   
    The highest concentration of curcumin (25 μM) was cytotoxic to both cell 
lines, and similar results were previously reported on the cytotoxicity of curcumin 
in KU7 and RT4V6 bladder cancer cells (338).  The effects of curcumin on the 
distribution of 253JB-V and KU7 cells in G0/G1, S and M phases of the cell cycle 
are illustrated in Figures 12C and 12D, respectively.  Curcumin (5 - 25 μM) 
increased the percentage of 253JB-V cells in G0/G1 and decreased the 
percentage in S and G2/M phases, although the effects on G2/M were 
concentration-dependent and variable.   
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Figure 12. Curcumin inhibits bladder cancer cell growth and modulates the 
cell cycle. 
 
   Inhibition of 253JB-V (A) and KU7 (B) cell growth.  Cells were treated with 
DMSO (solvent control), 5, 10 or 25 μM curcumin and the effects of cell growth 
were determined after treatment for 2, 4 or 6 days as described in the Materials 
and Methods. Effects of curcumin on distribution of 253JB-V (C) and KU7 (D) 
cells in G0/G1, S and G2/M phases.  Cells were treated with DMSO (0), 5, 10 or 
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25 μM curcumin for 24 hr, and the distribution of cells in G0/G1, S and G2/M 
phases was determined by FACS analysis as described in the Materials and 
Methods.  Results are expressed as means ± SE for each data point in (A) - (D), 
and significantly (p < 0.05) increased (*) or decreased (**) responses compared 
to DMSO (0, control) are indicated. 
In contrast, in KU7 cells, minimal effects were observed after treatment with 5 
or 10 μM curcumin, whereas 25 μM curcumin decreased the percentage of cells 
in G0/G1 and increased the percentage in S and G2/M phases (Figure 12D).  
These results demonstrate that curcumin-induced changes in the distribution of 
253JB-V and KU7 cells in different phases of the cycle were dependent on cell 
context. 
 The effects of curcumin on selected proteins involved in cell cycle 
progression are summarized in Figure 13A.  The cyclin-dependent kinase 
inhibitors p21 and p27 were decreased in both cell lines by curcumin, but at 
different concentrations.  p21 was decreased by 25 - 50 and 10 - 50 μM 
curcumin in 253JB-V and KU7 cells, respectively, whereas 25 - 50 μM curcumin 
decreased p27 expression in both cell lines.  The role of these responses in 
mediating the distribution of bladder cancer cells in different phases of the cell 
cycle is unclear. 
Previous studies showed that curcumin induced apoptosis in bladder 
cancer cells (333) and, in pancreatic tumors; curcumin suppressed proliferation 
and inhibited angiogenesis (326).  Results in Figure 13B demonstrate that 
curcumin induced PARP cleavage in 253JB-V and KU7 cells, and this was also 
accompanied by downregulation of the antiapoptotic gene survivin.  Decreased 
survivin and increased PARP cleavage were initially observed at curcumin 
concentrations of 10 and 25 μM in 253JB-V and KU7 cells, respectively, and 
maximal responses were observed in cells treated with 25 and 50 μM curcumin.  
In addition, curcumin also decreased expression of two angiogenic proteins, 
VEGF and VEGFR1, in both cell lines (Figure 13B). 
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Figure 13. Curcumin modulates expression of cell cycle, survival and 
angiongenic  proteins and induces apoptosis.  
 
Decreased expression of p27 and p21 proteins.  253JB-V and KU7 cells 
were treated with DMSO, 5, 10, 25, or 50 μM curcumin for 24 hr, and whole cell 
lysates were analyzed by Western blot analysis as described in the Materials 
and Methods.  (B) Decreased expression of survivin, VEGF and VEGFR1, and 
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increased PARP cleavage.  253JB-V and KU7 cells were treated with DMSO, 5, 
10, 25 or 50 μM curcumin for 24 hr, and whole cell lysates were analyzed by 
Western blot analysis as described in the Materials and Methods.  β-Actin 
served as a loading control.  (C) TUNEL assay.  
 253JB-V and KU7 cells were treated with DMSO, 40 μM curcumin for 12 
hr, and TUNEL staining was determined as described in the Materials and 
Methods.  Results of the Western blot (A and B) and TUNEL staining 
experiments were similar in replicate experiments in both cell lines and, for 
TUNEL staining, significant (p < 0.05) increases are indicated by an asterisk. 
  The proapoptotic activity of curcumin was also confirmed in a TUNEL 
assay (Figure 13C) where 40 μM curcumin induced increased TUNEL staining in 
253JB-V and KU7 cells, whereas minimal effects were observed in the solvent 
(DMSO)-treated cells. 
Results in Figures 14A and 14B show that after treatment of 253JB-V and 
KU7 cells with curcumin (5 - 50 μM) for 24 hr, there was a concentration-
dependent decrease in the expression of Sp1, Sp3 and Sp4 proteins.  
Curcumin-induced downregulation of Sp proteins was dependent on the 
concentration of curcumin, Sp protein (i.e. Sp1, Sp3 or Sp4), and cell context.  
However, in both 253JB-V and KU7 cells, decreased expression of all three 
proteins was observed after treatment with 10 μM and higher concentrations of 
curcumin for 24 hr.   
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Figure 14. Effects of curcumin on Sp proteins and Sp-dependent 
transactivation. 
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    Curcumin decreases Sp proteins in 253JB-V (A) and KU7 (B) bladder 
cancer cells.  Cells were treated with DMSO, 5, 10, 25 or 50 μM curcumin for 24 
hr and whole cell lysates were analyzed by Western blot analysis as described 
in the Materials and Methods.  β-Actin served as a loading control and similar 
results were observed in duplicate experiments.  Curcumin decreases luciferase 
activity in cells transfected with Sp1/Sp3 promoter (C) and Sp-regulated 
promoter (D) constructs.  Bladder cancer cells were transfected with the 
indicated constructs, treated with DMSO or different concentrations of curcumin, 
and luciferase activity determined as described in the Materials and Methods.  
Results are expressed as means ± SE for at least three separate determinations 
for each treatment group and significantly (p < 0.05) decreased activity is 
indicated by an asterisk. 
Since curcumin decreased expression of Sp1, Sp3, Sp4 and Sp-dependent 
survivin, VEGF and VEGFR1 proteins, we also investigated the effects of 
curcumin on luciferase activity in 253JB-V and KU7 cells transfected with 
constructs containing GC-rich promoters that bind Sp proteins.  Luciferase 
activity was decreased in 253JB-V and KU7 cells treated with 10 - 40 μM 
curcumin and transfected with GC-rich Sp1For4 and Sp3For5 constructs 
containing the -751 to -20 and -417 to -38 regions of the Sp1 and Sp3 gene 
promoters, respectively (339) (340) (linked to the luciferase gene) (Figure 14C).  
In addition, curcumin (10 - 40 μM) also decreased luciferase activity in 253JB-V 
and KU7 cells transfected with GC-rich pVEGF and pSurvivin constructs that 
contain the -2018 to +50 and -269 to +49 GC-rich regions of the VEGF and 
survivin gene promoters, respectively (Figure 14D).  Thus, like tolfenamic acid 
and betulinic acid, curcumin-induced downregulation of Sp1, Sp3 and Sp4 not 
only decreased expression of Sp-regulated proteins such as VEGF and survivin, 
but also decreased transactivation in 253JB-V and KU7 cells transfected with 
pVEGF and pSurvivin constructs containing GC-rich promoter inserts. 
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Figure 15.  MG132 inhibition of curcumin-induced effects on Sp proteins 
and Sp-dependent transactivation.  
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  MG132 inhibits curcumin-dependent downregulation of Sp proteins in 
253JB-V (A) and KU7 (B) cells.  Bladder cancer cells were treated with DMSO 
alone, 25 μM curcumin, or 10 μM MG132 in the presence or absence of 25 μM 
curcumin for 24 hr, and whole cell lysates were analyzed by Western blots as 
described in the Materials and Methods.  β-Actin served as a loading control, 
and similar results were observed in duplicate experiments.  MG132 inhibits the 
effects of curcumin on luciferase activity in bladder cancer cells transfected with 
Sp1/Sp3 promoter (C) and Sp-regulated promoter (D) constructs.  Cells were 
transfected with the indicated constructs, treated with DMSO, 10 μM MG132, 25 
μM curcumin, or MG132 plus curcumin (combined), and luciferase activity was 
determined as described in the Materials and Methods.  Results are expressed 
as means ± SE for at least three separate determinations for each treatment 
group, and significantly decreased activity after treatment with curcumin (*) and 
reversal of the effect after cotreatment with MG132 (**) are indicated.       
 Previous studies show that tolfenamic and betulinic acids induce 
proteasome-dependent degradation of Sp1, Sp3 and Sp4 in pancreatic and 
prostate cancer cells (299), and Figures 15A and 15B summarize the effects of 
the proteasome inhibitor MG132 on curcumin-induced downregulation of these 
proteins.  In KU7 cells, MG132 inhibited curcumin-induced downregulation of 
Sp1, Sp3 and Sp4 proteins, and similar effects were observed in 253JB-V cells.  
However, in the latter bladder cancer cell line, MG132 alone also decreased Sp 
protein expression and this response was most pronounced for Sp1.  Other 
proteasome inhibitors such as lactacystin and gliotoxin gave similar results and, 
in combination with curcumin, high cytotoxicity was observed in 253JB-V cells 
(data not shown).  Nevertheless, it was apparent that MG132 plus curcumin 
blocked Sp protein downregulation in both cell lines, suggesting that curcumin, 
like betulinic and tolfenamic acids (299), induced proteasome-dependent 
downregulation of Sp1, Sp3 and Sp4 proteins in 253JB-V and KU7 cells.  Figure 
15 C summarizes the effects of MG132 on curcumin-dependent decreased 
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luciferase activity in 253JB-V and KU7 cells transfected with pSp1For4 and 
pSp3For5.  In 253JB-V cells, MG132 only partially reversed downregulation of 
activity by 25 μM curcumin, whereas in KU7 cells, MG132 completely inhibited 
the effects of curcumin on luciferase activity.  The relative effectiveness of 
MG132 as an inhibitor of curcumin-dependent downregulation of luciferase 
activity in cells transfected with pVEGF or pSurvivin also differed in 253JB-V and 
KU7 cells (Figure 15D).  MG132 reversed the effects of curcumin in KU7 cells 
(80 - 100%) but was less efficient in 253JB-V cells.  This may be due, in part, to 
the cytoxocity of MG132 alone and in combination with curcumin in 253JB-V 
cells.  These results demonstrate that curcumin primarily induced proteasome-
dependent degradation of Sp1, Sp3 and Sp4 in the bladder cancer cells, and 
similar effects have been observed for tolfenamic acid and betulinic acid in 
pancreatic and prostate cancer cells (299) (21). 
Results illustrated in Figures 16A show that 10 - 40 μM curcumin 
decreased luciferase activity in 253JB-V cells transfected with pNFκB, a 
construct containing 5 tandem NFκB response elements that regulate a 
luciferase reporter gene.  Thus, curcumin decreases NFκB-dependent 
transactivation in the 253JB-V cell line.  Since curcumin also decreases 
expression of Sp1, Sp3 and Sp4 in bladder cancer cells, we investigated the 
effects of Sp protein knockdown on luciferase activity in cells transfected with 
pNFκB-luc (Figure 16B).  253JB-V and KU7 cells were transfected with iSp 
which is a cocktail of small inhibitory RNAs for Sp1 (iSp1), Sp3 (iSp3), and Sp4 
(iSp4) (341). 
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 Figure 16. Effects of curcumin and Sp knockdown on NFκB. 
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Curcumin decreases NFκB promoter activity in 253JB-V and KU7 cells.  
253JB-V and KU7 cells were transfected with pNFκB-luc treated with DMSO, 
10, 25 or 40 μM curcumin, and luciferase activity was determined as described 
in the Materials and Methods.  Results are expressed as means ± SE for three 
replicate determinations for each treatment group, and significantly (p < 0.05) 
decreased activity is indicated (*).  (B)  Effects of iSp on NFκB.  253JB-V and 
KU7 cells were transfected with iSp (a cocktail of iSp1, iSp3 and iSp4) or 
iLamin, and transfected with pNFκB-Luc; luciferase activity was determined as 
described in the Materials and Methods.  Results are means ± SE for three 
replicate determinations, and significantly (p < 0.05) decreased activity is 
indicated by an asterisk.  The efficiency of Sp knockdown and the effects of p65 
and p50 protein levels were determined by Western blots as described in the 
Materials and Methods.  Effects of curcumin on bcl-2 and cyclin D1 (C) and p65 
and p50 (D) proteins in 253JB-V and KU7 cells.  Cells were treated with DMSO, 
different concentrations of curcumin, and nuclear extracts were analyzed by 
Western blots as described in the Materials and Methods. 
The results showed that transfection with iSp significantly inhibited NFκB-
dependent activity and this was not directly related to a decrease in p65 or p50 
protein levels after transfection with iSp (Figure 16B).  There was a minimal but 
not significant decrease in these proteins over replicated experiments, 
suggesting that decreased NFκB-dependent transactivation by iSp was not 
dependent on decreased expression of p65 or p50.  We also investigated the 
effects of iSp1, iSp3 and iSp4 on p65 and p50 protein expression in 253JB-V 
and KU7 cells.  In the former cell line, iSp3 and iSp4 (but not iSp1) slightly 
decreased p65 protein levels, whereas none of the small inhibitory RNAs 
affected p65 or p50 expression in KU7 cells and p50 expression in 253JB-V 
cells.  Figure 16C shows that curcumin decreased expression of cyclin D1 and 
the antiapoptotic protein bcl-2 in 253JB-V and KU7 cells, and both of these 
genes are also regulated by NKκB and Sp transcription factors  (342, 343). It is 
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possible that curcumin-induced downregulation of Sp proteins may directly affect 
NFκB since both p65 and p50 are Sp-dependent genes in some cell lines (344, 
345). However, treatment of 253JB-V and KU7 cells with DMSO, 10, 25 or 40 
μM curcumin for 24 hr did not affect nuclear p65 expression, whereas nuclear 
p50 protein levels were decreased only at the higher (40 μM) concentration 
(Figs. 16D) and 25 μM curcumin, which decreases Sp protein levels, did not 
affect p65 or p50 expression.  Thus, curcumin-mediated inhibition of NFκB-
dependent gene expression is not due to direct effects on p65 or p50.   
Athymic nude mice bearing KU7 cells as xenografts were treated with 
corn oil (control) or curcumin in corn oil (50 mg/kg/d), and tumor volumes (mm3) 
and weights were determined as described in the Material and Methods.  
Western blot analysis of tumor lysates from three mice in the treated and control 
groups were also determined as described in the Materials and Methods.  
Significant (p < 0.05) decreases are indicated by an asterisk. 
A close inspection of many NFκB-regulated genes such as cyclin D1, bcl-
2, survivin and VEGF indicates that these genes also contain multiple GC-rich 
promoter sequences and are coregulated by Sp proteins in many cell lines  
(299) (346) (335) (336) (342) (343) (345, 347, 348) (349). Results in Figure 17A 
show that in 253JB-V and KU7 cells transfected with iLamin (control) or the iSp 
cocktail (containing iSp1, iSp3 and iSp4), there was a significant decrease in 
levels of bcl-2, cyclin D1, survivin and VEGF and this correlated with the effects 
of curcumin on these same proteins (Figures. 13B and 16C).  In contrast, 
combined knockdown of p65 and p50 by RNA interference (Figure 17B) did not 
affect expression of all these proteins.  Only VEGF and bcl-2 proteins were 
decreased by p65/p50 knockdown, suggesting that basal expression of cyclin 
D1 and survivin were NFκB-independent in the bladder cancer cells.  Figure 17C 
illustrates gel mobility shift assays in which nuclear extracts from 253JB-V and 
KU7 cells bound a 32P-labeled GC-rich oligonucleotide to form Sp-DNA retarded 
bands as previously characterized in other cell lines (335) (336) (337). 
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Treatment with 25 or 40 μM curcumin decreased retarded band 
intensities and coincubation with unlabeled wild-type GC-rich or mutant 
oligonucleotides decreased or did not affect retarded band intensities, 
respectively (Figure 17C).  Supershift experiments with Sp1 antibodies did not 
give a defined supershifted (SS) antibody-protein complex but a diffuse band.  
However, the Sp1 band intensity was decreased due to immunodepletion.  We 
also determined the effects of curcumin on NFκB-DNA binding in a gel mobility 
shift assay using a consensus NFκB response element and extracts from cells, 
and the results showed that curcumin decreased retarded band intensities 
associated with the NFκB-DNA complex.  These data confirm that curcumin 
decreases Sp proteins and Sp-DNA complex formation and the NFκB-DNA 
retarded band and this correlated with decreased expression of NFκB regulated 
proteins which are also coregulated by Sp transcription factors.   
These factors suggest that curcumin-dependent downregulation of Sp 
proteins contributes to decreased expression of several NFκB-dependent 
proteins which are coregulated by both Sp and NFκB transcription factors (299) 
(346) (336) (342) (343) (345, 347-349). We also investigated the antitumorigenic 
activity of curcumin in athymic nude mice bearing KU7 cells as xenografts.  At a 
dose of 50 mg/kg/d, curcumin significantly decreased tumor volumes and tumor 
weights (Figure 17D).  Moreover, Western blot analysis of tumor lysates from 
three control and three treated mice show that Sp1, Sp3 and Sp4 protein 
expression is decreased in the latter group.  These results complement the in 
vitro studies and demonstrate that curcumin-induced effects on Sp proteins also 
plays a role in the mechanism of action of this compound in bladder cancer cells.   
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Figure 17. Role of Sp protein and NFκB on protein expression and the 
effects of curcumin on Sp-DNA binding and bladder tumor growth.  
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Effects of iSp and iLamin (A) and small inhibitory RNAs for p65 (ip65) and 
p50 (ip50) [combined (B)] on genes regulated by Sp and NFκB.  253JB-V and 
KU7 cells were transfected with iSp (a cocktail of iSp1, iSp3 and iSp4) or iLamin, 
or ip65 plus ip50, and protein expression was determined by Western blots of 
whole cell lysates.  β-Actin served as a loading control and for standardizing 
quantitative protein determinations where iLamin protein levels were set at 
100%.  Results are means ± SE for three separate determination and 
significantly (p < 0.05) decreased protein levels are indicated by an asterisk.  (C) 
Gel mobility shift assay.  253JB-V and KU7 cells were treated with DMSO (0), 25 
or 40 μM curcumin for 24 hr, and nuclear extracts were incubated with 32P-
labeled GC-rich oligonucleotide alone or in the presence of other factors.  
Retarded bands were analyzed by EMSA as described in the Materials and 
Methods.  The identities of the retarded Sp-DNA bands and Sp1 antibody 
supershifted complex (SS) are indicated.  (D)  Curcumin inhibits bladder tumor 
growth.   
Discussion 
 
 Curcumin has been widely used in traditional medicines, and its 
chemoprotective and chemotherapeutic effects are due to many different 
activities that are also dependent on cell context (318).  One of the most 
predominant effects of curcumin observed in many studies is associated with 
inhibition of constitutive or induced NFκB-dependent genes/proteins associated 
with cell survival, angiogenesis and inflammation (318) (283) (341, 350) (351) 
(352).  However, other pathways contribute to the effects of curcumin, and these 
may be NFκB-independent.  For example, curcumin induces endoplasmic 
reticulum (ER) stress in human leukemia HL-60 cells, and this results in 
activation of ER stress-dependent proapoptotic pathways associated with 
cleavage of caspases 8, 9, 3 and 4 (338).  In addition, curcumin-induced 
apoptosis in human leukemia U937 cells was also linked to the direct effects of 
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this compound on mitochondria function and subsequent activation of the 
intrinsic apoptosis pathway (353). 
 Recent studies in this laboratory have demonstrated that compounds 
such as celecoxib, tolfenamic acid, and betulinic acid inhibit cancer cell and 
tumor growth and metastasis, and exhibit both antiangiogenic and proapoptotic 
activity through decreased expression of Sp proteins such as Sp1, Sp3 and Sp4 
(21) (346) (335). The role of Sp proteins in mediating these responses was 
consistent with RNA interference studies showing that Sp proteins regulate 
angiogenic, growth promoting, and prosurvival genes in cancer cells (336) (337) 
(204) (348). Results in Figure 12 illustrates that curcumin decreased proliferation 
of bladder cancer cells and induced apoptosis as evidenced by induction of 
PARP cleavage (Figure 13B) and DNA laddering (Figure 13C) in 253JB-V and 
KU7 bladder cancer cells.  These results are consistent with a report (17) 
showing that curcumin exhibited growth inhibitory and proapoptotic activity in 
KU7 and RT4V6 bladder cancer cells.  In the prior study 10 μM curcumin slightly 
inhibited G0/G1 to S phase progression in KU7 cells, whereas our results 
showed that 10 μM curcumin inhibited G0/G1 to S phase progression in 253JB-V 
but not in KU7 cells which were essentially unaffected by 10 μM curcumin 
(Figures 12C and 12D).  Differences in the effects of curcumin on cell cycle 
progression in these cell lines may be due, in part, to the effects of curcumin on 
p21, p27 and cyclin D1 expression (Figures 13A and 16C), and this is currently 
being investigated. 
 Curcumin also decreased expression of the angiogenic proteins VEGF 
and VEGFR1 in both bladder cancer cell lines, and decreased expression of the 
antiapoptotic protein survivin was accompanied by induction of caspase-
dependent PARP cleavage (Figure 13B) and increased staining in the TUNEL 
assay (Figure 13C).  This evidence for activation of apoptosis by curcumin is 
consistent with previous studies on this compound in bladder and other cancer 
cell lines (318) (319)  (319) (325) (326) (327) (328) (329) (333). However, the 
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coordinate decrease in expression of survivin, VEGF and VEGFR1 in bladder 
cancer cells treated with curcumin was reminiscent of similar effects observed in 
prostate and pancreatic cancer cells treated with betulinic acid and tolfenamic 
acid, respectively (299) (21) (346).  In those studies, it was shown that 
decreased expression of survivin, VEGF and VEGFR1 was due to degradation 
of Sp1, Sp3 and Sp4 which are known to regulate basal expression of survivin, 
VEGF, VEGFR1 and VEGFR2 (335) (348).  Results summarized in Figure 14 
illustrate that treatment of 253JB-V and KU7 cells with curcumin caused a 
concentration-dependent decrease in Sp1, Sp3 and Sp4 protein expression.  
The Sp1 and Sp3 promoters contain GC-rich motifs that bind Sp proteins (339) 
(340) (31, 32), and curcumin inhibited transactivation in 253JB-V and KU7 cells 
transfected with constructs (pSp1For4 and pSp3For5) containing Sp1 and Sp3 
gene promoter inserts (Figure 14C).  Sp proteins also regulate expression of 
survivin and VEGF (345, 347, 349) and curcumin decreased luciferase activity in 
bladder cancer cells transfected with pVEGF and pSurvivin.   
 Betulinic acid- and tolfenamic acid-induced downregulation of Sp1, Sp3 
and Sp4 in prostate and pancreatic cancer cells is due to activation of 
proteasomes, and these are blocked by the proteasome inhibitor MG132 (299)  
(21) (346). This same inhibitor inhibited curcumin-induced downregulation of 
Sp1, Sp3 and Sp4 proteins in 253JB-V and KU7 cells (Figures. 15A and 15B), 
and similar effects were observed in cells transfected with pS1For4, pSp3For5, 
pVEGF and pSurvivin and treated with curcumin plus MG132 (Figures. 15C and 
15D).  MG132 and other proteasome inhibitors such as gliotoxin and lactacystin 
were cytotoxic to 253JB-V cells, and MG132 alone decreased Sp1 protein in this 
cell line.  However, despite these effects, our results show that curcumin-
dependent downregulation of Sp1, Sp3 and Sp4 proteins was partially reversed 
in 253JB-V cells cotreated with curcumin plus MG132.  Moreover, similar results 
were observed in the transfection studies (Figures. 15C and 15D), suggesting 
that curcumin-dependent downregulation of Sp1, Sp3 and Sp4 in KU7 and 
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253JB-V cells was primarily due to activation of the proteasome pathway.  
These results suggest that some of the proapoptotic and antiangiogenic 
activities of curcumin in bladder cancer cells are due, in part, to degradation of 
Sp proteins and Sp-dependent survivin, VEGF and VEGFR1. 
 In cancer cells and tumors, NFκB regulates expression of prosurvival and 
angiogenic genes, and the efficacy of several chemotherapeutic agents 
including curcumin has also been linked to their inhibition of NFκB-mediated 
responses (318) (283) (319) (324) (329). Inhibition of NFκB by curcumin has 
been associated with modulation of multiple pathways; however, the effects of 
curcumin-dependent downregulation of Sp proteins on NFκB have not been 
determined.  p65 and p50/105 are regulated by Sp1 in some cell lines (343) 
(344, 354), and our results show that concentrations of curcumin that decreased 
NFκB-dependent activity (≤ 25 μM) did not affect nuclear p65 or p50 levels in 
KU7 or 253JB-V cells (Figure 16D).  Moreover, in KU7 and 253JB-V cells 
transfected with the iSp cocktail containing small inhibitory RNAs for Sp1, Sp3 
and Sp4, there was also only a minimal decrease in expression of p65 or p50 
(Figure 16B). Curcumin decreased expression of several NFκB-dependent 
genes including VEGF, survivin, bcl-2 and cyclin D1 (Figures. 13B and 16C) 
(299)  (346) (336) (337) (343) (345, 347-349), and similar results were observed 
in bladder cancer cells transfected with iSp (Figure 17A).  Since curcumin 
decreases both Sp proteins and NFκB-dependent transactivation in bladder 
cancer cells, the role of NFκB in mediating these responses was investigated by 
p65 and p50 knockdown (Figure 17B).  Only VEGF and bcl-2 were decreased in 
both cell lines after transfection with small inhibitory RNAs for p65 and p50 
(combined).  This suggests that curcumin-induced effects on bcl-2, cyclin D1, 
VEGF and survivin expression are primarily due to Sp downregulation; however, 
the contribution of Sp proteins and NFκB on regulation of these gene products 
are gene- and cell context-dependent even though their promoters contain both 
GC-rich and NFκB elements (299) (336)  (337) (342, 343, 345) (348, 349).  
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 We also examined the in vivo activity of curcumin (50 mg/kg/d) in athymic 
nude mice bearing KU7 cells as xenografts (Figure 17D).  Curcumin inhibited 
tumor growth and weight and this corresponded to parallel effects in 253JB-V 
and KU7 cells (Figures. 12A and B) where curcumin inhibited cell proliferation.  
Moreover, curcumin-induced effects on Sp protein expression in bladder cancer 
cells (Figures. 14A and B) were also observed in bladder tumors (Figure 17D) 
demonstrating that curcumin-dependent Sp protein degradation is an integral 
part of the anticancer activity of this compound in bladder cancer cells and 
tumors. 
 In summary, results of this study demonstrate for the first time that 
curcumin induces proteasome-dependent degradation of Sp1, Sp3 and Sp4 in 
bladder cancer cell lines, and this is accompanied by decreased expression of 
Sp-dependent survival and angiogenic proteins.  The results suggest that at 
least some of the important anticancer activities of curcumin may be due, in part, 
to decreased expression of Sp proteins.  A recent study (355) reported that 
curcumin decreased Sp1 protein expression in pancreatic cancer cells and this 
was related to increased microRNA-22 which directly targets Sp1 but not Sp3 or 
Sp4.  Since curcumin induces proteasome-dependent degradation of all three 
Sp proteins in bladder cancer cells, the mechanism of curcumin action clearly 
differs in pancreatic and bladder cancer cells.  Current studies are focused on 
the cancer cell context-dependent differences in the contributions and 
mechanisms of action of curcumin-dependent downregulation of Sp proteins on 
the overall activity of this compound as an anticancer agent. 
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III. EPIDERMAL GROWTH FACTOR RECEPTOR IS DOWNREGULATED BY 
DRUGS THAT REPRESS SPECIFICITY PROTEIN TRANSCRIPTION 
FACTORS 
 
The epidermal growth factor receptor (EGFR) is an important 
chemotherapeutic target for tyrosine kinase inhibitors and antibodies that block 
the extracellular domain of EGFR.  Betulinic acid (BA) and curcumin are 
phytochemical anticancer agents, and we hypothesized that both compounds 
decrease EGFR expression in bladder cancer through downregulation of 
specificity protein (Sp) transcription factors.  The comparative effects of BA, 
curcumin and the tyrosine kinase inhibitor gefitinib on EGFR mRNA and protein 
expression were determined in 253JB-V and KU7 bladder cancer cells.  The 
effects of curcumin and BA on Sp proteins (Sp1, Sp3 and Sp4) and their role in 
downregulation of EGFR and EGFR-dependent responses were confirmed by 
RNA interference.  BA and curcumin decreased expression of EGFR, Sp and 
Sp-dependent proteins in 253JB-V and KU7 cells; EGFR was also decreased in 
cells transfected with a cocktail (iSp) containing small inhibitory RNAs for Sp1, 
Sp3 and Sp4.  BA, curcumin and iSp also decreased phosphorylation of Akt in 
these cells and downregulation of EGFR by BA, curcumin and iSp was 
accompanied by induction of LC3 and autophagy which is consistent with recent 
studies showing that EGFR suppresses autophagic cell death.  The results show 
that EGFR is an Sp-regulated gene in bladder cancer and drugs such as BA and 
curcumin that repress Sp proteins also ablate EGFR expression.  Thus, 
compounds such as curcumin and BA that downregulate Sp transcription factors 
represent a novel class of anticancer drugs that target EGFR in bladder cancer 
cells and tumors by inhibiting receptor expression.   
 
 
  
                                                                                                                                        116
 
 
 
Introduction 
 
 The epidermal growth factor receptor (EGFR) is a receptor tyrosine 
kinase and a member of the ErbB family of transmembrane receptors.  Ligand-
dependent activation of these receptors results in homo- or heterodimerization, 
autophosphorylation and induction of multiple downstream pathways required for 
cellular homeostasis (356).  ErbB family members are frequently activated in 
many tumor types and this is due to several factors including activating 
mutations, gene amplifications, overexpression of the receptor and/or its 
cognate ligands and loss of inhibitory factors that regulate receptor activity (357).  
Enhanced EGFR activity in cancer cells and tumors is associated with increased 
growth, survival and angiogenesis of tumors and thereby contributes significantly 
to the phenotypic characteristics of cancer cells (357) (358).  Not surprisingly, 
the EGFR has become a major target for cancer chemotherapy and 
development of two major classes of anti-EGFR agents, namely monoclonal 
antibodies against the extracellular domain of these receptors and low molecular 
weight drugs that competitively inhibit ATP binding to the intracellular tyrosine 
kinase domain.  EGFR1 (ErbB1/HER1) and EGFR2 (ErbB2/HER2) are two 
family members that exhibit increased activity in tumors and monoclonal 
antibodies against EGFR1 (Cetuximab) and EGFR2 (Trastuzumab) are used 
alone or in combination for cancer chemotherapy, and other antibodies are also 
being developed.  
 Tyrosine kinase inhibitors have also been developed for EGFR1 and 
EGFR2 (ErbB2) and these include gefitinib, erlotinib, lapatinib and others which 
are used as single agents or in combination for treatment of multiple cancers 
(359).  Initial studies of kinase inhibitors in non-small cell lung cancer (NSCLC) 
patients observed minimal treatment benefits (360) and recent reports have also 
shown that administration of gefitinib after radiotherapy did not improve survival 
of NSCLC patients (361).  In contrast, treatment of NSCLC patients with tyrosine 
kinase inhibitors was highly successful for subsets of patients expressing EGFR 
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kinase domain mutations (362) and similar results were observed for gefitinib in 
lung cancer cell lines (363). 
 Bladder tumors also overexpress the EGFR, and ligands for this receptor  
(364)  and clinical applications of EGFR blocking agents in combination with 
other drugs are underway or in development (365).  Shrader and coworkers 
(366) identified gefitinib-sensitive and -insensitive bladder cancer cell lines 
typified by 253JB-V and KU7 bladder cancer cells, respectively, and markers of 
responsiveness included induction of p27 and decreased DNA synthesis after 
treatment with the tyrosine kinase inhibitor.  Recent studies in this laboratory 
have demonstrated that tolfenamic acid, betulinic acid (BA) and curcumin inhibit 
growth of pancreatic, prostate and bladder cancer cells and tumors and this was 
associated with proteasome-dependent degradation of Sp1, Sp3 and Sp4 
transcription factors that are overexpressed in these cells and tumors (336).  
The effects on Sp proteins were accompanied by a parallel decrease in several 
Sp-dependent genes that enhance cancer cell survival (survivin), growth (cyclin 
D1) and angiogenesis [vascular endothelial growth factor (VEGF) and its 
receptors (VEGFR1 and VEGFR2)].  Expression of EGFR is Sp-dependent in 
some cancer cell lines (367) and this study demonstrates that both BA and 
curcumin decrease EGFR expression in bladder cancer cells and tumors, 
demonstrating that drug-induced Sp repression represents an alternative 
pathway for targeting EGFR in bladder cancer cells and tumors. 
Materials and methods 
 
 Cell lines.  KU7 and 253JB-V human bladder cancer cells were provided 
by Dr. A. Kamat, (M.D. Anderson Cancer Center, Houston, TX).  253JB-V and 
KU7 cell lines were maintained in RPMI 1640 supplemented with 10% fetal 
bovine serum (FBS), 0.15% sodium bicarbonate, 0.011% sodium pyruvate, 
0.24% HEPES and 10 ml/L of antibiotic/antimycotic cocktail solution (Sigma 
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Aldrich, St. Louis, MO).  Cells were grown in 150 cm2 culture plates in an air/CO2 
(95:5) atmosphere at 37°C and passaged approximately every 3 days. 
 Antibodies, chemicals and other materials.  Sp1 (PEP2), Sp3 (D-20), 
Sp4 (V-20), VEGF (147), Survivin (FL-142), AKT (sc-8312), p-AKT (sc-7985-R) 
and EGFR1 (1005) antibodies were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA).  Cleaved PARP (ASP 214), p-MAPK (197G2) and MAPK 
(137F5) antibody was purchased from Cell Signaling Technology (Danvers, MA) 
and SGLT antibody was purchased from Abcam Inc, (Cambridge, MA) (ab7970-
1).  LC3 antibody was purchased from MBL International Corporation, (Woburn, 
MA).  Monoclonal β-actin antibody was purchased from Sigma-Aldrich.  
Horseradish peroxidase substrate for western blot analysis was obtained from 
NEN Life Science Products (Boston, MA).  Lipofectamine 2000 was purchased 
from Invitrogen (Carlsbad, CA).  BA was purchased from Sigma-Aldrich, 
curcumin (98% pure) was purchased from Indofine Chemical Company, Inc. 
(Hillsborough, NJ) and gefitinib (>99% pure) was obtained from LC Laboratories 
(Woburn, MA).  The GFP-LC3 plasmid was kindly provided by Dr. Tamotsu 
Yoshimori (Osaka University, Osaka, Japan).  
 Cell proliferation assays.  Bladder cancer cells (3 x 104 cells per well) 
were seeded using DMEM:Ham's F-12 medium containing 2.5% charcoal-
stripped FBS in 12-well plates and left to attach for 24 hr.  Cells were then 
treated with either vehicle (DMSO) or the indicated concentrations of BA, 
curcumin and gefitinib.  Fresh medium and test compounds were added every 
24 hr for curcumin, BA and gefitinib.  Cells were then counted at the indicated 
times using a Coulter Z1 particle counter.  Each experiment was done in 
triplicate and results are expressed as means ± SE for each determination. 
 Western blot assays.  Bladder cancer cells were seeded in 
DMEM:Ham's F-12 medium containing 2.5% charcoal-stripped FBS.  Twenty-
four hr later, cells were treated with either vehicle (DMSO) or the indicated 
compounds for 48 hr.  Cells were collected using high-salt buffer (50 mmol/L 
  
                                                                                                                                        119
 
 
 
HEPES, 0.5 mol/L NaCl, 1.5 mmol/L MgCl2, 1 mmol/L EGTA, 10% glycerol, and 
1% Triton-X-100, pH 7.5) and 10 μL/mL of Protease Inhibitor Cocktail (Sigma 
Aldrich).  The lysates were incubated on ice for 1 hr with intermittent vortexing 
for 90 min, followed by centrifugation at 20,000 g for 10 min at 4C.  Lysates 
were then incubated for 3 min at 100°C before electrophoresis, and then 
separated on 10% SDS-PAGE 120 V for 3 to 4 hr in 1X running buffer (25 mM 
tris-base, 192 mM glycine, and 0.1% SDS).  Proteins were transferred onto 
polyvinylidene difluoride (PVDF) membranes by wet electroblotting in a buffer 
containing 25 mmol/L Tris, 192 mmol/L glycine, and 20% methanol for 1.5 hr at 
180 mA at 4°C.  The membranes were blocked for 30 min with 5% TBST-Blotto 
[10 mmol/L Tris-HCl, 150 mmol/L NaCl (pH 8.0), 0.05% Triton X-100, and 5% 
nonfat dry milk] and incubated in fresh 5% TBST-Blotto with 1:200 - 1:1000 
primary antibody overnight with gentle shaking at 4°C.  After washing with TBST 
for 10 min, the PVDF membrane was incubated with secondary antibody 
(1:5000) in 5% TBST-Blotto for 2 hr by gentle shaking.  The membrane was 
washed with TBST for 10 min, incubated with 6 mL of chemiluminescence 
(PerkinElmer Life Sciences, Waltham, MA) substrate for 1.0 min, and exposed to 
Kodak X-OMAT AR autoradiography film (American X-ray supply Inc, Jackson, 
CA).  The tumor tissues were also processed similarly and probed for EGFR1 
protein and β-actin served as loading control.  Quantification of the proteins was 
done using Image J software and the optical densities were plotted after 
normalization with lamin / β-actin. 
 siRNA interference assay.  The two bladder cancer cell lines, 253JB-V 
and KU7 were seeded (1 x 105 per well) in 12-well plates in DMEM:Ham's F-12 
medium supplemented with 2.5% charcoal-stripped FBS without antibiotic and 
left to attach for one day.  The triple Sp siRNA knockdown (iSp1, iSp3, iSp4 
complex) along with iLamin as control was performed using Liopfectamine 
reagent according to the manufacturer’s instructions.  Small inhibitory RNAs 
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were prepared by Dharmacon RNA Technologies (Chicago, IL).  The iRNA 
complexes used in this study are indicated as follows:   
 LMN  5' - CUG GAC UUC CAG AAG AAC ATT 
 Sp1  SMARTpool L-026959-00-0005 
 Sp3  5' - GCG GCA GGU GGA GCC UUC ACU TT  
 Sp4  5' - GCA GUG ACA CAU UAG UGA GCT T   
 Xenograft study.  Female athymic nude mice, age 4-6 weeks were 
purchased from Harlan (Indianapolis, CA).  KU7 cells (1x106 cells) in 1:1 ratio of 
Matrigel (BD Biosciences, San Jose, CA) were injected into the either side of 
flank area of nude mice.  A week after the tumor cell inoculation, the mice were 
divided into two groups of 10 animals each.  The first group received 100 μL 
vehicle (corn oil) by intraperitoneal route, and the second group of animals 
received 50 mg/kg/d dose of curcumin in corn oil every second day for 18 d (9 
doses) by intraperitoneal route.  At the end of 21 d, the animals were sacrificed; 
the tumors in control and treated animals were homogenized and probed for 
EGFR1 protein levels using western blotting. 
 Real-time PCR.  Total RNA was isolated using the RNeasy Protect Mini 
kit (Qiagen, Valencia, CA) according to the manufacturer's protocol.  RNA was 
eluted with 30 μL of RNase-free water and stored at -80°C.  RNA was reverse-
transcribed using Superscript II reverse transcriptase (Invitrogen) according to 
the manufacturer's protocol. cDNA was prepared from the 253JB-V and KU7 
bladder cancer cell lines at different time intervals using a combination of 
oligodeoxythymidylic acid and dNTP mix (Applied Biosystems, Foster City, CA) 
and Superscript II (Invitrogen).  Each PCR was carried out in triplicate in a 25 μL 
volume using SYBR Green Master mix (Applied Biosystems) for 15 min at 95°C 
for initial denaturing, followed by 40 cycles of 95°C for 30 s and 60°C for 1 min in 
the ABI Prism 7700 sequence detection system (Applied Biosystems).  The ABI 
Dissociation Curves software was used after a brief thermal protocol (95°C for 
15 s and 60°C for 20 s, followed by a slow ramp to 95°C) to control for multiple 
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species in each PCR amplification.  The comparative CT method was used for 
relative quantitation of samples.  Primers were purchased from Integrated DNA 
Technologies (Coralville, IA). The sequences of primers for EGFR1 were 5′ - 
TTT CGA TAC CCA GGA CCA AGC CAC AGC AGG - 3′ and 5′ - AAT ATT CTT 
GCT GGA TGC GTT TCT GTA - 3′. 
 Fluorescence microscopy and GFP-LC3 localization.  Monolayers of 
cells were cultured for 24 hr in 2-well coverglass chamber slides and treated as 
indicated.  The GFP-LC3 plasmid was kindly provided by Dr.Tamotsu Yoshimori 
(Osaka University, Osaka, Japan).  KU7 cell lines were transfected with 1 
μg/well GFP-LC3 plasmid using Lipofectamine 2000 transfection reagent 
(Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol.  Slides were 
examined by fluorescence microscopy using Zeiss Stallion Dual Detector 
Imaging System (Carl Zeiss Microimaging Inc., Thornwood, NY).  The 
intracellular distribution of GFP-LC3 was evaluated by monitoring GFP-LC3 and 
DIC images throughout the entire thickness of the cell by optical slices at 0.5 μM 
intervals using a C-Apochromat 63X, 1.2 NA water immersion lens.  Digital 
images were acquired using Slide Book software (Intelligent Imaging 
Innovations, Denver, CO).  The entire z-stack was subjected to fluorescence 
deconvolution to remove out of plane fluorescence.  Cells were examined in 
more than five fields per slide on multiple slides.  Data represent the average of 
all the fields.  
 Staining for acridine orange.  253JB-V and KU7 bladder cancer cells 
were seeded in monolayers and, at 70% confluence, cells were untreated or 
treated with 10 μM BA and 40 μM curcumin for various time points.  At the 
appropriate time points, cells were incubated with 1 μg/ml acridine orange 
(Molecular Probes, Eugene, OR) in serum-free medium for 15 min.  The acridine 
orange was removed and fluorescence images were obtained before and after 
removing the dye.  The cytoplasm and nucleus of the stained cells fluoresced 
bright green, whereas the acidic autophagic vacuoles fluoresced bright red.  
  
                                                                                                                                        122
 
 
 
Results 
 
Figure 18. Effects of gefitinib (A), BA (B) and curcumin (C) on cell survival. 
 
253JB-V and KU7 cells were treated with DMSO (solvent control) or 
different concentrations of gefitinib, BA and curcumin for 72 hr, and cells were 
counted and expressed as a percentage of DMSO as described in the Materials 
and Methods.  Results are expressed as means ± SE for at least 3 replicate 
experiments for each treatment group and significantly (p < 0.05) decreased 
survival is indicated (*). 
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 253JB-V and KU7 cells were reported to be gefitinib-responsive and non-
responsive, respectively, and results in Figure 18A demonstrate that treatment 
of 253JB-V and KU7 cells with 1 - 10 μM gefitinib for 72 hr significantly 
decreased cell survival only in the former cell line.  BA and curcumin, two 
relatively non-toxic phytochemical anticancer agents that decrease Sp protein 
expression in prostate and bladder cancer cells, respectively  (299), inhibited 
survival of both 253JB-V and KU7 bladder cancer cells (Figures. 18B and 18C).  
253JB-V cells were more sensitive than KU7 cells to the antiproliferative effects 
of both compounds at lower concentrations but at the higher concentrations 
used in this study, their effects on survival were similar in both cell lines.   
 
Figure 19. BA and curcumin decrease Sp proteins and Sp-dependent 
genes. 
Compound-induced repression of Sp1, Sp3 and Sp4 in 253JB-V (A) and 
KU7 (B) cells.  Cells were treated with DMSO or different concentrations of the 
compounds for 48 hr, and whole cell lysates were analyzed by western blots as 
described in the Materials and Methods.  Compound-induced repression of Sp-
dependent genes in 253JB-V (C) and KU7 (D) cells.  Protein expression was 
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determined as outlined above in (A) and (B).  Results (A - D) were observed in 
replicate experiments (at least 3). Results in Figures 19A and 19B show that 
both BA and curcumin decrease expression of Sp1, Sp3 and Sp4 proteins in 
253JB-V and KU7 cells.  This was accompanied by a parallel decrease in the 
Sp-dependent genes/proteins VEGF and survivin and induction of PARP 
cleavage (Figures. 19C and 19D).  Thus, curcumin specifically targets Sp 
transcription factors in bladder cancer cells as previously reported  (263), and 
we show for the first time that BA also exhibits comparable activity in bladder 
cancer cell lines.  In contrast, the tyrosine kinase inhibitor gefitinib did not affect 
Sp protein expression in these cell lines (data not shown).   
 Previous studies show that EGFR1 is regulated by Sp1 in some cancer 
cell lines  (367), and we hypothesized that BA and curcumin, which repress Sp1, 
Sp3 and Sp4 protein levels in bladder cancer cells (Figures. 19A and 19B), will 
also decrease EGFR1 and thereby provide an alternative pathway for the 
blockade of EGFR1 signaling.  EGFR1 also enhances cancer cell survival by 
inhibition of autophagic cell death in breast cancer cells through stabilization of 
the sodium/glucose cotransporter 1 (SGLT1) and this response is independent 
of the kinase activity of this receptor (263).  Results in Figures 21A and 21B also 
demonstrate that after treatment of 253JB-V and KU7 cells with BA or curcumin, 
there was a decrease in SGLT1 protein expression in both cell lines.  Moreover, 
this was also accompanied by induction of LC3 which is a protein biomarker of 
autophagy (368).  Thus, knockdown of EGFR1 in bladder cancer cells after 
treatment with curcumin or BA inhibited both EGFR1 kinase-dependent (PI3-K) 
and kinase-independent (SGLT downregulation and LC3 induction) survival 
pathways.  Gefitinib also decreases expression of phospho-Akt and phospho-
MAPK in 253JB-V cells (Figure 21C) which is consistent with inhibition of 
EGFR1 tyrosine kinase activity by this compound.   
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Figure 20. BA and curcumin decrease EGFR1 expression. 
 
Downregulation of EGFR1 protein.  253JB-V and KU7 cells were treated 
with DMSO or different concentrations of BA and curcumin for 48 hr, and 
EGFR1 protein expression was determined on whole cell lysates by western blot 
analysis as described in the Materials and Methods.  (B)  BA and curcumin 
decrease EGFR1 mRNA levels.  Cells were treated with DMSO or different 
concentrations of BA or curcumin for 18 hr, and EGFR1 mRNA levels were 
determined by RT-PCR as described in the Materials and Methods.  Results are 
expressed as means ± SE for 3 replicate determinations for each treatment 
group and significantly (p < 0.05) decreased expression (relative to DMSO) is 
indicated (*).  (C)  Curcumin decreases EGFR1 in tumor lysates.  Tumor lysates 
from athymic nude mice bearing KU7 cells as xenografts were treated with 
curcumin (50 mg/kg/d for 18 d) and analyzed by western blot analysis as 
described in the Materials and Methods.  Relative EGFR1 protein levels in the 
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curcumin treated group were significantly (p < 0.05) (*) lower than in tumors from 
corn oil-treated mice.  Results were obtained from lysates from individual 
animals (3 per treatment group) and normalized to β-actin protein. 
 Results in Figures 20A and 20B show that after treatment of 253JB-V and 
KU7 cells with BA or curcumin for 48 hr, there was a decrease in EGFR1 protein 
expression.  We also observed that BA and curcumin decreased EGFR1 mRNA 
levels in 253JB-V and KU7 cells (Figure 20B).  Previous studies showed that in 
a mouse xenograft model using KU7 cells, curcumin inhibited tumor growth and 
decreased Sp1, Sp3 and Sp4 expression in tumors (367) and Figure 20C also 
shows that curcumin decreased EGFR1 protein expression in these tumors.  
These in vivo results complement the in vitro data showing that BA and 
curcumin decrease EGFR1 in bladder cancer cells. 
 EGFR1 regulates multiple genes and pathways through activation of 
downstream kinases such as PI3-K and MAPK.  Figure 21A summarizes the 
effects of BA and curcumin on Akt/phospho-Akt and MAPK/phospho-MAPK 
expression in 253JB-V cells.  Cells treated with 10 or 15 μM BA and 25 μM 
curcumin decreased constitutive phospho-MAPK expression; however, the same 
concentrations of BA also decreased levels of MAPK protein, whereas curcumin 
had minimal effects on MAPK protein levels. Both BA and curcumin also 
decreased phospho-Akt in 253JB-V cells and this was accompanied by 
decreased Akt protein.  In KU7 cells, BA and curcumin increased levels of 
phospho-MAPK but did not affect MAPK protein and both compounds decreased 
phospho-Akt and Akt protein expression.   
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 Thus, in the gefitinib-resistant cells, BA and curcumin inhibited the PI3-K 
and not the MAPK signaling pathways.   
 
Figure 21. Modulation of putative EGFR1-dependent responses. 
 
 
Effects of BA and curcumin on EGFR1-dependent effects in 253JB-V (A) 
and KU7 (B) cells compared to effects of gefitinib (C) in both cell lines.  Cells 
were treated with DMSO or different concentrations of BA, curcumin or gefitinib 
for 48 hr, and whole cell lysates were analyzed by western blot analysis as 
described in the Materials and Methods.  Similar results were observed in 
replicate (2) experiments. 
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However, in KU7 cells, gefitinib did not affect expression of phospho-Akt 
and induced phospho-MAPK (Figure 21D) which is consistent with previous 
studies showing that this cell line is gefitinib-resistant.  Gefitinib did not affect 
SGLT or LC3 protein expression in either cell line which is in contrast to the 
effects of BA and curcumin (Figures. 21A and 21B).  
Since Sp1, Sp3 and Sp4 are overexpressed in bladder and other cancer 
cell lines, we used a cocktail (iSp) of small inhibitory RNAs for Sp1 (iSp1), Sp3 
(iSp3), and Sp4 (iSp4) for simultaneous knockdown of all three transcription 
factors (Figure 22A) as previously described (263).  Figure 22B demonstrates 
that transfection of 253JB-V and KU7 cells with the iSp cocktail also decreased 
EGFR protein confirming that expression of EGFR1 is Sp-dependent in bladder 
cancer cells which is consistent with the multiple GC-rich Sp binding sites 
identified in the EGFR1 promoter (367). 
Cells were treated with DMSO (untreated), 10 μM BA, or 40 μM curcumin 
for 18 hr, and detection of autophagic vacuoles by acridine orange staining was 
determined as described in the Materials and Methods.  (C)  Induction of 
punctate green fluorescence in KU7 cells transfected with GFP-LC3.  Cells were 
transfected with the GFP-LC3 plasmid for 24 hr and treated with DMSO 
(untreated), BA or curcumin for 18 hr, and GFP-LC3 fluorescence was 
determined as described in the Materials and Methods.  Observations in (A) - 
(C) were typical of replicate experiments.  (D)  Model for the effects of BA, 
curcumin and iSp in bladder cancer cells. 
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Figure 22. Effects of Sp knockdown by RNA interference on EGFR1 and 
EGFR1-dependent responses. 
 
253JB-V and KU7 cells were transfected with a cocktail (iSp) containing 
siRNAs for Sp1, Sp3 and Sp4 or iLamin (non-specific control) and levels of Sp1, 
Sp3 and Sp4 (A), EGFR1 (B) and possible EGFR1-dependent responses (C) 
were analyzed by western blot analysis of whole cell lysates as described in the 
Materials and Methods.  Similar results (A and B) were observed in replicate (at 
least 3) experiments.  (D)  Quantitation of phospho-Akt and LC3 proteins.  The 
effects of iSp in phospho-Akt and LC3 proteins were determined as a % of 
Lamin/β-actin protein ratios from 3 replicate western blot analyses as indicated 
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in (C) and described in the Materials and Methods.  Results are expressed as 
means ± SE and significant (p < 0.05) increases or decreases in the iSp 
transfected compared to the iLamin transfected groups are indicated (*). 
  Decreased EGFR expression in 253JB-V and KU7 cells transfected with 
iSp did not affect phospho-MAPK, MAPK or Akt expression but decreased 
phospho-Akt protein levels (Figures. 22C and 22D), and this was similar to the 
effects of curcumin and BA on phospho-Akt in these cell lines, suggesting that 
this response is EGFR-dependent (Figures. 21A and 21B).  SGLT expression 
was not affected, whereas LC3 was induced in 253JB-V and KU7 cells 
transfected with iSp (Figures. 22C and 22D). 
 
 
Figure 23. Induction of autophagy; Induced acridine orange staining in 
253JB-V (A) and KU7 (B) cells. 
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 These results demonstrate both similarities and differences between the 
effects of BA and curcumin vs. transfection with iSp in bladder cancer cells and 
this is due, in part, to responses induced by both compounds that are 
independent of Sp transcription factors and EGFR1 (301).  Induction of LC3, a 
protein biomarker for autophagy was observed after ablation of EGFR1 by 
treatment of 253JB-V and KU7cells with curcumin and BA (Figures. 21A and 
21B) or transfection with iSp (Figures. 22C and 22D), and this was consistent 
with induction of autophagy in prostate and breast cancer cells in which EGFR1 
expression was decreased directly by RNA interference (369).  Further 
confirmation that BA, curcumin and Sp knockdown by RNA interference induced 
autophagy in 253JB-V and KU7 cells is illustrated in Figures 23A and 23B.  
Compared to the DMSO (untreated controls), BA, curcumin and iSp induced 
acridine orange staining which is consistent with formation of acidic autophagic 
vacuoles (autophagolysomes) which are characteristically observed in 
autophagic cells (370).  In KU7 cells transfected with the GFP-LC3 construct, 
there was a diffuse pattern of green fluorescence through the cells (Figure 23C); 
however, treatment with 10 μM BA and 40 μM curcumin or transfection with iSp 
induced a punctate fluorescent staining which is also characteristic of autophagy 
(371). Transfection with GFP-LC3 was unsuccessful in 253JB-V due to 
cytotoxicity (data not shown).  Thus, BA, curcumin and iSp decrease Sp-
dependent proteins including EGFR1 and also decrease EGFR1-dependent 
phospho-Akt and induction of autophagy in bladder cancer cells (Figure 23D). 
Discussion 
 
 Sp transcription factors are critical for early embryonic development in 
mouse models; however, there is evidence that expression of Sp1 decreases 
with age in humans and laboratory animal models (372).  Several different 
cancer cell lines overexpress Sp1, Sp3 and Sp4 proteins including breast cancer 
cell lines (263) (299); however, in immortalized but not transformed MCF10A 
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cells, expression of these proteins was significantly decreased (373).  Similar 
differences were observed in human prostate tumors (xenografts) in athymic 
nude mice and mouse liver, and ongoing studies in mouse tissue/organs 
including proliferative gastrointestinal tissue and bone marrow confirm the low to 
non-detectable expression of Sp1, Sp3 and Sp4 in mature mice (data not 
shown).  Differences in expression of Sp proteins in tumor vs. non-tumor tissue 
suggests that these transcription factors are potential targets for cancer 
chemotherapy, particularly since expression of several pro-oncogenic genes 
including survivin, cyclin D1, VEGF, VEGFR1 and VEGFR2 are Sp-dependent 
(23-25).  Anticancer drugs such as curcumin and BA act, in part, by decreasing 
expression of Sp1, Sp3 and Sp4 in bladder and prostate tumors, respectively, 
and the low toxicity of these compounds suggest that their effects on Sp proteins 
are specific for cancer cells and tumors (263). 
 The EGFR1 is overexpressed in bladder tumors and tumors derived from 
other tissues, and wild-type EGFR is primarily expressed in bladder tumors 
(374).  The EGFR tyrosine kinase inhibitor gefitinib is effective only on NSCLC 
patients that express activating kinase domain mutations of the EGFR; however, 
in bladder tumors and cancer cell lines, differential gefitinib responsiveness is 
not dependent on these mutations.  Figure 18A shows that gefitinib differentially 
decreases survival of 253JB-V cells (gefitinib-responsive) compared to gefitinib 
non-responsive KU7 cells (366).  In contrast, curcumin and BA decrease survival 
of both 253JB-V and KU7 bladder cancer cells (Figures. 18A and 18B) with only 
minimal differences in their responsiveness to both compounds.  BA, like 
curcumin, also decreased Sp1, Sp3 and Sp4 expression in both cell lines and 
this was accompanied by decreased expression of Sp-dependent genes 
(survivin, VEGF and bcl-2) and induction of PARP cleavage (Figure 19).  These 
results are typically observed in cancer cell lines following treatment with 
compounds that decrease Sp proteins or transfection with iSp that decreases 
Sp1, Sp3 and Sp4 levels by RNA interference.  EGFR1 expression in some 
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cancer cell lines is also dependent on Sp transcription factors (375) (263).  In 
this study, we focused on curcumin- and BA-mediated effects on EGFR1 
expression in bladder cancer cells since this pathway may significantly 
contribute to the anticancer activity of these compounds. 
 Figures 20A and 20B illustrate that EGFR1 protein and mRNA levels 
were decreased in 253JB-V and KU7 cells after treatment with BA or curcumin, 
and analysis of tumor lysates from a prior mouse xenograft study with KU7 cells 
shows that curcumin also significantly decreased EGFR in tumors (Figure 20C) 
and this was accompanied by decreased expression of Sp1, Sp3 and Sp4 (299) 
(263).  A comparison of the effects of gefitinib, BA and curcumin in gefitinib-
responsive 253JB-V indicates that all three agents decreased EGFR-dependent 
phosphorylation of MAPK and Akt (Figures. 21A and 21C).  In contrast, BA and 
curcumin but not gefitinib decreased phospho-Akt levels in KU7 cells, and BA 
and curcumin increased phospho-MAPK expression in KU7 cells, whereas 
minimal effects were observed for gefitinib.  These responses, coupled with the 
downregulation of Akt protein (KU7 and 253JB-V cells) by BA and curcumin and 
MAPK protein by BA only in 253JB-V cells, may be associated with effects of 
these compounds that are independent of their downregulation of Sp or EGFR 
proteins (Figure 23D) and are currently being investigated. 
 A recent study in prostate and breast cancer cell lines investigated 
EGFR1 kinase-dependent and -independent responses by directly decreasing 
EGFR1 by RNA interference or by overexpression of wild-type and kinase 
domain mutant EGFR1 expression plasmids (369).  One of the important 
observations was identification of a kinase-independent function of EGFR1 in 
which the wild-type and mutant (kinase domain) EGFR1 stabilized SGLT1 to 
prevent autophagic cell death and EGFR1 knockdown resulted in decreased 
SGLT1 expression and enhanced accumulation of LC3.  Formation of the 
cleaved form of LC3 is critical for autophagosome formation and is a positive 
marker for autophagolysosomes (368).  Both BA and curcumin induced LC3 
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accumulation and downregulated SGLT1 in 253JB-V and KU7 cells (Figures. 
21A and 21B) and knockdown of EGFR by transfection with iSp also induced 
LC3 accumulation but did not decrease SGLT1 expression (Figure 22C).  Not 
surprisingly, gefitinib did not affect expression of either SGLT1 or LC3 (Figure 
21C).  BA, curcumin and iSp transfection decreased EGFR1 expression 
(Figures. 20A and 22B) and therefore, their differences with respect to 
expression of SGLT1 in bladder cancer cells may be EGFR1-independent and 
associated with other activities of BA and curcumin (Figure 23D).  The induction 
of autophagy by BA, curcumin and iSp was also confirmed by their induction of 
acridine orange staining (Figures. 23A and 23B) and induction of punctuate 
perinuclear green fluorescence in KU7 cells transfected with GFP-LC3 (Figure 
23C).  Both of these staining/fluorescent responses are characteristic of 
autophagy (370) (371). 
 In summary, results of this study demonstrate that BA- and curcumin-
dependent repression of Sp1, Sp3 and Sp4 in bladder cancer cells also 
decrease expression of the Sp-dependent gene EGFR1 in both gefitinib-
responsive 253JB-V and gefitinib-nonresponsive KU7 cells.  Thus, BA and 
curcumin represent a new type of EGFR1 inhibitor that indirectly targets EGFR1 
and EGFR1-mediated responses through repression of Sp transcription factors.  
This results in inhibition of EGFR1-dependent kinases and activation of 
autophagic cell death which is repressed by EGFR1 (kinase-independent) (369).  
An additional chemotherapeutic advantage of these compounds is that they also 
induce pro-apoptotic, antiproliferative and antiangiogenic activities through 
downregulation of Sp-dependent survivin, cyclin D1 and VEGF/VEGFR1 
expression, respectively (263) (Figures. 2C and 2D) and several other 
responses that are Sp-independent (263) (Figure 23D).  Relative contributions of 
Sp-dependent and Sp-independent pathways to the overall anticarcinogenic 
activity of curcumin and BA and other drugs that repress Sp proteins and Sp-
regulated proteins such as EGFR1 will also vary with tumor type.  Currently, we 
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are investigating the mechanisms of action and clinical applications of drugs 
such as BA and curcumin alone and in combination with other cytotoxic 
compounds that are used for clinical treatment of bladder cancer. 
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IV. CELASTROL DECREASES SPECIFICITY PROTEINS (Sp) AND 
FIBROBLAST GROWTH FACTOR RECEPTOR-3 (FGFR3) IN BLADDER 
CANCER CELLS 
 
Bladder cancer incidence has been increasing and even after 
chemotherapy with highly cytotoxic drugs, the prognosis for disease-free survival 
in most patients is only 1 to 2 years.  Celastrol, a naturally occurring triterpenoid 
acid from an ivy-like vine exhibits anticancer activity against 253JB-V and KU7 
bladder cancer cells. Celastrol decreased cell proliferation, induced apoptosis 
and decreased expression of specificity protein (Sp) transcription factors Sp1, 
Sp3 and Sp4 and several Sp-dependent genes/proteins including vascular 
endothelial growth factor (VEGF), survivin, and cyclin D1. Fibroblast growth 
factor receptor 3 (FGFR3) is overexpressed in bladder tumors and celastrol also 
caused a dose-dependent downregulation of this receptor in 253JB-V and KU7 
bladder cancer cells. Using small inhibitory RNAs (siRNA) for Sp1, Sp3 and Sp4 
(in combination) we showed that FGFR3 receptor expression in bladder cancer 
cells is regulated by Sp transcription factors. The mechanism of Sp 
downregulation by celastrol was due to induction of reactive oxygen species 
(ROS) and inhibitors of ROS blocked celastrol-induced growth inhibition and Sp 
repression.  In vivo studies using KU7 cells as xenografts, showed that celastrol, 
decreased tumor growth and expression of Sp proteins confirming that celastrol 
represents novel class of anticancer drugs that act, in part through targeting 
downregulation of Sp transcription factors.  
Introduction 
 
Bladder cancer is the ninth most common cancer worldwide and ranks 
thirteenth as the cause of cancer deaths (376). It is estimated that in 2009 
68,000 new cases will be diagnosed and 14,000 deaths will occur from this 
disease in the United States.  At the time of detection, approximately 25% of 
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bladder cancer cases are already muscle-invasive and are usually treated by 
cystectomy. However, after removal of primary tumors by transurethral 
resection, multiple recurrences continue to develop in 70% of the patients (377). 
In spite of the initial response to intra-vesicular Bacillus Calmette-Guerin (BCG) 
administration, bladder tumors eventually recur to form an invasive phenotype 
which often leads to surgical removal of the bladder (333, 378). MVAC 
(Methotrexate, Vinblastine, Adriamycin and Cisplatin) chemotherapy which is 
extensively used for treatment of advanced bladder cancer is accompanied by 
toxic side effects and thus it is important to develop less toxic alternate 
therapies. The cytotoxic paradigm might not offer a successful means to change 
the outcome for metastatic bladder cancer patients (333), however 
epidemiological and cross-cultural studies show some success of dietary 
management strategies in the prevention of this disease (379).   
New mechanism based drugs for bladder cancer chemotherapy have 
been reported and these include tyrosine kinase inhibitor against the epidermal 
growth factor receptor (EGFR) and antiangiogenic drugs or antibodies that block 
vascular endothelial growth factor (VEGF) and activation of VEGF receptors. 
Diindolylmethane derivatives developed in this laboratory inhibit bladder cancer 
cell and tumor growth through both orphan nuclear receptor-dependent and 
independent pathways (380). In addition, curcumin, the active component of 
turmeric also exhibits anticancer activity in vitro and in vivo against bladder 
cancer (333) and studies in this laboratory suggest that the mechanism of action 
of curcumin was due, in part, to downregulation of specificity (Sp) transcription 
factors (263) .   
In this study we have investigated the activity of the triterpenoid celastrol 
(CSL) as an inhibitor of bladder cancer cell and tumor growth. Celastrol (CSL) is 
a quinone methide triterpene extracted from the root of Tripterygium wilfordii, 
(also known as Thunder of God vine) and this compound has been used in 
traditional Chinese medicine to treat immune-inflammatory diseases such as 
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rheumatoid arthritis (381), chronic nephritis, chronic hepatitis and lupus 
erythematous (314) and celastrol acts as a cytokine release inhibitor (382), anti-
allergic (383) (312) (384). Although CSL is in clinical trials for rheumatiod 
arthritis (385), the antitumor activity of this drug has not been extensively 
investigated. In prostate cancer cells the antitumorigenic activity of CSL was 
related to inhibition of VEGFR expression, induction of apoptosis and inhibition 
of proteosome activity (314).  Our results show that CSL inhibits growth of 
253JB-V and KU7 bladder cancer cells and tumor growth in athymic nude mice 
bearing KU7 cells as xenografts. We also observed that celastrol also induced 
apoptosis in both bladder cancer cell lines and decreased expression of Sp1, 
Sp3 and Sp4 proteins and Sp-dependent genes important for survival (survivin), 
growth (cyclin D1), angiogenesis (VEGF). In addition we observed that fibroblast 
growth factor receptor 3 (FGFR3) which is overexpressed in bladder cancer is 
also an Sp-regulated gene and is downregulated in bladder cancer cells after 
treatment with celastrol. Celastrol-induced downregulated of Sp proteins was 
due to induction of reactive oxygen species (ROS) which has recently been 
shown to decrease Sp protein expression in cancer cells. 
Materials and methods 
 
Cell lines. KU-7 and 253JB-V human bladder cancer cells were provided 
by Dr. A. Kamat, (M.D Anderson Cancer Center, Houston, TX).  253JB-V and 
KU7 cell lines were maintained in RPMI 1640 supplemented with 10% fetal 
bovine serum (FBS), 0.15% sodium bicarbonate, 0.011% sodium pyruvate, 
0.24% HEPES and 10 ml/L of antibiotic/antimycotic cocktail solution (Sigma 
Aldrich, St. Louis, MO).  
Antibodies, chemicals and other materials. Sp1, Sp3, Sp4, VEGF, 
survivin, CD1, p65, p50 and FGFR3 antibodies were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). Cleaved PARP (ASP 214) antibody was 
purchased from Cell Signaling Technology (Danvers, MA). Monoclonal β−actin 
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antibody was purchased from Sigma-Aldrich. Horseradish peroxidase substrate 
for western blot analysis was obtained from NEN Life Science Products (Boston, 
MA). Lipofectamine 2000 was purchased from Invitrogen (Carlsbad, CA). 
Celastrol, 98% pure, was purchased from Biopurify (Sichuan, China) and 
Calbiochem (Gibbstown, NJ). GSH is a tripeptide composed of L-glutamic acid, 
L-cysteine, and L-glycine. Glutathione (GSH), 98% pure was purchased from 
Aldrich (Sigma-Aldrich Inc, (St. Louis, MO). Dithiothreitol (DTT), 98% was 
obtained from Boehringer Mannheim Corp, (Indpls, IN). ). The pVEGF-2018 
construct contains VEGF promoter inserts (positions –2018 to +50) linked to 
luciferase reporter gene. The pSurvivin-269 contains survivin promoter inserts 
inserts (positions –269 to +49) linked to luciferase reporter gene and was kindly 
provided by Dr. M. Zhou (Emory University, Atlanta, GA). The pSp1 and pSp3 
promoter constructs (pSp1-FOR4-luc and pSp3-FOR5-luc) were provided by Drs 
Carlos Cuidad and Veronique Noe (University of Barcelona). Sp1-FOR4-luc 
(contains the –751 to –20 region of the Sp1 gene promoter) and pSp3-FOR5-luc 
(contains the –417 to –38 region of the Sp3 promoter) constructs respectively. 
YH633p(-220/-27)FR3-luc(C4) FGFR3 plasmid was a kind gift from Dr. Young-
Kwon Hong (USC, CA) and Dr. David Ornitz, (WUSTL, MO). 
Cell proliferation assays. Bladder cancer cells (3 x 104 cells per well) 
were seeded using DMEM:Ham's F-12 medium containing 2.5% charcoal-
stripped FBS in 12-well plates and left to attach for 24 hr. Cells were then 
treated with either vehicle (DMSO) or the indicated concentrations of celastrol. 
Fresh medium and test compounds were added every 24 hr and cells were then 
counted at the indicated times using a Coulter Z1 particle counter. Each 
experiment was carried out in triplicate and results are expressed as means ± 
SE for each treatment group. 
Western blot assays. Bladder cancer cells were seeded in 
DMEM:Ham's F-12 medium containing 2.5% charcoal-stripped FBS. Twenty-
four hr later, cells were treated with either vehicle (DMSO) or the indicated 
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compounds for 24 hr. Cells were collected using high-salt buffer [50 mmol/L 
HEPES, 0.5 mol/L NaCl, 1.5 mmol/L MgCl2, 1 mmol/L EGTA, 10% glycerol, and 
1%  Triton-X-100 pH 7.5] and 10 µL/mL of Protease Inhibitor Cocktail (Sigma 
Aldrich). The lysates were incubated on ice for 1 hr with intermittent vortexing 
every 10 min for a total of 90 min, followed by centrifugation at 20,000 g for 10 
min at 4°C. Lysates were then incubated for 3 min at 100°C before 
electrophoresis, and then separated on 10% SDS-PAGE 120 V for 3 to 4 hr in 
1X running buffer [25 mM tris-base, 192 mM glycine and 0.1%SDS]. Proteins 
were transferred onto polyvinylidene difluoride (PVDF) membranes by wet 
electroblotting in a buffer containing 25 mmol/L Tris, 192 mmol/L glycine, and 
20% methanol for 1.5 hr at 0.9A at 4°C. The membranes were blocked for 30 
min with 5% TBST-Blotto [10 mmol/L Tris-HCl, 150 mmol/L NaCl (pH 8.0), 
0.05% Triton X-100, and 5% nonfat dry milk] and incubated in fresh 5% TBST-
Blotto with 1:200- 1:1000 primary antibody overnight with gentle shaking at 4°C. 
After washing with TBST for 10 min, the PVDF membrane was incubated with 
secondary antibody (1:5000) in 5% TBST-Blotto for 2 hr by gentle shaking. The 
membrane was washed with TBST for 10 min, incubated with 6 mL of 
chemiluminescence (PerkinElmer Life Sciences, Waltham, MA) substrate for 1.0 
min, and exposed to Kodak X-OMAT AR autoradiography film (American X-ray 
supply Inc, Jackson, CA). The tumor tissues were also processed and β-actin 
served as loading control. The tumor lysates were processed and probed for Sp 
and FGFR3 proteins and protein quantitation was determined using Image J 
software and the optical band intensities were plotted after normalization with 
lamin /β-actin. Nuclear and cytoplasmic extracts were separated using NE-PER 
nuclear and cytoplasmic extraction reagents (Pierce). 
SiRNA interference assay. The two bladder cancer cell lines, 253JB-V 
and KU7 cells were seeded (1 x 105 per well) in 6-well plates in DMEM:Ham's F-
12 medium supplemented with 2.5% charcoal-stripped FBS without antibiotic 
and left to attach for one day. The triple Sp SiRNA knockdown (iSp1, iSp3, iSp4 
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complex) along with iLamin as control was performed using Liopfectamine 
reagent according to the manufacturer’s instructions. Small inhibitory RNAs were 
prepared by Dharmacon RNA Technologies (Chicago, IL) and the 
oligonucleotides used in this study are the same as previously described before 
(263). 
Transfection and luciferase assays. The luciferase construct of FGFR3 
containing minimal Sp binding sites on FGFR3 YH633p(-220/-27)FR3-luc(C4) 
was transfected into the two bladder cancer cell lines. Bladder cancer cells (1 x 
105 per well) were plated in 12-well plates in DMEM:Ham's F-12 medium 
supplemented with 2.5% charcoal-stripped FBS. After 16-24 hr, various amounts 
of DNA (i.e., 0.4 µg pGL2/pGL3; 0.04 µg β-galactosidase; and 0.4 µg FGFR3, 
YH633p(-220/-27)FR3-luc(C4), pVEGF, pSurvivin, pSp1For4 and pSp1For5  
constructs were transfected using Lipofectamine reagent according to the 
manufacturer's protocol and then treated with control solvent (DMSO) and 
different concentrations of celastrol. SiRNAs for  lamin (control) and siSp1, siSp3 
and siSp4 (combined) were also transfected into these cells and luciferase 
activity (normalized to β-galactosidase) was determined essentially as 
described.  
Terminal deoxyribonucleotide transferase–mediated nick-end 
labeling assay.  253JB-V and KU7 cells (7 x 104) were seeded in four-
chambered glass slides and left 12 hr to attach. After celastrol treatment for 20 
hr, the in situ cell death detection POD kit was used for the terminal 
deoxyribonucleotide transferase–mediated nick-end labeling (TUNEL) assay 
according to the instructions in the protocol manual for fixed cells. The 
percentage of apoptotic cells was calculated by counting the stained cells in 
eight fields, each containing 50 cells. The total number of apoptotic cells was 
plotted as a percentage in both cell lines. 
ROS estimation. Cellular reactive oxygen species (ROS) levels were 
evaluated with the cell-permeant probe CM-H2DCFDA (5-(and-6)-chloromethyl-
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2'7' dichlorodihydrofluorescein diacetate acetyl ester). CM-H2DCFDA is 
nonfluorescent until removal of the acetate groups by intracellular esterases and 
oxidation occurs within the cell.  Following treatment for 20-24 hr, cells were 
grown in a 96 well cell culture plate, then treated with 10 μM CM-H2DCFDA for 
30 min, washed once with serum free medium, and analyzed for  ROS levels 
using the BioTek Synergy 4 plate reader (BioTek Instruments, Inc., Winooski, 
VT) set at 480 nm and 525 nm excitation and emission wavelengths 
respectively.  Following determination of ROS, cultures were washed twice with 
PBS and fixed with methanol for 3 min at room temperature. Methanol was then 
completely removed and 1 mg/ml Janus green was added to the cultures for 3 
min.  Following removal of Janus green, cultures were washed twice with PBS 
and 100 μl of 50% methanol was added to each well. Cell counts were then 
determined with the plate reader set to an absorbance of 654 nm and ROS 
intensities were then corrected accordingly. Two experiments were preformed 
on different days. At least 16 wells per treatment were analyzed for each 
experiment.   
Xenograft study. Female athymic nude mice, age 4-6 weeks were 
purchased from Harlan (Indianapolis, CA) and KU7 cells (1×106 cells) in Matrigel 
(BD Biosciences, San Jose, CA) (1:1) were injected into the either side of flank 
area of nude mice. When tumors were palpable, mice were divided into two 
groups of ten animals each. The first group received 100 µL vehicle (corn oil) by 
intraperitoneal route, and the second group of animals received 4 mg/kg/d dose 
of celastrol in corn oil every second day for 22 days (eleven doses) by the intra 
peritoneal route of administration. After 23 days, the mice were sacrificed; 
tumors in control and treated groups were homogenized and probed for Sp 
proteins by western blots. Weights of animals and tumor areas were recorded 
every alternate day before the treatment. 
Statistical analysis. Statistical significance of differences between 
treatment groups was determined by an analysis of variance and student t-test, 
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and the levels of probability were noted.  IC50 values were calculated using 
linear regression methods and expressed as μM concentrations. 
Results 
 
 
Figure 24. CSL inhibits growth of bladder tumors and bladder cancer cells 
and induces apoptosis. 
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Figure 24 continued. 
 
A. CSL decreases KU7 xenograft tumor volume and weight. Mice were 
injected and treated as described in the materials and methods. B.  Inhibition of 
253JB-V and KU7 cell growth by CSL. Cells were treated with DMSO (solvent 
control); 0.5, 1.0 or 2.5 µmol/L CSL and the effects on cell growth were 
determined after treatment for 72 hr as described in Materials and Methods. C. 
Induction of apoptosis by CSL. 
253JB-V and KU7 cells were treated with DMSO (0) and 1.0, 2.5 or 5.0 
µmol/L CSL for 24 hr and induction of cleaved PARP protein was determined as 
described in Materials and Methods. D. CSL increases TUNEL positive cells.  
253JB-V and KU7 cells were treated with DMSO (0) and 2.0 or 4.0 µmol/L CSL 
for 20 hr and increase in TUNEL positive cells was determined as described in 
Materials and Methods. Results are expressed as means ± SE for three 
replicate determinations for each treatment group, and significant (P < 0.05) 
CSL-induced increases (**) or decreases (*) compared to the solvent (DMSO) 
control are indicated.  
The in vivo antitumor activity of CSL (4 mg/Kg/d) was investigated using 
female athymic nude mice bearing KU7 bladder xenograft model. Figure. 24A 
shows that CSL significantly attenuated tumor growth in nude mice as evidenced 
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by decreased tumor volumes and tumor weights (Figure. 24A). These results 
are comparable to previous prostate tumor studies where growth inhibition by 
celastrol was observed at doses of ≤ 4 mg/kg/d (314). Cleastrol (0.5-2.5 μM) 
also inhibited growth of 253JB-V and KU7 bladder cancer cells (Figure 24B) and 
growth inhibitory IC50 values for 253JB-V and KU7 cells are 0.93 and 1.13 μM 
respectively after treatment for 72 hr.  Earlier reports show that CSL-induced 
apoptosis in LNCaP prostate cancer cells was associated with PARP cleavage 
(314) and results illustrated in Figure. 24C indicate that CSL also significantly 
induced PARP cleavage, a signature protein for apoptosis in both the cell lines. 
We further confirmed this finding using the TUNEL (terminal dUTP nick end 
labeling) assay where apoptotic TUNEL positive staining is significantly 
increased in both 253JB-V and KU7 bladder cancer cell lines after treatment 
with 4 μM CSL for 20 hr (Figure. 24D). The % apoptotic cells obtained by 
counting apoptotic cells in various representative fields are plotted in (Figure. 
24D), and confirm a statistically significant induction of apoptosis by CSL.  
Figure 25A summarizes the effects of CSL on expression of survivin, 
VEGF, and cyclin D1 proteins in both 253JB-V and KU7 bladder cancer cells. 
We observed that concentrations of CSL ≤ 1.0 μM decreased the expression of 
all three proteins in 253JB-V cells whereas higher concentration (≥ 1.0 μM) were 
required to induce similar effects in KU7 cells. We further investigated the effects 
of CSL on luciferase activity in 253JB-V and KU7 bladder cancer cells 
transfected with pVEGF and pSurvivin constructs containing -2019 to +50 and -
269 to +49 GC rich inserts from the VEGF and survivin gene promoters 
respectively. 
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Figure 25. Effects of CSL on angiogenic, survival and cell cycle proteins. 
 
CSL decreases VEGF, survivin and cyclin D1 proteins in 253JB-V and 
KU7 at 24 hr (A), and also decreases luciferase activity of the cells transfected 
with VEGF and survivin gene promoters (B). Bladder cancer cells were treated 
with DMSO (solvent control); 0.5, 1.0, 2.5 or 5.0 µmol/L CSL and whole cell 
lysates were analyzed by western blots or luciferase activity was determined as 
indicated in Materials and Methods. C. CSL degrades NFκB subunits. Cells 
were treated with DMSO (solvent control); 0.5, 1.0, 2.5 or 5.0 µmol/L CSL and 
KU7
L uc
pVEGF
-2018
pSurvivin
Luc
-269
= GC 
KU7 253JB-V
R
el
at
iv
e 
Lu
c 
A
ct
iv
it
y
253JB-V
Celastrol (µM)
0      0.5      1     2.5
Celastrol (µM)
0      0.5      1     2.5
Celastrol (µM)
0     0.5   1   2.5
Celastrol (µM)
0     0.5      1       2.5
p50
p65
β-Actin
KU7
0           1        2.5       5 
p50
p65
β-Actin
253JB-V
0       0.5    1.0      2.5CSL (uM) CSL (uM)
B
C
KU7
0      1       2.5      5 
VEGF
Survivin
β-Actin
CD1
253JB-V
VEGF
Survivin
β-Actin
CD1
0      1        2.5       5 CSL (uM) CSL (uM)
* *
* * * * *
*
*
  
                                                                                                                                        147
 
 
 
the nuclear fraction was analyzed by Western blot analysis for p65 and p50 
subunits as described in Materials and Methods. β-Actin served as a loading 
control and similar results were observed in duplicate experiments. Results are 
expressed as means ± SE for three replicate determinations for each treatment 
group, and significant (P < 0.05) CSL-induced decreases (*) compared to the 
solvent (DMSO) control are indicated.  
The results show that CSL also significantly decreased luciferase 
activities in 253JB-V and KU7 cells transfected with these constructs suggesting 
that CSL also affected transcription of these genes (Figure 25A). The 253JB-V 
cells were also more responsive to the effects of CSL than KU7 cells in the 
transfection assays and this was similar to that observed for protein 
downregulation shown in Figure 25A. 
Since CSL has been used in clinical trails to treat inflammatory conditions 
(383), the effects of CSL on the expression of the p65 and p50 subunits of 
NFκB, in nuclear extracts of 253JB-V and KU7 bladder cancer cells were 
determined (Figure 25C). CSL, significantly decreased p65 and p50 protein 
subunits of NFκB and these results are consistent with previous findings that 
CSL inhibits NFκB activation in multiple cell lines (386). 
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Figure 26. In vitro and in vivo effects of CSL on Sp proteins. 
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Figure 26 continued. 
 
CSL decreases Sp proteins at 24 hr in blader cancer cells. Cells were treated 
with DMSO and 1.0, 2.5 or 5.0 µmol/L CSL for 24 hr and whole-cell lysates were 
analyzed by Western blot analysis as described in Materials and Methods. 
 β-Actin served as a loading control and similar results were observed in 
duplicate experiments. B. CSL decreases luciferase activity in cells transfected 
with Sp gene promoters. Bladder cancer cells were transfected with the 
indicated constructs, treated with DMSO and 0.5, 1.0 or 2.5 µmol/L CSL for 24 
hr and luciferase activity was determined as described in Materials and 
Methods. Results are expressed as means ± SE for three replicate 
determinations for each treatment group, and significant (P < 0.05) CSL-induced 
decreases (*) compared to the solvent (DMSO) control are indicated. C. Sp 
downregulation in tumors.  Western blot analysis of tumor lysates from three 
mice in the treated and control groups was also determined as described in 
Materials and Methods. D. Quantitation results. Relative Sp protein band 
intensities of control and CSL treated groups determined in western blots  were 
quantitated as described in Materials and Methods and significant (P < 0.05) 
decreases are indicated (*). Levels of Sp proteins in tissues from CSL treated 
mice were compared to controls (set at 100%).  
0
20
40
60
80
100
120
%
 c
o
n
tr
o
l/β-A
c
ti
nn
o
rm
al
iz
ed Corn oil
CSL 4mg/Kg
Sp1 Sp3 Sp4
* *
*
D
  
                                                                                                                                        150
 
 
 
Studies in this laboratory showed that knockdown of Sp1, Sp3 and Sp4 
proteins by RNA interference decreased expression of VEGF, survivin and cyclin 
D1 in bladder and other cancer cell lines and therefore we investigated the 
effects of CSL on levels of Sp1, Sp3 and Sp4 proteins which are highly 
expressed in bladder cancer cells (263). Results in Figure 26A shows that CSL 
induced a concentration-dependent decrease in expression of Sp1, Sp3 and 
Sp4 proteins in both the cell lines. 253JB-V cells were more sensitive to this 
response than KU7 cells and this was consistent with the responsiveness of 
these cell lines to CSL-induced growth inhibition and downregulation of CD1, 
survivin and VEGF (Figure 2A). 
Results in Figure 26B show that there was a concentration-dependent 
decrease in luciferase activity in KU7 and 253JB-V cells transfected with pSp1 
(Sp1For4) and pSp3 (Sp3For5) constructs which contain -751 to -20 and -417 to 
-38 regions of Sp1 and Sp3 gene promoters, respectively suggesting that CSL 
also affects transcription of Sp1 and Sp3 (note: the Sp4 promoter is not yet 
available)   
The in vitro effects of CSL were also observed in the in vivo study where CSL (4 
mg/kg/d) also significantly decreased Sp1, Sp3 and Sp4 protein levels in tumors 
compared to corn oil treated controls (Figures 26C&26D). In contrast, 
expression of Sp1, Sp3 and Sp4 proteins in non-tumor tissue was minimal. 
Previous studies in this laboratory reported that tolfenamic acid (TA), 
betulinic acid (BA) and curcumin induced proteasomal degradation of Sp 
proteins in pancreatic, prostate and bladder cancer cells (6) (299) (346). Results 
summarized in Figure 27A show that the proteosome inhibitor MG132 inhibited 
CSL-induced Sp degradation in KU7 cells as previously reported for curcumin in 
the cell line,  however MG132 did not inhibit the CSL-induced downregulation of 
Sp proteins in 253JB-V cells and similar results were obtained with other 
proteasome inhibitors (data not shown). Thus the role of CSL-induced 
proteasome activation on degradation of Sp1, Sp3 and Sp4 was cell context-
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dependent. Recent studies in this laboratory show that reactive oxygen species 
(ROS) is a critical upstream regulator of Sp downregulation and this was typified 
by effects of arsenic trioxide which also decreases Sp proteins through 
perturbation of mitochondria and the subsequent induction of ROS in 253JB-V 
and KU7 cells (submitted). Results summarized in Figure 27B illustrate that 
treatment of 253JB-V and KU7 cells with CSL decrease mitochondrial 
membrane potential and this was accompanied by induction of ROS was 
determined using cell-permeant dye CM-H2DCFDA.  
The potential role of CSL-induced ROS on Sp proteins expression was 
investigated in 253JB-V and KU7 cells treated with 2.5 μM or 5 μM CSL alone or 
in combination with the antioxidants DTT or GSH (Figure 27C). CSL-induced 
downregulation of Sp1, Sp3 and Sp4 was inhibited after cotreatment with DTT 
where as the inhibitory effects of GSH were less than observed for DTT.  
The contributions of ROS to growth inhibition were confirmed in both cell 
lines where treatment with 2.5 or 4.0 μM CSL inhibited cell proliferation and 
cotreatment with 1 mM DTT significantly reversed the growth inhibitory effects of 
CSL (Figure 27D). We also observed that both DTT and GSH blocked the 
growth inhibitory and morphological changes induced by CSL in both bladder 
cancer cell lines as determined by differential interference contrast microscopy. 
FGFR3 is overexpressed and/or activated by mutations in bladder cancer and 
recent reports show that FGFR3 knock-down attenuated tumor progression in a 
mouse xenograft study indicating that FGFR3 is a potential drug target in 
bladder cancer (387). Since the FGFR3 promoter also contains GC-rich Sp 
binding sites we have investigated the effects of CSL on FGFR3 expression and 
the role of Sp downregulation in mediating these effects. 
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Figure 27.  CSL modulates differential - proteasome dependent, ROS 
dependent Sp protein degradation and cell growth. 
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Figure 27. continued. 
 
Cells were treated with DMSO, CSL alone or in combination with DTT 
and ROS levels were determined as described in the Materials and Methods. 
CSL-induced growth inhibition (C) and ROS mediated cell growth and Sp protein 
degradation (D) reversed by thiol antioxidants. 253JB-V and KU7 cells were 
treated with DMSO and 1.0, 2.5, 4.0 or 5 µmol/L CSL for 24 hr, in the presence 
or absence of antioxidants DTT and GSH and cells were either counted or whole 
cell lysates were analyzed by western blots as described in Materials and 
Methods. β-Actin served as a loading control. Results are expressed as 
means ± SE for three replicate determinations for each treatment group, and 
significant (P < 0.05) CSL-induced increases (**) or decreases (*) compared to 
the solvent (DMSO) control are indicated.  
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Bladder cancer cells transfected with FGFR3 (C4)-luciferase promoter 
and then treated with DMSO and 0.5, 1.0 or 2.5 µmol/L CSL for 24 hr and 
luciferase activity was determined as described in Materials and Methods. C. 
effects of iSp on FGFR3 protein. 253JB-V and KU7 cells were transfected with 
iSp (a cocktail of iSp1, iSp3, and iSp4) or iLamin, and whole cell lysates were 
analyzed for the efficiency of Sp knockdown and the effects on FGFR3 protein 
levels by Western blots as described in Materials and Methods. D. effects of iSp 
on FGFR3 promoter. 253JB-V and KU7 cells were transfected with iSp (a 
cocktail of iSp1, iSp3, and iSp4) or iLamin, and transfected with FGFR3 (C4)-
Luc; luciferase activity was determined as described in Materials and Methods. 
Results are expressed as means ± SE for three replicate determinations 
for each treatment group, and significant (P < 0.05) CSL-induced decreases (* ) 
compared to the solvent (DMSO) or Lamin control are indicated. 
Treatment of 253JB-V and KU7 cells with CSL significantly decreased 
FGFR3 protein levels in both bladder cancer cell lines in a dose dependent 
manner (Figure 28A). The western blot illustrates multiple FGFR3 bands 
(including the non-glycosylated, precursor and glycosylsated forms) and CSL 
decreased expression of all forms of FGFR3 in both cell lines.   
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Figure 28. CSL decreases FGFR3 protein and promoter expression by 
reducing Sp protein expression. 
 
A. CSL degrades FGFR3 protein in bladder cancer cells. 253JB-V and 
KU7 cells were treated with DMSO alone, 0.5, 1.0, 2.5 or 5.0 µmol/L CSL and 
whole-cell lysates were analyzed by Western blots as described in Materials and 
Methods. B. CSL decreases luciferase activity in cells transfected with the 
FGFR3 promoter luciferase construct.  
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Figure 29. CSL degrades FGFR3 protein in vivo and induces ROS-
dependent degradation of FGFR3. 
 
A. CSL decreases FGFR3 protein expression in KU7 xenograft tumors 
when compared to corn oil control group. Western blot analysis of tumor lysates 
from three mice in the treated and control groups was determined as described 
in Materials and Methods. CSL modulates ROS mediated FGFR3 degradation in 
253JB-V (B) and KU7 (C) bladder cancer cells.  253JB-V and KU7 cells were 
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treated with DMSO and 2.0 or 4.0 µmol/L CSL for 24 hr, in the presence or 
absence of antioxidant DTT and whole cell lysates were analyzed for FGFR3 
protein by western blots as described in Materials and Methods. β-Actin served 
as a loading control and similar results were observed in duplicate experiments. 
Moreover, CSL also decreased the luciferease activity in bladder cancer 
cells transfected with a construct containing the minimal -220 to -27 GC rich 
region of the FGFR3 gene promoter (Figure 28B). The role of Sp proteins in 
mediating the expression of FGFR3 were further investigated using a small 
inhibitory RNA (siRNA) cocktail (iSp) containing siRNAs targeted to Sp1 (iSp1), 
Sp3 (iSp3) and Sp4 (iSp4) as previously described (263). Cells were transfected 
with iSp and whole cell lysates were examined in western blots which show that 
Sp1, Sp3 and Sp4 were decreased with variable overall efficiency in both cell 
lines (Figure 28C). We also observed that transfection of iSp also decreased 
FGFR3 protein levels by 16.8 and 48.1 % in 253JB-V and KU7 cells (Figure 
28C).  
We also investigated the effects of iSp (iSp1, iSp3 and iSp4) on the 
FGFR3 promoter activity and the results indicate that transfection with the iSp 
cocktail, significantly decreased the FGFR3 promoter activity (Figure 28D) and 
this was consistent with our results showing that FGFR3 is, in part, regulated by 
Sp transcription factors in bladder cancer cells.  
Figure 29A shows that CSL also downregulated expression of FGFR3 in 
tumors compared to tumors from control (corn oil treated) mice and these results 
were similar to those observed for decreased Sp1, Sp3 and Sp4 expression in 
these tumors (Figure 26C). In addition we also observed that the antioxidants 
DTT and GSH that blocked CSL-dependent downregulation of Sp proteins 
(Figure 27C) and also inhibited downregulation of FGFR3 in 253JB-V (Figure 
29B) and KU7 (Figure 29C) cells treated with CSL. Thus the antitumorigenic 
activity of CSL is due, in part to induction of ROS which in turn induces 
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downregulation of Sp1, Sp3 and Sp4 and Sp-dependent genes/proteins 
including FGFR3. 
Discussion 
 
Traditional medicines have been providing leading edge pharmaceutical 
agents for decades and interest in the use of traditional medicines for cancer 
prevention and treatment is increasing. Moreover, a large percentage of FDA 
approved anti-cancer drugs are obtained from plant derived natural products 
(94). Celastrol, a pentacyclic triterpene, from the root bark of Tripterygium 
wilfordii, the thunder god vine, has been used for treatment of several diseases 
including arthritis (381), lupus erythematosus (388), amylotropic lateral sclerosis 
(389), Alzheimer's disease (313) and cancer. Recent studies have identified 
various molecular targets for the anti-tumor activity of CSL and these include 
inhibition of NFκB (386, 390) proteasome activity (314), inhibition of HSP90 
(391) and topoisomerase II (392), suppression of VEGFR (393) (394)  and 
inhibition of ATF2 activation (395).  The electrophilic nature of the quinone 
methide moiety of CSL has been linked to irreversible binding to proteins, 
possibly through cysteinyl residues and this is associated with the cytotoxic 
effects of CSL in melanoma cells (395).  
Recent studies in this laboratory demonstrated that curcumin inhibited 
growth of 253JB-V and KU7 bladder cancer cells and tumors in athymic nude 
mice bearing KU7 cells as xenografts (222). Results illustrated in Figure 1 
demonstrate that CSL, like curcumin also exhibited growth inhibitory and 
anticarcinogenic activity in bladder cancer cells and tumors. CSL induced 
apoptosis in bladder cancer cells (Figures 24C&24D) and decreased expression 
of VEGF, survivin and cyclin D1 proteins (Figure 25A) and these results were 
also observed for curcumin in bladder cancer cells (263). Interestingly, CSL 
decreased expression of the p65 and p50 proteins that form the NFκB complex 
(Figure 25C) whereas curcumin only decreased p50 in 253JB-V and KU7 cells 
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but had minimal effects on p65 expression. The pathways associated with CSL-
dependent inhibition of p65/p50 and NFκB is currently being investigated. 
Research in this laboratory has previously reported that the glycyrrhetinic acid 
derivative methyl 2-cyano-3,11-dioxo-18β-olean-1,12-dien-30-oate (CDODA-
Me), NSAID tolfenamic acid, betulinic acid and curcumin inhibited growth and 
induced apoptosis in several different cancer cell lines and this was due, in part, 
to downregulation of Sp transcription factors and Sp-regulated genes (263) (299) 
(211). Sp proteins such as Sp1, Sp3 and Sp4 are overexpressed in cancer cell 
lines and tumors (21) and Sp1 is a negative prognostic factor for survival of 
pancreatic and gastric cancer patients (396). Moreover, we have confirmed the 
important causal role of Sp transcripton factors in carcinogenesis since 
knockdown of Sp1, Sp3 and Sp4 by RNA interference decreases expression of 
VEGF, VEGFR1, VEGFR2, cyclin D1, bcl-2, survivin and the epidermal growth 
factor receptor (EGFR) in several cancer cell lines (263). Since both CSL and 
Sp1/Sp3/Sp4 knockdown both decrease expression of VEGF, survivin and cyclin 
D1, we hypothesized that CSL also decreased Sp proteins and this was 
confirmed in KU7 and 253JB-V bladder cancer cell lines and KU7 tumors in a 
xenograft experiment (Figures 26A&27A). 
Several studies show that a high percentage of bladder cancers 
overexpress FGFR3 gene (397) (398) (399) and somatic mutations in the 
FGFR3 gene were identified in 60-70% papillary and 16-20% of muscle invasive 
bladder cancers (397) (398) (400) . FGFR3 was shown to be a vital oncogenic 
factor due to its transforming activity and knockdown of FGFR3 arrested cell 
cycle progression and inhibited tumor growth in an in vivo model for bladder 
cancer demonstrating that FGFR3 is an important target for bladder cancer 
therapy (387). Regulation of FGFR3 expression in bladder cancer has not been 
previously defined; however, since the FGFR3 promoter contains GC-rich Sp 
binding sites (401), we investigated the effects of CSL and the role of Sp 
proteins in regulating FGFR3 expression in 253JB-V and KU7 cells.  
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Figure 28A illustrates that CSL decreased FGFR3 expression in both 253JB-V 
and KU7 cancer cell lines in a concentration-dependent manner and CSL also 
inhibited luciferase activity in these cell lines transfected with pFGFR3 (-220), a 
construct containing the GC-rich -220 to -27 region of the FGFR3 promoter 
linked to luciferase reporter gene (Figure 28B). 
Furthermore, knockdown of Sp1, Sp3 and Sp4 in 253JB-V and KU7 cells 
by RNA interference also significantly decreased FGFR3 protein and luciferase 
activity in 253JB-V and KU7 cells (Figure 28C&28D). These results demonstrate 
for the first time that FGFR3 is an Sp-regulated gene in bladder cancer cells and 
that compounds such as CSL that decrease expression of Sp1, Sp3 and Sp4 in 
cancer cell lines also repress FGFR3 along with other Sp-regulated 
genes/proteins. Previous studies with drugs that decrease Sp protein levels in 
cancer cells indicate that downregulation is either proteasome-dependent or 
independent; for the latter response we have demonstrated that for CDODA-Me, 
this compound downregulates microRNA-27a (miR-27a) resulting in 
upregulation of ZBTB10, an Sp repressor (300).  
Results illustrated in figure 27A show that CSL induces proteasome-
dependent downregulation of Sp1, Sp3 and Sp4 proteins in KU7 cells; however, 
in 253JB-V cells this response was proteasome-independent. CSL did not affect 
miR-27a or ZBTB10 expression in bladder cancer cells (data not shown) and the 
mechanisms associated with downregulation of Sp proteins is currently being 
investigated. Recent studies with the anti-cancer drug arsenic trioxide have 
indicated that this compound inhibits growth of solid tumors and their derived 
cancer cell lines and in bladder cancer cells (data not shown ) this response is 
associated with induction of ROS and the subsequent ROS-dependent 
downregulation of Sp1, Sp3 and Sp4 (submitted). Moreover arsenic trioxide-
induced growth inhibition and Sp downregulation are blocked by the ROS 
inhibitors DTT and/or GSH and results summarized in Figures 27C and 27D 
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show that the growth inhibitory effects of CSL and downregulation of Sp proteins 
by this compound are also reversed by DTT.  
In summary this study reports for the first time that celastrol decrease 
expression of Sp1, Sp3 and Sp4 transcription factors and Sp-dependent genes 
which include FGFR3, a clinically important therapeutic target for bladder cancer 
treatment. CSL also decreased expression of other Sp dependent genes such 
as survivin, cyclin D1 and VEGF which are important for cell survival, growth and 
angiogenesis. CSL also decreased MMP in bladder cancer cells resulting in 
induction of ROS which exhibits intrinsic anticancer activities and this includes 
ROS-dependent downregulation of Sp proteins & Sp-dependent genes. The 
importance of induction of ROS as a chemotherapeutic pathway has been 
previously reported (402) , however this study demonstrates that CSL-induced 
ROS leads to downregulation of Sp transcription factors which are highly 
overexpressed in cancer cells and tumors and are important drug targets. 
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V. STRUCTURE-DEPENDENT INHIBITION OF BLADDER AND PANCREATIC 
CANCER CELL GROWTH BY 2-SUBSTITUTED GLYCYRRHETINIC AND 
URSOLIC ACID DERIVATIVES * 
 
Derivatives of oleanolic acid, ursolic acid and glycyrrhetinic acid 
substituted with electron withdrawing groups at the 2-position in the A-ring which 
also contains a 1-en-3-one structure are potent inhibitors of cancer cell growth. 
In this study, we have compared the effects of several 2-substituted analogs of 
triterpenoid acid methyl esters derived from ursolic and glycyrrhetinic acid on 
proliferation of KU7 and 253JB-V bladder and Panc-1 and Panc-28 pancreatic 
cancer cells. The results show that the 2-cyano and 2-trifluoromethyl derivatives 
were the most active compounds. The glycyrrhetinic acid derivatives with the 
rearranged C-ring containing the 9(11)-en-12-one structure were generally more 
active than the corresponding 12-en-11-one isomers. However, differences in 
growth inhibitory IC50 values were highly variable and dependent on the 2-
substitutent (CN vs. CF3) and cancer cell context.  
Introduction 
 
Pentacyclic triterpenoid acids such as betulinic acid, oleanolic acid, 
ursolic acid, and glycyrrhetinic acid are phytochemicals that have been 
extensively used in traditional medicines for treatment of a wide variety of 
human ailments (403). Most of these compounds exhibit anti-inflammatory and 
anticarcinogenic activities as well as a large number of compound-specific 
effects.  
 
* Reprinted with permission from “Structure-dependent inhibition of bladder and 
pancreatic cancer cell growth by 2-substituted glycyrrhetinic and ursolic acid 
derivatives” by Chadalapaka, G., Jutooru, I., McAlees, A., Stefanac, T. and Safe, 
S. Bioorg. Med. Chemistry Lett. 18:2633-2639, 2008. Copyright 2009 by 
Bioorganic and Medicinal Chemistry Letters, Inc. 
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For example, the major bioactive component of licorice extracts is 
glycyrrhizic acid glycoside which is readily hydrolyzed to glycyrrhetinic acid and 
these extracts/compounds possess anti-inflammatory, antiviral and endocrine 
activities (404).  All of these triterpenoid acids have been used as building blocks 
for the synthesis of more active analogs. Oleanolic acid has been converted into 
2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO), the corresponding 
methyl ester (CDDO-Me) and other structurally-related analogs, and these 
compounds are potent anticancer agents (405) (310). These synthetic 
triterpenoids activate the nuclear receptor peroxisome proliferator-activated 
receptor γ (PPARγ) (405) (406) and also induce several other responses 
including apoptosis in various cancer cell lines. The cytotoxicity and anti-
inflammatory activity of CDDO-Me and related compounds are due to the 2-
cyano group and the 1-en-3-one and 9-en-12-one functionalities in the A- and C-
rings, respectively   (407)   (408). We also showed that the glycyrrhetinic acid 
analog methyl 2-cyano-3,11-dioxo-18β-olean-1,12-dien-30-oate (β-CDODA-Me) 
and the corresponding 18αderivative α-CDODA-Me) which contain 2-cyano-1-
en-3-one and 12-en-11-one functionalities in their A- and C-rings, respectively, 
activated PPARγ and were also highly cytotoxic in colon cancer cells (409). 
Similar results were obtained for the betulinic acid derivatives containing a 2-
cyano-1 en-3-one function (305). In this study, we have further investigated the 
structure-dependent growth inhibitory effects of β-CDODA-Me and analogs 
containing different electronegative 2-substituents and a selected number of the 
corresponding ursolic acid 2-substituted-1-ene-3-one derivatives. In addition, we 
also show that for the glycyrrhetinic acid derivatives growth inhibitory differences 
of the 9-en-12-one and 12-en-11-one isomers are lower than previously reported 
for anti-inflammatory activity of CDDO-Me and the 12-en-11-one isomers (408). 
Growth inhibition by the 2-substituted glycyrrhetinic acid and ursolic acid methyl 
ester analogs is dependent on the nature of the 2-substituent and cancer cell 
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context among two bladder (KU7 and 253JB-V) and two pancreatic (Panc-1 and 
Panc-28) cancer cell lines. 
Materials and methods 
 
 Chemicals.  The ursolic acid and glycyrrhetinic acid starting materials 
were purchased from Sigma-Aldrich (St. Louis, MO) all chemical reagents used 
for synthesis were purchased from Sigma-Aldrich. Dulbecco’s modified/Ham’s F-
12 and RPMI media and the antibiotic/antimycotic solution were also obtained 
from Sigma Aldrich. 
 Cell lines, chemicals and other materials.  KU7 human bladder cancer 
and Panc-1 pancreatic cancer cells were obtained from the American Type 
Culture Collection (Manassas, VA) and 253JB-V cells were provided by Dr. A. 
Kamat, M.D Anderson Cancer Center, Houston, TX. The Panc-28 cell line was a 
generous gift from Dr. Paul Chiao, The University of Texas M.D. Anderson 
Cancer Center (Houston, TX). 
 Both 253JB-V and KU7 cell lines were maintained in RPMI 1640 
supplemented with 10% fetal bovine serum (FBS), 0.15% sodium bicarbonate, 
0.011% sodium pyruvate, 0.24% HEPES and 10 ml/L of antibiotic/antimycotic 
cocktail solution. The pancreatic cancer cells were maintained in Dulbecco's 
modified/Ham's F-12 with phenol red supplemented with 0.22% sodium 
bicarbonate, 0.011% sodium pyruvate, 5% fetal bovine serum and 10 ml/L 100x 
antibiotic/antimycotic solution. The cells were grown in 150 cm2 culture plates in 
an air/CO2 (95:5) atmosphere at 37°C and passaged approximately every 3 
days. 
 Cell proliferation assays.  All four cancer cell lines (3 x 104 cells per 
well) were plated using DMEM:Ham's F-12 medium containing 2.5% charcoal-
stripped FBS in 12-well plates and left to attach for 24 hours. Cells were then 
treated with either vehicle (DMSO) or the indicated concentrations of different 
compounds. Fresh medium and test compounds were added every 48 hours 
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and cells were then counted at the indicated times using a Coulter Z1 particle 
counter. Each experiment was done in triplicate, and results are expressed as 
means ± SE for each determination. The IC50 values were calculated using 
linear regression method and were expressed in µM. 
Results 
 
 
Figure 30. Synthesis of 2-substituted-1-en-3-one derivative of methyl 
glycyrrhetinate. 
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diazomethane to give methyl glycyrrhetinate (2) which was then treated with 4 
equivalents of 2-iodoxybenzoic acid (IBX) in DMSO at 85°C for 21 hours. The 
resulting methyl 3,11-dioxo-18β-oleana-1,12-dien-30-oate product (3) was then 
converted into the 2-iodo derivative (4) by treating with 2 equivalents of iodine 
and 3 equivalents of pyridine in tetrahydrofuran (refluxing). The methyl 2-iodo-
3,11-dioxo-18β-oleana-1,12-dien-30-oate derivative (4) was used as the 
precursor for the synthesis of the 2-cyano (5), 2-methanesulfonyl (6), 2-
trifluoromethyl (7) and 2-dimethylphosphonyl (8) analogs (Figure 30). The 2-
cyano derivative was prepared by treating 4 with 2 equivalents of cuprous 
cyanide in N-methylpyrrolidinone (NMP) for 2 hours at 130°C. The 2-
methanesulfonyl derivative was obtained by treating 4 with sodium 
methanesulfinate and cuprous iodide in DMSO at 120-125°C for 20 hours. The 
2-dimethylphosphonyl analog was synthesized by treating 4 with 
dimethylphosphite, cesium carbonate, N,N-dimethylethylenediamine in toluene 
at 95-100°C for 26 hours. Finally the 2-trifluoromethyl derivative was obtained by 
treating 4 with cuprous iodide and methyl 2,2-difluoro-2-(fluorosulfonyl) acetate 
in dimethylformamide/HMPT at 70°C for 20 hours. The synthetic scheme used 
for conversion of ursolic acid (9) into the 2-iodo derivative (12) and the 
corresponding 2-cyano (13) and 2-trifluoromethyl (14) derivatives (Figure 31) 
involved intermediates (10) and (11) and was identical to that carried out for 
conversion of methyl glycyrrhetinate into the analogous 2-substituted compound 
as illustrated in Figure 30.  
Previous studies with oleanolic acid derivatives reported the synthesis of 
several analogs including CDDO which contain the 1-en-3-one A-ring and a 9-
en-12-one C-ring(407), and Figure 32 outlines an analogous route for 
conversion of methyl glycyrrhetinate into the rearranged C-ring analogs of 
CDODA-Me. Methyl glycyrrhetinate was reduced with H2/platinum oxide catalyst 
in acetic acid, then acetylated with acetic anhydride/ pyridine in 
dimethylaminopyridine (DMAP) to give the acetylated ester (15) in which the 9-
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oxo group had been reduced. Treatment with m-chloroperbenzoic acid (m-
CPBA) in methylene chloride gave the 12,13-epoxide which was converted into 
the 12-oxo derivative by boron trifluoride etherate in methylene chloride. 
Bromination of the 12-oxo derivative followed by dehydrobromination in acetic 
anhydride followed by basic hydrolysis of the acetate group gave the rearranged 
C-ring derivative of methyl glycyrrhetinate (16). Subsequent treatment with 2-
iodoxybenzoic acid and iodine/ pryridine in tetrahydrofuran gave methyl 2-iodo-
3,12-dioxo-oleana-1,9-dien-30-oate (17) which is converted into the C-ring 
rearranged cyano (18) and trifluoromethyl (19) derivatives as outlined in 
Schemes 1 and 2. 
 Previous studies with CDDO-Me and related compounds showed that the 
1-en-3-one structure containing electronegative 2-substituent groups such as 
cyano were highly cytotoxic (310) and similar results were observed for 
β−CDODA-Me, the corresponding 2-cyano analog of glycyrrhetinic acid (409). In 
this study, we used 253JB-V and KU7 bladder and Panc-1 and Panc-28 
pancreatic cancer cells to investigate the growth inhibitory effects of CDODA-Me 
analogs containing several electronegative 2-substituents including iodo, cyano, 
trifluoromethyl, dimethylphosphonyl and methanesulfonyl groups (Table 5). β-
CDODA, the parent free acid derivative of β-CDODA-Me is used as a control for 
this group of compounds, and IC50 values for inhibition of bladder and pancreatic 
cancer cell growth varied from 5.9 – 7.3 μM.   
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Figure 31. Synthesis of 2-substituted-1-en-3-one derivatives of methyl 
ursolate. 
 
The corresponding range of IC50 values for β−CDODA-Me was 0.25 to 
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potencies were dependent on cell context; β-CF3DODA-Me was more active 
than β−CDODA-Me in KU7 (IC50: 0.38 vs. 1.59 μM), Panc-1 (IC50: 0.82 vs. 1.22 
μM) and Panc-28  (IC50: 1.14 vs. 1.80μM) cells, whereas β-CDODA-Me was 
more active in 253JB-V cells (IC50: 0.25 vs. 0.67 μM). Both the 2-
dimethylphosphonyl and 2-methanesulfonyl analogs were relatively inactive with 
IC50 values ranging from 3.34 - 12.0μM over the four cell lines. 
 Since the 2-cyano and 2-trifluoromethyl derivatives were the most active 
of the glycyrrhetinic acid group of 2-substituted 1-en-3-one compounds, we 
synthesized a similar series of analogs from methyl ursolate and compared their 
growth inhibitory IC50 values to the 2-iodo analog and methyl ursolate (Table 6). 
 
Figure 32. Synthesis of C-ring rearranged analogs of CDODA-Me. 
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 Differences in IC50 values for the 2-cyano methyl-glycyrrhetinate isomers 
with 12-en-11-one and 9(11)-en-12-one functionalities were more dramatic and 
varied from a 2.2- (253JB-V cells) to a 39.1-fold (Panc-28) lower IC50 values for 
isomers containing the former C-ring structure. These differences for the 2-
cyano derivatives of methyl glycyrrhetinate were significantly lower than 
differences observed for CDDO-Me and the corresponding 12-en-11-one isomer 
where IC50 values for inhibition of nitric oxide production in mouse macrophages 
was 0.1 nM and 20 nM, respectively, a 200-fold difference (406).  We also 
directly compared the effects of the rearranged 2-cyano methyl glycyrrhetinate 
derivative (18) with CDDO-Me in the four cell lines; the former compound (18) 
was more active than CDDO-Me in Panc-1 and Panc-28 cells, whereas IC50 
values were similar in KU7 cells and CDDO-Me (IC50 = 0.03μM) was more active 
in 253JB-V cells. Thus, a direct comparison of the 2-cyano derivative of methyl 
glycyrrhetinate (18) and CDDO-Me (derived from methyl oleanolate) on their 
inhibition of cancer cell proliferation indicates that both synthetic triterpenoids 
are highly potent and differences in their IC50 values in four cell lines were less 
than an order of magnitude. 
 
Table 5. Cytotoxicity of 2-substituted compounds derived from methyl 
glycyrrhetinate. 
 
O
O
CO 2 R
1
R2
8.146.113.737.90
9.757.693.3411.97
1.140.820.380.67
1.801.221.590.25
12.754.083.042.67
7.323.815.886.10
PANC 28PANC 1KU72 53JB-V
IC50 (µM)
R1 = CH3 : R2 = I (4)
R1 = CH3 : R2 = CN (5)
R1 = CH3 : R2 = CF3 (6)
R1 = H : R2 = CN
R1 = CH3 : R2 = CH3SO2 (7)
R1 = CH3 : R2 = (CH3O)2PO (8)
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IC50 values for methyl ursolate (9) and the 2-iodo-1-en-3-one analog (12) 
varied from 6.13 - 11.75 and 4.90 - 13.50μM, respectively, in the bladder and 
pancreatic cancer cell lines and there was less than a 2-fold difference in their 
IC50 values. IC50 values for the 2-cyano (13) and 2-trifluoromethyl (14) analogs 
varied from 0.17 - 0.97 and 0.17 - 1.13 μM, respectively, and were at least an 
order of magnitude more potent in the growth inhibition assay than the 2-iodo 
compound or methyl ursolate. 
 These data confirm that 2-cyano and 2-trifluoromethyl groups coupled 
with introduction of a 1-en-3-one functionality into the A-ring of methyl ursolate 
resulted in enhanced growth inhibition with comparable IC50 values in KU7, 
253JB-V, Panc-1 and Panc-28 cancer cells. 
 
Table 6. Cytotoxicity of 2-substituted compounds derived from methyl 
ursolate. 
 Previous studies with CDDO-Me and related compounds showed that the 
functionality of the C-ring markedly influenced the activity of oleanolic acid 
derivatives with 2-cyano-1-en-3-one functionality (406). For example, CDDO-Me 
which contains a 9(11)-en-12-one C-ring structure is 200 times more potent as 
an inhibitor of nitric oxide production in mouse macrophages than the 
corresponding 12-en-11-one isomer (406). We therefore synthesized a series of 
O
CO 2 R
1R 2
IC50 (µM)
1.130.650.470. 17
0.970.530.300. 17
13.496.916.024. 90
10.5811.758.956. 13Methyl Ursolate (a)
P ANC 28P ANC 1KU7253 JB-V
R1 = CH3 : R2 = I (12)
R1 = CH3 : R2 = CN (13)
R1 = CH3 : R2 = CF3 (14)
  
                                                                                                                                        172
 
 
 
2-iodo, 2-cyano, and 2-trifluoromethyl-1-en-3-one analogs of glycyrrhetinic acid 
which also contain a 9(11)-en-12-one C-ring functionality (Table 7) and 
compared their growth inhibitory effects to the 12-en-11-one isomers (Table 5)
 The effects of the C-ring en-one functionality on the activity of these 
isomers was dependent not only on the 2-substituent but also on cell context. 
IC50 values were similar for both 2-iodo isomers in 253JB-V, KU7 and Panc-1 
cells, whereas IC50 values for the 12-en-11-one and 9(11)-en-12-one isomers in 
Panc-28 cells were 12.75 and 3.66 M, respectively. Thus, for the 2-iodo 
derivative, the C-ring structure had minimal effects on growth inhibitory activity, 
except for one cell line where IC50 differences were < 4-fold. 
 
Table 7. Cytotoxicity of 2-substituted compounds derived from methyl 
glycyrrhetinate with C-ring rearrangement. 
 
  
The antiproliferative activity of the trifluoromethyl derivative (6) (Table 5) 
was <2 fold lower than the 9(11)-en-12-one isomer in 253JB-V and Panc-1 cells, 
whereas similar IC50 values were observed in Panc-28 cells. In contrast the 12-
en-11-one (unrearranged) trifluoromethyl analog was more active (IC50 = 0.38 
μM) in KU7 cells than the corresponding 9(11)-en-12-one isomer (IC50 = 1.37 
μM).  Figure 1 illustrates the structure-dependent differences in growth inhibitory 
activities in KU7 cells of the 2-cyano and 2-trifluoromethyl analogs containing the 
unrearranged 12-en-11-one (5 and 7) and rearranged 9(11)-en-12-one (18 and 
19) C-ring in the methyl glycyrrhetinate series of isomers. 
IC50 (µM)
1.130.681.370.36
0.050.070.120.11
3.664.452.613.62R1 = CH3 : R2 = I (17)
0.290.270.120.03CDDO-Me
PANC  28P ANC 1KU7253J B-V
O
CO2 R
1
R2
O
R1 = CH3 : R2 = CN (17)
R1 = CH3 : R2 = CF3 (18)
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Discussion 
 
In summary, the results of this study show that the antiproliferative 
activities of several 2-substituted glycyrrhetinic acid and ursolic acid derivatives 
containing the 1-en-3-one functionality in their A-rings were maximal for both the 
cyano and trifluoromethyl derivatives. The corresponding 2-iodo substituted 
analogs were less active (Tables 5 and 6). The 2-dimethylphosphonyl and 2-
methanesulfonyl derivatives of glycyrrhetinic acid (Table 5) also exhibited higher 
IC50 values than the corresponding 2-cyano and 2-trifluoromethyl derivatives. 
The rationale for the observed differences in the activity of the different 2-
substituted analogs containing electronegative substituents is unclear and is 
currently being investigated using other assay systems. 
Compared to previous studies with oleanolic acid derivatives  (406) the 
effects of the C-ring functionality [9(11)-en-12-one vs. 12-en-11-one] on 
inhibition of cancer cell growth were minimal (Tables 5 and 7) and dependent on 
the 2-substituent (cyano vs. trifluoromethyl) (Figure 33) and cancer cell context. 
This suggests that for the glycyrrhetinic acid derivatives it may not be necessary 
to carry out the additional synthetic steps to convert the 12-en-11-one to the 
9(11)-en-12-one functionality in the C-ring. This is confirmed, in part, by ongoing 
in vivo studies in mouse xenograft experiments where significant inhibition of 
tumor growth by β-CDODA-Me is observed at doses of 10 to 15 mg/kg/day (data 
not shown). 
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Figure 33. Effects of 2-CN- and 2-CF3-1-en-3-one analogs containing 12-en-
11-one or 9(11)-en-12-one functionality in the C-ring. 
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Ongoing work includes further investigation of structure-dependent 
anticarcinogenic potencies of the cyano and trifluoromethyl glycyrrhetinic acid 
analogs, and studies of their underlying mechanism of action and clinical 
applications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                                                                                                                                        176
 
 
 
VI. SYNTHETIC OLEANOLIC ACID-DERIVED TRITERPENOIDS INHIBIT 
BLADDER CANCER CELL GROWTH AND SURIVIVAL AND 
DOWNREGULATE SPECIFICITY PROTEIN (Sp) TRANSCRIPTION FACTORS 
 
Methyl 2-cyano-3,11-dioxo-18β-olean-1,12-dien-30-oate (CDODA-Me) is 
a synthetic triterpenoid derived from glycyrrhetinic acid which inhibits 
proliferation of KU7 and 253JB-V bladder cancer cells with inhibitory IC50 values 
< 5 μM.  CDODA-Me-dependent growth inhibition is accompanied by caspase-
dependent PARP cleavage and downregulation of survival (survivin and bcl-2) 
and angiogenic [vascular endothelial growth factor (VEGF) and its receptor 
(VEGFR1)] genes.  CDODA-Me also decreased expression of specificity protein-
1 (Sp1), Sp3 and Sp4 transcription factors and this was consistent with 
downregulation of the Sp-dependent genes survivin, bcl-2, VEGF and VEGFR1.  
Similar results were observed for a structurally-related triterpenoid, methyl 2-
cyano-3,12-dioxooleana-1,9-dien-28-oate (CDDO-Me), which is currently in 
clinical trials.  Both CDODA-Me and CDDO-Me decreased mitochondrial 
membrane potential and induced reactive oxygen species (ROS), and these 
responses were also critical for triterpenoid-induced downregulation of Sp 
proteins which was inhibited by the antioxidants dithiothreitol and glutathione.  
This demonstrates a common mechanism of action for CDODA-Me and CDDO-
Me which is due, in part, to mitochondriotoxicity. 
Introduction 
 
 It is estimated that in 2008, there will be 68,810 new cases of bladder 
cancer and 14,100 deaths from this disease in both men and women.  In the 
United States, bladder cancer is the fourth most common cancer and ranks ninth 
overall in cancer deaths (410).  In western countries, bladder cancer incidence 
increases with age and is associated with smoking, exposure to occupational 
carcinogens, and other lifestyle and environmental factors (411) (412). The 
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predominant tumors are transitional cell carcinomas in patients from 
industrialized countries, and 70% or more of the cancers are papillary non-
invasive tumors, whereas 20-30% are non-papillary invasive bladder cancers 
(413) (414).  The prognosis and treatment for invasive and non-invasive 
("superficial") transitional cell carcinomas are different.  Patients with non-
invasive bladder tumors may have recurrence but their overall prognosis is 
good, whereas patients with invasive tumors have a poor prognosis with <50% 
survival after 5 years. 
 Early stage superficial bladder cancer is usually treated surgically (radical 
cystectomy) followed by adjuvant therapy with a range of cytotoxic drug 
combinations and the success of different regimens has been correlated with 
tumor histopathology or grade and molecular markers  (415) (416).  For 
example, patients with superficially early invasive bladder cancer that express 
mutant p53 have a higher relapse rate than those expressing the wild-type tumor 
suppressor gene  (417) (418).   
 Treatment for more advanced invasive bladder cancers includes surgery 
and adjuvant chemotherapies and, in some cases, neoadjuvant chemotherapy is 
used to decrease tumor size prior to surgery.  One of the most common adjuvant 
chemotherapies has been the combination of methotrexate, vinblastine, 
doxorubicin and cisplatin (M-VAC), and there has been an increase in the use of 
cisplatin plus gemicitabine (CG) due to lower toxicity of CG (419).  The limited 
success of bladder cancer chemotherapies has stimulated development and 
applications of new targeted therapies that block or inhibit the function of critical 
genes and pathways that contribute to the growth, survival, angiogenesis and 
metastasis of bladder cancer (420) (421). These include tyrosine kinase 
inhibitors that block epidermal growth factor receptor (EGFR) or vascular 
endothelial growth factor receptors (VEGFRs) or neutralizing antibodies such as 
bevacizumab that interact with VEGF. 
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 Studies in this laboratory have shown that a series of 1,1-bis(3'-indolyl)-1-
(p-substituted phenyl)methane (C-DIM) compounds that activate orphan nuclear 
receptors inhibit bladder cancer cell growth (17, 18).  We have recently reported 
that the triterpenoid methyl 2-cyano-3,11-dioxo-18β-olean-1,12-dien-30-oate 
(CDODA-Me) is a potent inhibitor of bladder, colon, pancreatic and prostate 
cancer cell growth (422) (423). CDODA-Me induces apoptosis, inhibited growth 
and expression of genes associated with cell proliferation (cyclin D1, EGFR), cell 
survival (survivin, bcl-2), and angiogenesis (VEGF, VEGFR1) in bladder cancer 
cells and these responses are due, in part, to downregulation of specificity 
protein (Sp) transcription factors Sp1, Sp3 and Sp4.  CDODA-Me-dependent 
responses are due to targeting mitochondria which results in the induction of 
reactive oxygen species (ROS) which in turn induces downregulation of Sp 
proteins and Sp-dependent genes.   
Materials and methods 
 
Cell lines: KU-7 and 253JB-V human bladder cancer cells were provided 
by Dr. A. Kamat, (M.D Anderson Cancer Center, Houston, TX).  253JB-V and 
KU7 cell lines were maintained in RPMI 1640 supplemented with 10% fetal 
bovine serum (FBS), 0.15% sodium bicarbonate, 0.011% sodium pyruvate, 
0.24% HEPES and 10 ml/L of antibiotic/antimycotic cocktail solution (Sigma-
Aldrich, St. Louis, MO).  
Antibodies, chemicals and other materials: Sp1, Sp3, Sp4, VEGF, 
VEGFR1 survivin, CD1, bcl-2, caveolin-1 and EGFR antibodies were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA). Cleaved PARP (ASP 214) 
antibody was purchased from Cell Signaling Technology (Danvers, MA). 
Monoclonal β-actin antibody was purchased from Sigma-Aldrich. Horseradish 
peroxidase substrate for western blot analysis was obtained from NEN Life 
Science Products (Boston, MA). Lipofectamine 2000 was purchased from 
Invitrogen (Carlsbad, CA). GSH is a tripeptide composed of L-glutamic acid, L-
  
                                                                                                                                        179
 
 
 
cysteine, and L-glycine. Glutathione (GSH), 98% was purchased from Aldrich 
(Sigma- Aldrich Inc, (St. Louis, MO). Dithiothreitol (DTT), 98% was obtained 
from Boehringer Mannheim Corp, (Indpls, IN). The PPARγ antagonist 2-chloro-
5-nitro-N-phenylbenzamide (GW9662) was synthesized in this laboratory, and its 
identitiy and purity (>98%) were confirmed by gas chromatography-mass 
spectrometry. CDODA-Me was prepared as described previously (Chintharlapalli 
et al 2007).  Rosiglitazone was purchased from LKT Laboratories, Inc. (St. Paul, 
MN). CDDO-Me was provided by Dr. Edward Sausville (Developmental 
Therapeutics Program, National Cancer Institute, Bethesda, MD) through the 
Rapid Access to Intervention Developmental Program. The Gal4 reporter 
containing 5× Gal4 response elements (pGal4) was kindly provided by Dr. Marty 
Mayo (University of North Carolina, Chapel Hill, NC). Gal4DBD-PPARγ construct 
was a gift of Dr. Jennifer L. Oberfield (GlaxoSmithKline Research and 
Development). The pVEGF-2018 construct contains VEGF promoter inserts 
(positions –2018 to +50) linked to luciferase reporter gene. The pSurvivin-269 
contains survivin promoter inserts inserts (positions –269 to +49) linked to 
luciferase reporter gene and was kindly provided by Dr. M. Zhou (Emory 
University, Atlanta, GA). The pSp1 and pSp3 promoter constructs (pSp1-FOR4-
luc and pSp3-FOR5-luc) were provided by Drs Carlos Cuidad and Veronique 
Noe (University of Barcelona). Sp1-FOR4-luc (contains the –751 to –20 region of 
the Sp1 gene promoter) and pSp3-FOR5-luc (contains the –417 to –38 region of 
the Sp3 promoter) constructs respectively. 
Cell proliferation assays : Bladder cancer cells (3 x 104 cells per well) 
were seeded using DMEM:Ham's F-12 medium containing 2.5% charcoal-
stripped FBS in 12-well plates and left to attach for 24 hr. Cells were then 
treated with either vehicle (DMSO) or the indicated concentrations of 
compounds. Fresh medium and test compounds were added every 24 hr and 
cells were then counted at the indicated times using a Coulter Z1 particle 
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counter. Each experiment was carried out in triplicate and results are expressed 
as means ± SE for each treatment group.   
DNA fragmentation assay:  The isolation of DNA was performed 
according to the protocol 6.2 Rapid Isolation of Mammalian DNA.  Extracted 
DNA was run on 0.9% agarose gel and stained with 0.5 µg/mL ethdium bromide 
and the fragmented DNA was visualized using a Transilluminator on an 
ultraviolet light. 
Western blot assays: Bladder cancer cells were seeded in 
DMEM:Ham's F-12 medium containing 2.5% charcoal-stripped FBS. Twenty-
four hr later, cells were treated with either vehicle (DMSO) or the indicated 
compounds for 24 hr. Cells were collected using high-salt buffer [50 mmol/L 
HEPES, 0.5 mol/L NaCl, 1.5 mmol/L MgCl2, 1 mmol/L EGTA, 10% glycerol, and 
1%  Triton-X-100 pH 7.5] and 10 µL/mL of Protease Inhibitor Cocktail (Sigma 
Aldrich). The lysates were incubated on ice for 1 hr with intermittent vortexing 
every 10 min for a total of 90 min, followed by centrifugation at 20,000 g for 10 
min at 4°C. Lysates were then incubated for 3 min at 100°C before 
electrophoresis, and then separated on 10% SDS-PAGE 120 V for 3 to 4 hr in 
1X running buffer [25 mM tris-base, 192 mM glycine and 0.1%SDS]. Proteins 
were transferred onto polyvinylidene difluoride (PVDF) membranes by wet 
electroblotting in a buffer containing 25 mmol/L Tris, 192 mmol/L glycine, and 
20% methanol for 1.5 hr at 0.9A at 4°C. The membranes were blocked for 30 
min with 5% TBST-Blotto [10 mmol/L Tris-HCl, 150 mmol/L NaCl (pH 8.0), 
0.05% Triton X-100, and 5% nonfat dry milk] and incubated in fresh 5% TBST-
Blotto with 1:200- 1:1000 primary antibody overnight with gentle shaking at 4°C. 
After washing with TBST for 10 min, the PVDF membrane was incubated with 
secondary antibody (1:5000) in 5% TBST-Blotto for 2 hr by gentle shaking. The 
membrane was washed with TBST for 10 min, incubated with 6 mL of 
chemiluminescence (PerkinElmer Life Sciences, Waltham, MA) substrate for 1.0 
min, and exposed to Kodak X-OMAT AR autoradiography film (American X-ray 
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supply Inc, Jackson, CA). Quantification of the proteins was determined using 
Image J software and the optical densities were plotted after normalization with 
lamin / β−actin. 
Transfection assays: The two bladder cancer cell lines, 253JB-V and 
KU7 were seeded (1 x 105 per well) in 6-well plates in DMEM:Ham's F-12 
medium supplemented with 2.5% charcoal-stripped FBS without antibiotic and 
left to attach for one day. For transfection assays, bladder cancer cells (1 x 105 
per well) were plated in 12-well plates in DMEM:Ham's F-12 medium 
supplemented with 2.5% charcoal-stripped FBS. After 16-24 h, various amounts 
of DNA (i.e., 0.4 µg pGL2/pGL3); 0.04 µg β-galactosidase, pVEGF, pSurvivin, 
pSp1For4, pSp1For5, pGal4Luc and pGal4DBD-PPAR  were transfected using 
Lipofectamine reagent according to the manufacturer's protocol and then treated 
with control, indicated doses of CDODA-Me and luciferase activity (normalized 
to β-galactosidase) was determined essentially as described.  
ROS and MMP estimation: Cellular reactive oxygen species (ROS) 
levels were evaluated with the cell-permeant probe CM-H2DCFDA (5-(and-6)-
chloromethyl-2'7' dichlorodihydrofluorescein diacetate acetyl ester). CM-
H2DCFDA is nonfluorescent until removal of the acetate groups by intracellular 
esterases and oxidation occurs within the cell.  Following treatment for 20-24 hr, 
in the cells were plated using a 96 well culture dish, 10 uM CM-H2DCFDA was 
added for 30 min, the cells were then washed once with serum free medium, 
and analyzed for ROS levels using the BioTek Synergy 4 plate reader (BioTek 
Instruments, Inc., Winooski, VT) set at 480 nm and 525 nm excitation and 
emission wavelengths respectively.  Following determination of ROS, cultures 
were washed twice with PBS and fixed with methanol for 3 min at room 
temperature. Methanol was then completely removed and 1 mg/ml Janus green 
was added to the cultures for 3 min.  Following removal of Janus green, cultures 
were washed twice with PBS and 100 μl of 50% methanol was added to each 
well. Cell counts were then determined with the plate reader set to an 
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absorbance of 654 nm and ROS intensities were then corrected accordingly. 
Two experiments were preformed on different days. At least 16 wells per 
treatment were analyzed for each experiment.                      
Statistical analysis: Statistical significance of differences was 
determined by an analysis of variance and student t-test, and the levels of 
probability were noted.  IC50 values were calculated using linear regression 
method and expressed in μmol/L concentrations.      
Results 
 
 CDODA-Me is a potent growth-inhibitory compound in colon, pancreatic 
and prostate cancer cells (424) (423) (222) (425), and results in Figure 34A 
show that CDODA-Me inhibits growth of 253JB-V and KU7 cells after treatment 
for 48 or 72 hr.  IC50 values for inhibition of cell proliferation after treatment for 
24 or 72 hr were 1.79 and 1.64 μM and 1.97 and 1.71 μM for 253JB-V and KU7 
cells, respectively.  Figures 34B and 34C show that after treatment of 253JB-V 
and KU7 cells with CDODA-Me for 24 hr, there was an increase in DNA ladder 
formation and caspase-dependent PARP cleavage, respectively, in both cell 
lines confirming that CDODA-Me induces apoptosis in bladder cancer cells. 
 CDODA-Me is a PPARγ agonist (20), and results in Figure 34D show that 
CDODA-Me induced luciferase activity in 253JB-V and KU7 cells transfected 
with a PPARγ-GAL4 chimera and a pGAL4-luc reporter gene containing 5 
tandem GAL4 response elements linked to a luciferase reporter gene.  
Rosiglitazone, a thiazolidinedione PPARγ agonist, also activated PPARγ-GAL4 
in KU7 cells and served as a positive control for this assay.   Previous studies in 
bladder and other cancer cell lines report that the broad spectrum of anticancer 
activities of curcumin have been associated, in part, with decreased NFκB-
dependent activity (318) (283).   
 
  
                                                                                                                                        183
 
 
 
 
Figure 34. CDODA-Me inhibits bladder cancer cell growth, induces 
apoptosis and activates PPARγ receptor. 
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A. Inhibition of 253JB-V and KU7 cell growth. Cells were treated with 
DMSO (solvent control); 0.5, 1.0, 2.5 or 5.0 µmol/L CDODA-Me and the effects 
of cell growth were determined after treatment for 48 and 72 hr as described in 
the Materials and Methods. B. Effects of CDODA-Me on DNA laddering in 
253JB-V and KU7 cells. Cells were treated with DMSO (0) and 2.5 or 5.0 µmol/L 
CDODA-Me for 24 hr and induction of DNA laddering was determined as 
described in Materials and Methods. The standard (S) of 1 kb was used as a 
marker for DNA laddering. C. Induction of PARP cleavage.  253JB-V and KU7 
cells were treated with DMSO and 1.0, 2.5, or 5.0 µmol/L CDODA-Me for 24 hr, 
and whole-cell lysates were analyzed by Western blot analysis as described in 
Materials and Methods.  D, Activation of PPAR γ, 253JB-V and KU7 cells were 
transfected with PPAR -GAL4/pGAL4 constructs and then treated with DMSO, 
rosiglitazone or different concentrations of CDODA-Me, and luciferase activity 
was determined as described in Materials and Methods. Results are expressed 
as means ± SE for three replicate determinations for each treatment group, and 
significant (P < 0.05) CDODA-Me-dependent increases (**) or decreases (*) in 
percentages of a phase compared to the solvent (DMSO) control are indicated.                           
 Induction of the proapoptotic gene caveolin-1 by some PPARγ agonists in 
bladder cancer cells is receptor-dependent, whereas rosiglitazone does not 
induce caveolin-1 in these cells (426); like rosiglitazone, CDODA-Me did not 
induce caveolin-1 in bladder cancer cells (Figure. 35A).  CDODA-Me decreased 
expression of cyclin D1 and EGFR in 253JB-V and KU7 cells; however, 
cotreatment with the PPARγ antagonist GW9662 did not block the effects of 
CDODA-Me on cyclin D1 or EGFR (Figure. 35B).   
We also observed that the effects of CDODA-Me on PARP cleavage 
(Figure. 35C) and cell proliferation (Figure. 35D) were not inhibited by the 
PPARγ antagonist GW9662.  These results are consistent with previous studies 
with CDODA-Me in other cancer cell lines, indicating that the growth inhibitory 
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and proapoptotic activity of this compound is PPARγ-independent  (427) (428) 
(424).  
 
Figure 35. CDODA-Me modulates PPAR-independent cell cycle, cell growth 
and apoptotic proteins. 
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lysates were analyzed by Western blot analysis as described in Materials and 
Methods. Receptor-independent degradation of cyclin D1 and EGFR proteins 
(B) and induction of cleaved PARP (C). 253JB-V and KU7 cells were treated 
with DMSO and 1.0, 2.5 or 5.0 µmol/L CDODA-Me in the presence or absence 
of the PPAR- γ antagnoist GW9662 for 24 hr and whole-cell lysates were 
analyzed by Western blot analysis as described in Materials and Methods. β-
Actin served as a loading control. D, CDODA-Me causes receptor-independent 
growth inhibition. Cells were treated with DMSO (solvent control); 0.5, 1.0, 2.5 or 
5.0 µmol/L CDODA-Me Me in the presence or absence of PPARγ antagnoist 
GW9662 and the effects on cell growth were determined after treatment for 24 
hr as described in Materials and Methods. Results are expressed as 
means ± SE for three replicate determinations for each treatment group, and 
significant (P < 0.05) decrease in cell number compared to the solvent (DMSO) 
control are indicated (*).  Treatment of 253JB-V and KU7 cells with CDODA-Me 
for 24 hr (Figure. 36A) or 48 hr (Figure 36B) resulted in decreased expression of 
survival (survivin and bcl-2) and angiogenic (VEGF and VEGFR1) proteins in 
253JB-V and KU7 cells.  Significant downregulation of these proteins was 
observed at 1 - 2.5 μM concentrations of CDODA-Me.   
Cells were treated with DMSO and 0.5, 1.0,  2.5 or 5.0 µmol/L CDODA-
Me for 24 hr or 0.25, 0.5, 1.0 or 2.5 µmol/L for 48 hr and whole-cell lysates were 
analyzed by Western blot analysis as described in Materials and Methods. β-
Actin served as a loading control and similar results were observed in duplicate 
experiments. We also examined the effects of CDODA-Me on luciferase activity 
in 253JB-V and KU7 cells transfected with constructs containing Sp1 (-751 to -
20) and Sp3 (-417 to -38) promoter inserts (Figures. 37A and 37B, respectively).   
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Figure 36. Effects of CDODA-Me on angiogenic, survival and Sp proteins. 
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CDODA-Me decreases VEGF, VEGFR1, survivin and bcl-2 proteins in 
253JB-V and KU7 after treatment for 24 (A), or 48 hr (B) and also decreases Sp 
proteins after treatment for 24 (C), or 48 hr (D) in bladder cancer cells.  
Results are expressed as means ± SE for three replicate determinations 
for each treatment group, and significant (P < 0.05) CDODA-Me-dependent 
decreases in luciferase activity compared to the solvent (DMSO) control are 
indicated (*). CDODA-Me significantly decreased luciferase activity in both cells 
transfected with pSp1For4 or pSp3For5, and this was consistent with the loss of 
Sp proteins which self-regulate both Sp1 and Sp3. 
 Ongoing studies in this laboratory show that arsenic trioxide also 
decreases cell proliferation and Sp protein expression in bladder and other 
cancer cell lines and this is related to decreased mitochondrial membrane 
potential (MMP) and the induction of reactive oxygen species (ROS). Figure 38A 
shows that after treatment of 253JB-V and KU7 cells with CDODA-Me, there 
was a decrease in MMP in both cell lines which was reversed after cotreatment 
with the antioxidant thiol reducing agent DTT.  
 Using the same treatment protocol, CDODA-Me also decreased GSH 
levels and increased ROS in both bladder cancer cell lines and these responses 
were also inhibited after cotreatment with the thiol reducing agent DTT (Figure 
38B).  The role of CDODA-Me-induced ROS in mediating inhibition of cell 
proliferation and Sp downregulation is supported by results in Figures 38C and 
38D, respectively.  CDODA-Me-mediated growth inhibition and downregulation 
of Sp1, Sp3 and Sp4 proteins were significantly reversed after cotreatment with 
DTT and GSH.  
Bladder cancer cells were transfected with pSp1 (A), pSp3 (B), pVEGF 
(C) and pSurvivin (D) promoter constructs and treated with DMSO and 1.0,  2.5 
or 5.0 µmol/L CDODA-Me for 24 hr and luciferase activity was determined as 
described in Materials and Methods.  
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Figure 37. CDODA-Me decreases luciferase activity in cells transfected 
with Sp and Sp-dependent gene promoters. 
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Figure 38. Effects of CDODA-Me on mitochondrial membrane potential and 
ROS. 
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potential and ROS were determined as described in Materials and Methods. 
ROS mediated cell growth inhibition (C) and Sp degradation (D) in the presence 
or absence of antioxidants. Cell were treated with DMSO, 2.5, 4.0 or 5 µmol/L 
CDODA-Me in the presence or absence of thiol antioxidants for 24 hr and cells 
were then counted or the whole cell lysates were analyzed by western blots as 
described in Materials and Methods. β-Actin served as a loading control. Results 
in A- C are expressed as means ± SE for three replicate determinations for each 
treatment group, and significant (P < 0.05) CDODA-Me-dependent decreases (*) 
or increases (**) compared to the solvent (DMSO) control are indicated.  In 
addition, CDODA-Me also decreased luciferase activity in 253JB-V and KU7 
cells transfected with the pVEGF (Figure 37C) and pSurvivin (Figure 37D) 
constructs which contain the -2019 to +50 to -269 to +49 regions of the VEGF 
and survivin gene promoters, respectively.  These results are consistent with the 
effects of CDODA-Me on downregulation of Sp and Sp-dependent genes.   
CDDO-Me is an oleanolic acid derivative and structurally related to 
CDODA-Me and the former compound has been extensively investigated as an 
anticancer agent. Figure 6A shows that CDDO-Me inhibited growth of 253JB-V 
and KU7 cells and cotreatment with the antioxidant DTT partially reversed 
growth inhibition as observed for CDODA-Me (Figure 38C).  CDDO-Me also 
decreased expression of Sp1, Sp3 and Sp4 proteins (Figure 39B) at 
concentrations similar to those required for growth inhibition and these 
responses were also partially reversed after cotreatment with the thiol 
antioxidant DTT. In addition, like CDODA-Me, CDDO-Me decreased MMP in 
both cell lines (Figure 39C) and also induced ROS (Figure 39D), and both 
responses were inhibited after cotreatment with the thiol antioxidant.  These 
results demonstrate that both CDODA-Me and CDDO-Me induce ROS-
dependent downregulation of Sp1, Sp3 and Sp4 transcription factors in bladder 
cancer cells, and activation of these pathways contributes to their growth 
inhibitory and proapoptotic effects in KU7 and 253JB-V cells.      
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Figure 39. CDDO-Me dependent effects on cell proliferation and Sp protein 
degradation are ROS dependent. 
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ROS mediated cell growth inhibition (A) and Sp degradation (B) in the 
presence or absence of thiol antioxidants. Cell were treated with DMSO and 0.5 
or 1 µmol/L CDDO-Me for 24 hr and cells were either  or whole cell lysates were 
analyzed by western blots as described in Materials and Methods. β-Actin 
served as a loading control.  CDDO-Me decreases MMP (C) and induces ROS 
(D). 253JB-V and KU7 cells were treated with DMSO and 0.5 or 1 µmol/L 
CDDO-Me for 24 hr, in the presence or absence of antioxidant DTT and 
mitochondrial membrane potential (C) and ROS (D) were determined as 
described in Materials and Methods. Results are expressed as means ± SE for 
three replicate determinations for each treatment group, and significant 
(P < 0.05) CDDO-Me-dependent decreases (*) or increases (**) compared to the 
solvent (DMSO) control are indicated. 
Discussion 
 
 Specificity proteins are members of the Sp/KLF family of transcription 
factors, and Sp1 was the first transcription factor identified and has been 
extensively investigated (263). In transgenic mice in which Sp1 has been 
abrogated, embryos exhibit multiple abnormalities including retarded 
development, and the mice die at approximately gestation day 11 (429). The 
temporal changes in Sp1 and expression of other Sp/KLF proteins has not been 
extensively investigated; however, there is evidence that Sp1 expression 
decreases with age in both human and rodent tissue (430)  (221). In contrast, 
Sp1 protein is overexpressed in multiple tumor types (220) (221), and studies in 
the laboratory show that Sp3 and Sp4 are also highly expressed in breast, 
prostate, colon, esophageal, pancreatic and bladder cancer cells (396) (428) 
(299) (222) (431).  Sp1 overexpression in pancreatic and gastric cancer patients 
is a negative prognostic factor for survival (220) (396).  Research in this 
laboratory has been investigating the effects of Sp1, Sp3 and Sp4 
overexpression on the phenotype and genotype of cancer cells.  Results of RNA 
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interference in which cancer cells are transfected with a cocktail of small 
inhibitory RNAs against Sp1, Sp3 and Sp4 (simultaneous knockdown) indicate 
that these transcription factors regulate several genes and proteins that are 
themselves individually targeted by anticancer drugs and neutralizing antibodies.  
Results of the RNA interference studies show that Sp1, Sp3 and Sp4 regulate 
expression of VEGF and its receptors (VEGFR1 and VEGFR2), bcl-2, survivin, 
epidermal growth factor receptor (EGFR) and cyclin D1 (222) (262) (335). 
 Since Sp transcription factors regulate expression of angiogenic, growth 
promoting and survival genes, research in this laboratory has been investigating 
small molecules that target downregulation of Sp proteins and Sp-dependent 
genes (335) (222). CDODA-Me, a synthetic derivative of glycyrrhetinic acid, 
activates PPARγ, is cytotoxic to cancer cells (222), and induces downregulation 
of Sp1, Sp3 and Sp4 in colon cancer cells and tumors (mouse xenografts) (222).  
CDODA-Me also activates PPARγ in bladder cancer cells (Figure 34D); 
however, the growth inhibitory and proapoptotic effects of CDODA-Me were 
PPARγ-independent (Figures. 34 and 35).  However, we observed that CDODA-
Me decreased expression of Sp1, Sp3 and Sp4 (Figure 36D) and this was 
accompanied by a parallel decrease in Sp-dependent survival (survivin), 
angiogenic (VEGF and VEGFR1), and growth promoting (cyclin D1 and EGFR) 
genes and proteins.  These results, coupled with studies showing that Sp1, Sp3 
and Sp4 knockdown by RNA interference decreases bladder cancer cell growth 
and induces apoptosis (222), indicate that the cytotoxicity of CDODA-Me in 
bladder cancer cells is, in part, due to Sp downregulation. 
 Recent studies in this laboratory indicate that arsenic trioxide is also 
cytotoxic to bladder cancer cells and, like CDODA-Me, this is accompanied by 
downregulation of Sp proteins and Sp-dependent genes.  Downregulation of 
Sp1, Sp3 and Sp4 by arsenic trioxide was accompanied by induction of ROS 
and decreased MMP, and addition of antioxidant thiol reducing agents blocked 
all of these responses.  Treatment of 253JB-V and KU7 cells with CDODA-Me 
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also decreased MMP as indicated by JC-1 staining and this response was 
reversed by DTT (Figure 38A).  The same treatment protocol was also used to 
measure induction of ROS and GSH and depletion (Figure 38B) and inhibition of 
cell proliferation (Figure 38C), and all of these responses were induced by 
CDODA-Me and inhibited after cotreatment with DTT.  Moreover, like arsenic 
trioxide, CDODA-Me also induced downregulation of Sp1, Sp3 and Sp4, and 
both DTT and GSH significantly blocked this response.  The results clearly 
demonstrate that mitochondria are the major intracellular targets of CDODA-Me 
in cancer cells, and the mitochondiotoxicity of this drug plays a major role in the 
anticancer activity of this compound.   
 CDDO and its methyl ester (CDDO-Me) are oleanolic acid derivatives 
structurally similar to CDODA-Me, and previous studies have reported this 
mitochondiotoxicity of CDDO/CDDO-Me in several different cell lines (432) (433, 
434). Moreover, there are also reports of antioxidants ameliorating the 
proapoptotic effects of CDDO and CDDO-Me, and we have observed that like 
CDODA-Me, CDDO-Me-dependent inhibition of bladder cancer cell growth is 
blocked by antioxidants.  In addition, CDDO-Me downregulates Sp1, Sp3 and 
Sp4 and this response is also inhibited after cotreatment with GSH and DTT, 
demonstrating that one of the underlying mechanisms of action of CDDO-Me is 
associated with mitochondrial disruption and induction of ROS leading to 
decreased expression of Sp transcription factors. 
 These results demonstrate that the triterpenoid acid derivatives decrease 
MMP and induce ROS and these results in downregulation of Sp transcription 
factors and Sp-dependent genes and proteins including genes important for cell 
proliferation, survival and angiogenesis.  The role of CDODA-Me-dependent 
miR-27a downregulation and induction of the Sp-repressor ZBTB10 observed in 
colon cancer cells (435)  was also investigated in bladder cancer cells, and 
CDODA-Me did not significantly affect their expression (data not shown).  
Current studies are investigating other genes and microRNAs that may play a 
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role in CDODA-Me-induced downregulation of Sp1, Sp3 and Sp4 in bladder 
cancer cells, and CDODA-Me and related compounds are being investigated for 
clinical applications in bladder cancer chemotherapy.  
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VII. SUMMARY  
 
Specificity proteins are members of the Sp/KLF family of transcription 
factors, and Sp1 was the first transcription factor identified and has been 
extensively investigated. Sp1 is a critical transcriptional factor for embryonic 
development however there is evidence in humans and rodents that Sp1 
expression markedly decreases with age.  In contrast, Sp1 protein is 
overexpressed in multiple tumor types and studies in the laboratory show that 
Sp3 and Sp4 are also highly expressed in breast, prostate, colon, esophageal, 
pancreatic and bladder cancer cells.  Sp1 overexpression in pancreatic and 
gastric cancer patients is a negative prognostic factor for survival.   
 Recent studies in this laboratory have demonstrated that 
compounds such as celecoxib, tolfenamic acid, curcumin and betulinic acid 
inhibit cancer cell and tumor growth and metastasis, and exhibit both 
antiangiogenic and proapoptotic activity through decreased expression of Sp 
proteins such as Sp1, Sp3 and Sp4.  Results of the RNA interference studies 
show that Sp1, Sp3 and Sp4 regulate expression of VEGF and its receptors 
(VEGFR1 and VEGFR2), bcl-2, survivin, epidermal growth factor receptor 
(EGFR), fibroblast growth factor receptor 3 (FGFR3) and cyclin D1.Research in 
this laboratory has been also investigating the effects of Sp1, Sp3 and Sp4 
overexpression on the phenotype and genotype of cancer cells.  Results of RNA 
interference in which cancer cells are transfected with a cocktail of small 
inhibitory RNAs against Sp1, Sp3 and Sp4 (simultaneous knockdown) indicate 
that these transcription factors regulate several genes and proteins that are 
themselves individually targeted by anticancer drugs and neutralizing antibodies.  
Curcumin, an active component of tumeric has been extensively 
investigated as an anticancer drug. In this study, 10 - 25 μM curcumin inhibited 
253JB-V and KU7 bladder cancer cell growth, and this was accompanied by 
induction of apoptosis and decreased expression of the proapoptotic protein 
survivin and the angiogenic proteins vascular endothelial growth factor (VEGF) 
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and VEGF receptor 1 (VEGFR1).  Since expression of survivin, VEGF and 
VEGFR are dependent on specificity protein (Sp) transcription factors; we also 
investigated the effects of curcumin on Sp protein expression as an underlying 
mechanism for the apoptotic and antiangiogenic activity of this compound. 
Moreover, using RNA interference with small inhibitory RNAs for Sp1, Sp3 and 
Sp4, we observed that curcumin-dependent inhibition of nuclear factor κB 
(NFκB)-dependent genes such as bcl-2, survivin and cyclin D1, was also due, in 
part, to loss of Sp proteins.  Curcumin also decreased bladder tumor growth in 
athymic nude mice bearing KU7 cells as xenografts and this was accompanied 
by decreased Sp1, Sp3 and Sp4 protein levels in tumors.  These results 
demonstrate for the first time that one of the underlying mechanisms of action of 
curcumin as a cancer chemotherapeutic agent is due, in part, to decreased 
expression of Sp transcription factors in bladder cancer cells. 
Betulinic acid (BA) and curcumin are phytochemical anticancer agents, 
and we hypothesized that both compounds decrease EGFR expression in 
bladder cancer through downregulation of specificity protein (Sp) transcription 
factors. The epidermal growth factor receptor (EGFR) is an important 
chemotherapeutic target for tyrosine kinase inhibitors and antibodies that block 
the extracellular domain of EGFR.  The effects of curcumin and BA on Sp 
proteins (Sp1, Sp3 and Sp4) and their role in downregulation of EGFR and 
EGFR-dependent responses were confirmed by RNA interference.  BA and 
curcumin decreased expression of EGFR, Sp and Sp-dependent proteins in 
253JB-V and KU7 cells; EGFR was also decreased in cells transfected with a 
cocktail (iSp) containing small inhibitory RNAs for Sp1, Sp3 and Sp4.  BA, 
curcumin and iSp also decreased phosphorylation of Akt in these cells and 
downregulation of EGFR by BA, curcumin and iSp was accompanied by 
induction of LC3 and autophagy which is consistent with recent studies showing 
that EGFR suppresses autophagic cell death.  In summary, results of this study 
demonstrate that BA- and curcumin-dependent repression of Sp1, Sp3 and Sp4 
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in bladder cancer cells also decrease expression of the Sp-dependent gene 
EGFR in both gefitinib-responsive 253JB-V and gefitinib-nonresponsive KU7 
cells.  Thus, BA and curcumin represent a new type of EGFR inhibitor that 
indirectly targets EGFR and EGFR-mediated responses through repression of 
Sp transcription factors.  This results in inhibition of EGFR-dependent kinases 
and activation of autophagic cell death which is repressed by EGFR (kinase-
independent).  An additional chemotherapeutic advantage of these compounds 
is that they also induce pro-apoptotic, antiproliferative and antiangiogenic 
activities through downregulation of Sp-dependent survivin, cyclin D1 and 
VEGF/VEGFR1 expression, respectively. Relative contributions of Sp-
dependent and Sp-independent pathways to the overall anticarcinogenic activity 
of curcumin and BA and other drugs that repress Sp proteins and Sp-regulated 
proteins such as EGFR will also vary with tumor type.  Currently, we are 
investigating the mechanisms of action and clinical applications of drugs such as 
BA and curcumin alone and in combination with other cytotoxic compounds that 
are used for clinical treatment of bladder cancer. 
Methyl 2-cyano-3,11-dioxo-18β-olean-1,12-dien-30-oate (CDODA-Me) is 
a synthetic triterpenoid obtained from glycyrrhetinic acid which inhibits 
proliferation of KU7 and 253JB-V bladder cancer cells with inhibitory IC50 values 
< 5 μM.  CDODA-Me-dependent growth inhibition is accompanied by induced 
caspase-dependent PARP cleavage and downregulation of survival (survivin 
and bcl-2) and angiogenic [vascular endothelial growth factor (VEGF) and its 
receptor (VEGFR1)] genes.  CDODA-Me also decreased expression of 
specificity protein-1 (Sp1), Sp3 and Sp4 transcription factors and this was 
consistent with downregulation of the Sp-dependent genes survivin, bcl-2, VEGF 
and VEGFR1.  Similar results were observed for a structurally-related 
triterpenoid, methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate (CDDO-Me), 
which is currently in clinical trials.  Both CDODA-Me and CDDO-Me decreased 
mitochondrial membrane potential and induced reactive oxygen species (ROS), 
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and these responses were also critical for triterpenoid-induced downregulation of 
Sp proteins which was inhibited by the antioxidants dithiothreitol and glutathione.  
This demonstrates a common mechanism of action for CDODA-Me and CDDO-
Me which is due, in part, to mitochondriotoxicity. 
Celastrol, a triterpenoid acid from an ivy-like vine exhibits anticancer 
activity against 253JB-V and KU7 bladder cancer cells. Celastrol decreased cell 
proliferation, induced apoptosis and decreased expression of specificity protein 
(Sp) transcription factors Sp1, Sp3 and Sp4. Fibroblast growth factor receptor 3 
(FGFR3) is overexpressed in bladder tumors and celastrol also caused a dose-
dependent downregulation of this receptor in 253JB-V and KU7 bladder cancer 
cells. Using small inhibitory RNAs (siRNA) for Sp1, Sp3 and Sp4 (in 
combination) we showed that FGFR3 receptor expression in bladder cancer 
cells is regulated by Sp transcription factors. The mechanism of Sp 
downregulation by celastrol was due to induction of reactive oxygen species 
(ROS) and inhibitors of ROS blocked celastrol-induced growth inhibition and Sp 
repression.  In vivo studies using KU7 cells as xenografts, showed that celastrol, 
decreased tumor growth and expression of Sp proteins confirming that celastrol 
represents a novel class of anticancer drugs that act, in part through ROS-
dependent downregulation of Sp transcription factors which are also 
overexpressed in bladder cancer cells. This study also confirms that Sp 
transcription factors which are overexpressed in bladder and other cancer cells 
and tumors are important drug targets for cancer chemotherapy. 
Derivatives of oleanolic acid, ursolic acid and glycyrrhetinic acid 
substituted with electron withdrawing groups at the 2-position in the A-ring which 
also contains a 1-en-3-one moiety are potent inhibitors of cancer cell growth. 
The antiproliferative activities of several 2-substituted analogs of these synthetic 
triterpenoid acid methyl esters derived from ursolic and glycyrrhetinic acid on 
proliferation were investigated in KU7 and 253JB-V bladder and Panc-1 and 
Panc-28 pancreatic cancer cells. The results show that the 2-cyano and 2-
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trifluoromethyl derivatives were the most active compounds. The glycyrrhetinic 
acid derivatives with the rearranged C-ring containing the 9(11)-en-12-one 
structure were generally more active than the corresponding 12-en-11-one 
isomers. However, differences in growth inhibitory IC50 values were highly 
variable and dependent on the 2-substitutent (CN vs. CF3) and cancer cell 
context.  
Current studies are investigating other genes and microRNAs that may 
play a role in CDODA-Me-induced downregulation of Sp1, Sp3 and Sp4 in 
bladder and other cancer cells, and related compounds are being investigated 
for clinical applications in cancer chemotherapy. 
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